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Abstract
The epidermal growth factor receptor (EGFR) has been implicated in the growth and 
development of a number of human cancers including breast cancer. The activity and 
expression of membrane associated proteins such as the EGFR may be modulated by 
the physical state of the membrane. Activation of the EGFR depends on the lateral 
diffusion and dimérisation of receptor monomers. Changes in membrane fluidity may 
therefore affect activation of the EGFR and hence growth signalling via this receptor.
Using the technique of fluorescence recovery after photobleaching, the lateral 
diffusion of number of fluorescent lipid probes was studied in three breast cancer cell 
lines (MCF-7, MDA-MB-231 and MCF-7 AdrR). The antiestrogen drug tamoxifen 
which is widely used in the treatment of breast cancer, was demonstrated to decrease 
membrane fluidity in breast cancer cells e.g. in MCF-7 cells a 24 hour incubation 
with lO'^M tamoxifen decreased the lateral diffusion coefficient of the A F l8 probe 
from 203 xlO-lOcm^/s to 15.4 xlO-^^cm^/s. Tamoxifen treatment had a general 
effect on membrane fluidity which was observed using different lipid probes and was 
not dependent on the estrogen receptor status of the cell line. Tamoxifen's ability to 
decrease membrane fluidity may be due to its ability to adopt a conformation which 
resembles the steroid nucleus. The steroids cholesterol, 17P-estradiol and the 
steroidal antiestrogen ICI182,780 all had a similar effect on membrane fluidity.
Tamoxifen has previously been reported to have several actions unrelated to inhibition 
of estrogen action. Tamoxifen can inhibit the growth of cells in the complete absence 
of estrogens and also inhibit cells which do not express the estrogen receptor. 
Tamoxifen can inhibit EGF-stimulated growth of MCF-7 breast cancer cells by a 
mechanism distinct from induction of TGFp production. Tamoxifen had no effect on 
the cell surface expression or affinity of the EGFR and it did not inhibit the EGFR 
tyrosine kinase activity in isolated cell membranes. However, in intact cells tamoxifen 
treatment inhibited EGFR autophosphorylation. This effect could be due to
stabilisation of the membrane by tamoxifen and consequent reduction in the lateral 
diffusion of the EGF receptor, reducing dimérisation and autophosphorylation of the 
receptor. This would reduce growth stimulation initiated via the EGFR. Tamoxifen 
can be demonstrated to reduce EGFR mobility in A431 cells. These cells have 
elevated levels of EGFR which allow a sufficient level of signal for FRAP 
measurements of receptor mobility. It is therefore possible that tamoxifen's 
membrane effects contribute to its anticancer action by interfering with EGFR 
function.
1
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The rate of internalisation of the EGFR was not altered by tamoxifen treatment which 
suggests that EGFR lateral diffusion is not a rate-limiting factor in receptor
internalisation. Tamoxifen treatment also had no effect on the adriamycin sensitivity 
of the drug resistant cell line MCF-7 AdrR.
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Chapter 1 
Introduction
1. Breast Cancer
1.1. Introduction
Breast cancer is the most common single cause of death in Western women 
between the ages of 35 and 54. The estimated lifetime risk in Scotland of 
developing the disease was 7.2% between 1985 and 1994 [Cancer Registration 
Statistics, 1996]. In Scotland each year, approximately 2600 new cases of the 
disease are diagnosed and there are 1250 deaths [Sharp, et al, 1993]. In 1994 this 
accounted for 24.4% of all cancers in women in Scotland [Cancer Registration 
Statistics, 1996]. In common with many other countries, the incidence of breast 
cancer in Scotland is increasing with a 12% rise over the period 1981 to 1990 
[Sharp, et al, 1993]. Worldwide, the incidence of breast cancer varies in different 
countries - the lowest mortality rates are seen in East Asia (33 per 100,000 
population in females aged 45 to 84 in 1986) compared with Western Europe which 
had a rate of 88 per 100,000 for the same period [Hoel, et al, 1992]. Breast cancer 
also occurs in males but is rare (typically less than 1% of cases). The maximum 
observed incidence in Scotland was 34 cases in 1976 since when the incidence has 
declined [Black, etal, 1995]
Cancers of the breast can be classified into a number of histological types [World 
Health Organisation., 1981]. Carcinoma in situ (or non-invasive carcinoma) in 
which the tumour has not breached the basement membrane can be subdivided into 
two types : intraductal and lobular carcinoma in situ. Patients with either of these 
types of tumour have a 20 to 30% chance of developing invasive carcinoma within 
20 years of diagnosis [Bartow, 1995] Cancers where the basement membrane has 
been infiltrated are classified as invasive. The most common form is invasive, or 
infiltrating, ductal carcinoma which accounts for 65-80% of cases [Rosen, et al, 
1996]. Paget's disease of the nipple is an uncommon variant of ductal carcinoma, 
either invasive or in situ, which spreads to involve the epidermis of the nipple or 
areola. The second most common form of invasive carcinoma (10%) is lobular
carcinoma [Bartow, 1995]. Finally, 5-10% of invasive carcinomas are designated 
medullary carcinoma. This type of carcinoma has the best prognosis of the invasive 
carcinomas [Robbins, etal, 1987].
Invasive breast cancers spread primarily via the lymphatic system to regional lymph 
nodes including axillary, internal mammary and supraclavicular lymph nodes. 
More distant métastasés (blood-borne) are commonly found in the lungs and pleura, 
liver, bones, adrenal glands, brain and spleen [Bartow, 1995]. In a significant 
number of patients, the tumour has already metastasised at the time of diagnosis. 
Metastasis is usually the single most important criterion determining a patient's 
prognosis. The 5 year survival rate for a breast cancer patient with localised disease 
and no evidence of axillary lymph node involvement is around 80% but drops to 
around 30% when more than 10 lymph nodes are involved [Clark, 1996].
1. 2. Risk factors for breast cancer
Major risk factors for breast cancer established from epidemiological research 
appear to include early men arche and late menopause - a delay in menarche of 3 
years from age 12 to 15 can half the risk of breast cancer as can a natural 
menopause at 45 rather than 55. Early menopause through ovarian ablation is 
similarly associated with a reduction in risk [Brinton,gf al, 1988]. The age at which 
a woman has her first child is also a factor - a first child at 30 carries twice the risk 
associated with a first child at 18. Nulliparity is associated with increased risk 
although the risk is less than that associated with a first birth after 30 [MacMahon, 
et al, 1970; Ewetz, et al, 1990]. These factors all indicate an association with cyclic 
ovarian activity and consequent exposure to the known breast mitogen, estrogen 
which has been proposed to have a central etiological role in breast cancer [Fuqua, 
1996].
A number of lifestyle factors such as diet and alcohol also contribute to the overall 
risk of breast cancer but their exact roles in its cause remain unclear [Daudt, et al, 
1996]. The hypothesis o f an association between diet and cancer incidence stems 
largely from comparisons of incidence of cancers in various parts of the world. 
Offspring of parents who move from a country with a low rate, to one with a high 
incidence, tend to acquire rates similar to the new country suggesting a role for 
environmental and lifestyle influences [Hunter, et al, 1996]. The role of dietary fat 
intake is unclear [Whittemore, 1993]. There is an observed association between per 
capita fat consumption and breast cancer incidence in developed countries [Boyle, 
et al, 1988]. However, recent studies show that in the USA, an increase in breast 
cancer incidence has occurred during a period of decreased fat consumption [Daudt, 
et al, 1996]. Obesity has been shown to be an independent risk factor for breast 
cancer. This may be of particular relevance in post menopausal women where 
adipose tissue is the major source of estrogens [Rose, 1986]. A number of studies 
have shown that increased alcohol intake is associated with an increased in risk of 
the disease which is possibly linked to an increase in endogenous estrogen levels 
[Willet, 1989; Daudt, eta l, 1996].
Intake of vitamins A, C and E and selenium are all suggested to be protective 
against a variety of cancers including breast cancer. This may be related to the 
antioxidant effect of these compounds [Hunter, 1996] (section 5.5). Evidence 
suggests that consumption of green vegetable may be related to a reduced risk of 
breast cancer [Willett, 1995]. This may be due to antioxidant micronutrients or the 
presence of other constituents with a protective effect, or, may simply reflect a 
lower intake of fat or calories [Minchovicz, et al, 1990; Greenberg, et al, 1996]. 
The observed protective effect of a diet rich in soya may be due to its content of 
isoflavones such as genistein. These phytoestrogens have weak estrogen agonist 
activity which may interfere with endogenous estrogen [Daudt, et al, 1996]. Diet 
may also play a role in prolonged survival from breast cancer - certain dietary fatty
acids, in particular omega-3 fatty acids found in fish oils and gamma linolenic acid, 
have been found to inhibit growth of breast cell lines [Cantrill, et al, 1993].
Some breast cancers are associated with a family risk of the disease. A family 
history in a first degree relative is associated with an approximate doubling of the 
risk - this risk is even higher if both the mother and a sister have had breast cancer. 
Significant increases in this risk are found if the relative had bilateral disease or 
developed cancer at an early age [Brinton, et al, 1996], Approximately 5% of all 
breast cancers are inherited forms of the disease with the majority of these 
associated with abnormalities in two genes - BRCAl and BRCA2 [Daudt, et al, 
1996]. Between 5 and 10% of women diagnosed under the age of 40 may have 
BRCAl alterations [Blackwood, 1996]. In BRCAl carriers, the risk of breast 
cancer is estimated to be 51% by the age of 40 and 85% by age 70.
1. 3. Prognostic and predictive factors in breast cancer
To determine the best treatment for any patient, the likelihood that the patient will 
have a recurrence of disease in the future and the potential efficacy of the available 
treatments on that tumour must be examined. Prognostic indicators give the disease 
free or overall survival in the absence of systemic adjuvant therapy while predictive 
factors give an indication of the response, or lack of response, to therapy [Clark, 
1996]. A number of biomarkers are currently in use to classify individual patients. 
The standard prognostic factors currently in use for primary breast cancer include: 
axillary node status, histologic subtype, tumour size, tumour grade and estrogen and 
progesterone receptor status [Clark, 1996]. The presence or absence of metastatic 
involvement in the axillary lymph nodes is the single most powerful prognostic 
factor available for patients with primary breast cancer [Hynes, et al, 1994].
Many of the known risk factors for breast cancer indicate that a cumulative 
exposure to estrogen (and progesterone) plays an important causative role in breast
cancer (Section 1.2). The mitogenic effects of estrogen and progesterone on breast 
cancer cells in culture have been well documented [Dickson, et al, 1988]. Steroid 
receptor assays have become standard practice in the management of breast cancer- 
estrogen receptor (ER) positivity is generally indicative o f a relatively good 
prognosis in primary breast cancer [Fuqua, 1996], The ER status of a tumour is 
also used as a predictor of its response to endocrine therapy in advanced disease - 
50% of ER positive patients have an objective response to this therapy compared 
with only 10% of ER negative cases [Klijn, et al, 1993]. However this leaves a 
large number of ER positive metastatic tumours which fail to respond to endocrine 
therapy while some ER negative do respond. There is also a relatively small 
difference (8-10%) in relapse free survival (RES) between ER positive and ER 
negative tumours. Thus ER status, while useful, is a rather imperfect predictor of 
prognosis and response to therapy [Klijn, et al, 1993]. Progesterone receptor status 
in addition to ER status improves the ability to predict response to endocrine 
therapy - tumours with both steroid receptors have response rates higher than 70% 
[Fuqua, 1996].
Since none of these factors alone or in combination separates completely patients 
who are cured by local therapy from those whose cancer will recur, newer 
biomarkers must be examined for their significance. Since evidence exists that 
breast epithelial cells are under growth control of members of the EGFR family, 
this protein has been examined for its prognostic value. A number of studies have 
reported that this protein is indeed an indicator of poor prognosis and can be used to 
predict lack of response to endocrine therapy [Klijn, et al, 1993] (Section 3.).
1. 4. Treatment of breast cancer
A number of options are available in the treatment of breast cancer including 
surgery, radiation, chemotherapy and endocrine therapy. Treatment for localised 
breast cancer usually involves lumpectomy either alone or in conjunction with
radiotherapy. Data shows that patients treated in this way have the same five year 
survival rate as patients treated by total mastectomy for localised disease [Morrow, 
et al, 1996]. Adjuvant therapy is used after primary surgery to kill or inhibit 
clinically occult micro-metastases. In cases where the disease has metastasised to 
the axillary lymph nodes, chemotherapy is used. The most widely used form is a 
combination (CMF) of cyclophosphamide, methotrexate and fluorouracil although a 
number of alternative treatments exist. Endocrine therapy may involve the use of 
anti-estrogens such as tamoxifen (Section 5), aromatase inhibitors which block an 
enzyme involved in estrogen synthesis, luteinizing hormone-releasing hormone 
analogues or progestins [Bajetta, et al, 1994]. Antiestrogens are considered the 
treatment of first choice for metastatic disease in post-menopausal patients or for 
adjuvant therapy. Selection of the appropriate treatment for individual patients 
whether chemotherapy or endocrine therapy is critical for the successful treatment 
of the disease.
1.5. Drug resistance in breast cancer
A major problem in the successful treatment of cancer, including breast cancer, is 
the phenomenon of drug resistance. Resistance to chemotherapy may be intrinsic 
where the tumour fails to respond when initially treated, or acquired as in tumours 
where there is a good response to chemotherapy initially, but eventually resistance 
develops, not only to the original drug used in treatment, but also to a wide variety 
of other drugs [Bosch, et al, 1996]. The drugs to which resistance is acquired do 
not necessarily have a common structure or intracellular target. They include 
anthracyclines, taxanes, vinca alkaloids, epipodophyllotoxins and mitoxantrone 
[Blackwood, 1996]. Such broad spectrum resistance to chemotherapy is called 
multi-drug resistance and efforts to reverse this phenomenon have important 
clinical implications for breast cancer patients.
Multi-drug resistance and was first reported in Chinese hamster lung cells in 1970 
[Biedler, et al, 1970]. In 1976, it was reported that multi-drug resistance was 
associated with a 170,000 molecular weight surface glycoprotein, p-glycoprotein, 
and that the degree of expression of this protein correlated with the degree of 
resistance [Juliano, et al, 1976]. P-glycoprotein, or p l70 , has since been 
characterised as an ATP-dependent transmembrane pump which acts to prevent 
intracellular accumulation of a variety of chemotherapeutic drugs [Horio, et al,
1988]. There is large body of evidence to support the theory that overexpression of 
this protein is responsible for drug resistance. Increased protein expression 
correlates well with the degree of drug resistance in a number of cell lines and it is 
the most consistent phenotypic alteration found in the condition [Kartner, et al, 
1985]. Transfection of the gene for p-glycoprotein is sufficient to confer multidrug 
resistance on a drug sensitive cell line [Gros, et al, 1986]. Elevated levels of the 
protein are found in tumours of every histological type and also in normal tissue 
such as the adrenal gland suggesting its normal physiological function may be 
related to the packaging and secretion of physiologically important substances 
[Bosch, et al, 1996].
Some expression of p-glycoprotein can be found in normal breast epithelial cells 
[Cordon-Cardo, et al, 1989]. In breast cancer, p-glycoprotein is expressed at high 
levels by between 20 and 70% of cancers although some studies failed to detect 
high levels of expression of either the protein or RNA [Bosch, et al, 1996]. 
Previously treated cancers are consistently more likely to express high levels of p- 
glycoprotein [Salmon,gr al, 1989]. Expression of p-glycoprotein may be associated 
with a loss of expression of steroid receptors and increased epidermal growth factor 
expression [Meyers, et al, 1986; Vickers, et al, 1988; Dickstein, et al, 1993].
2. Epidermal Growth Factor and its receptor
2 .1 . Epidermal growth factor
Epidermal growth factor (EGF) was first isolated in 1962 in an experiment to 
extract nerve growth factor (NGF) from mouse submaxillary glands. A fraction of 
extract from these glands, which was negative for NGF activity, was found to 
induce premature incisor eruption and eyelid opening when injected into newborn 
mice. The factor responsible was isolated and purified and found to be a small, heat 
stable polypeptide [Cohen, 1962]. These effects were due to stimulation of 
epidermal growth and keratinization [Cohen, et al, 1963]. The protein, named 
epidermal growth factor, is highly abundant in male mouse submaxillary gland 
where it accounts for 0.5% of the total protein content [Carpenter, et al, 1979]. The 
human form of EGF was isolated from urine and was named urogastrone since it 
was initially characterised as an agent which inhibited gastric acid secretion 
[Gregory, 1975]. Daily urinary excretion of the protein can exceed 50jig/ml and is 
significantly higher in females, particularly in those taking oral contraceptives or 
during pregnancy [Dailey, et al, 1978]. The human and mouse forms of EGF differ 
in molecular weight and immunological properties, but compete for receptor 
binding and have similar biological activities [Carpenter, et al, 1979]. EGF has 
since been isolated from many tissues and most body fluids including milk 
[Boonstra, et al, 1995]. In mouse the predominant site of EGF synthesis is the 
submaxillary glands although secondary sites are evident after removal of these 
glands. Expression has been detected in the submaxillary gland, the kidney and (in 
humans) Bruners gland in the gut, but the exact site of synthesis is uncertain 
[Carpenter, 1985].
Mouse EGF is a 53 amino acid chain (MW 6045) with 3 intramolecular disulphide 
bonds. Human EGF has a similar amino acid sequence to the mouse form but has a 
smaller molecular weight (MW 5400) [Schlessinger, et al, 1983]. The disulphide 
bonds are required for biological activity and their position is highly conserved
among different species and with related peptides such as TGFa [Carpenter, et al, 
1990]. cDNA cloning revealed that the peptide is produced as a larger 130KDa 
transmembrane precursor of approximately 1200 residues which is subsequently 
processed by proteases to produce the mature growth factor. In addition to EGF, 
this preproEGF contains seven EGF-like domains - the function of these is 
unknown [Boonstra, eta l, 1995]
EGF has a wide range of biological effects which have been demonstrated in 
different systems both in culture and in vivo. At a cellular level, EGF is a potent 
mitogen for a number of different cell types [Carpenter, et al, 1979]. In addition to 
its stimulatory effects on the proliferation of the epidermis and corneal epithelium, 
liver, lung and kidney are also stimulated. Of relevance to breast cancer is its 
stimulatory role in mammary tissue which has been demonstrated both in cell lines 
and in vivo [Osborne, etal, 1980; Gabelman, etal, 1992].
EGF produces a number of cellular responses which precede cell division. These 
include phosphorylation of many cellular proteins including the EGFR itself, 
increased ion and nutrient transport, changes in cytoskeletal organisation and in cell 
morphology. EGF also induces expression of a number of genes such as c-myc and 
c-fos and stimulates biosynthesis of fibronectin and keratin [Schlessinger, et al, 
1983; Harris, et al, 1988]. In a number of cell types including kératinocytes, EGF 
mediates chemotaxis and migration [MeCawley, et al, 1997].
2. 2. EGF in the breast
Several studies have indicated that EGF has an important role in regulating the 
growth of the mammary epithelium: EGF has been detected in milk, breast cyst 
fluid and breast tumour tissue [Nickell, e ta l, 1983; Zweibel, etal, 1986; Connolly, 
et al, 1988]. mRNA for EGF and its receptor are found in normal breast tissue 
indicating that the EGF/EGFR pathway is involved in normal breast growth and
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differentiation [Bates, et al, 1990]. The pattern of EGF receptor staining in normal 
tissue is variable - immunohistochemical staining detects receptor in lobular, ductal, 
myoepithelial and stromal cells [Chrysogelos, e ta l, 1994]. EGF stimulates both 
normal and malignant mammary growth in rats and is necessary for lobulo-alveolar 
development of mouse mammary glands in organ culture [Turkington, 1969; 
Tonelli, et al, 1980]. EGF may also play a physiological role in development of 
the mouse mammary gland during pregnancy [Okamoto, et al, 1984]. EGF 
enhances growth of normal human mammary epithelial cells in short term culture 
[Taylor-Papadimitriou, et al, 1977; Gabelman, et al, 1992] and stimulates 
proliferation of breast cancer cell lines [Osborne, et al, 1980]. EGF may have role 
in the promotion of mammary carcinoma. In a strain of mice with a high incidence 
of mammary tumours, removal of the submaxillary gland which is the major site of 
EGF synthesis reduced the occurrence of tumours. The high incidence of mammary 
tumours is restored if EGF is given [Kurachi, et al, 1985].
2. 3. Epidermal Growth Factor Receptor (EGFR)
Specific, saturable receptors for EGF were first demonstrated by binding iodinated 
growth factor to human fibroblasts [Carpenter, et al, 1976]. EGF binds to the 
receptor with a high affinity -Kq values are in the range lO'^ to Ifrl^M. Studies in 
fibroblasts indicate that a normal cell has between 10,000 and 100,000 binding sites 
for EGF [Carpenter, et al, 1979]. Exceptions to this include the A431 cell line and 
several epithelial carcinoma cell lines which express in the region of 2x10^ 
receptors/cell [Carpenter, 1987]. Most cells with the exception of haemopoetic 
cells, express receptors for EGF [Carpenter, 1987]. EGFR have been detected in 
the undifferentiated basal cells of stratified epithelia and other proliferating cells of 
adnexal structures. Levels are also detectable on non-proliferating cells and the 
ducts of bronchial glands, bile ducts and breast ducts. It is clear therefore that 
EGFR is not necessarily a marker for growth in normal tissue and may have other 
physiological effects in differentiated cells [Gusterson, et al, 1984].
11
The isolation and characterisation of the receptor for EGF was greatly facilitated by
line vastly overexpresses the receptor by 20-100 fold - EGF receptor comprises 
0.15% of the total protein content of this cell line [Stoscheck, et al, 1984]. Although 
many of the physiological responses of the cell line are atypical e.g. EGF produces 
growth inhibition under most circumstances, the line remains a useful tool for the 
study of the receptor and early responses to its activation [Gill, et al, 1981].
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■
the study of the epidermoid carcinoma cell line A431 [Giard, et al, 1973]. This cell
The EGF receptor purified from the A431 cell line by affinity chromatography was
characterised as a ITOkDa glycoprotein with intrinsic protein tyrosine kinase
activity [Cohen, et al, 1980; Ushiro, et al, 1980; Cohen, et al, 1982]. Subsequent
cDNA cloning and amino acid sequencing of the receptor revealed more
.information about the receptor structure which can be divided into 3 domains: 
extracellular, transmembrane and cytoplasmic (Figure 1) [Ullrich, etal, 1984].
The extracellular domain is responsible for ligand binding. This region, which 
contains the N terminus of the protein, consists of 622 amino acids with 12 possible 
sites for N-linked glycosylation of which probably 11 are actually glyosylated 
[Mayes, et al, 1984]. The receptor is cotranslationally glycosylated to give an 
immature 160K glycoprotein. Further processing on the oligosaccharide chains of
■this precursor yields the mature protein [Soderquist, et al, 1986]. No evidence exists 
that the receptor contains 0-linked oligosaccharides [Carpenter, 1987]. The domain 
has a relatively high cysteine content (9%) found in two Cys rich regions [Ullrich, 
et al, 1984]. Cys-rich extracellular domains are a common feature of other tyrosine 
kinase receptors including the insulin receptor and are found in EGFR from 
organisms as diverse as Drosophila and humans [Livneh, et al, 1985]. The ligand 
binding domain of the receptor lies between these two Cys rich regions [Lax, et al,
1989]. Quantitative binding experiments indicate that each receptor binds one EGF 
molecule [Weber, et al, 1984].
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The transmembrane domain is a region of 23 mainly hydrophobic amino acids 
which would be predicted to span the membrane once in an alpha helical structure 
[Ullrich, et al, 1984]. This domain may play only a structural role in linking 
external and internal domains where only length, hydrophobicity and stability in an 
alpha helical conformation are essential. Mutation of this domain has no effect on 
signal transduction [Kashles, et al, 1988]. However in the related molecules neu 
and c-erbB-2, the domain has a role in stabilising dimeric forms of the receptor 
since a point mutation within this region (Val to Glu) results in dimérisation and 
activation of the receptor.[Segatto, et al, 1988] (Section 2.3.2.).
The cytoplasmic domain consists of 542 amino acid residues including a region of 
approximately 300 residues which has homology to the src family of protein 
kinases. Sequence data demonstrated that this domain is highly homologous to the 
product of the v-erbB oncogene from avian erythroblastosis virus (Section 2.3.2.) 
[Ullrich, et al, 1984]. A conserved ATP binding site is found within this domain 
with an essential Lys residue at 721 [Russo, et al, 1985]. Mutation of this Lysine 
residue abolishes kinase activity [Honegger, et al, 1987a & 1987b] and immediate 
and late signalling events via the receptor such as alterations in intracellular 
calcium, activation of gene transcription, receptor down-regulation and cell 
proliferation [Chen, et al, 1987]. The C terminal region also contains the three 
major sites of receptor autophosphorylation, Tyr 1068, 1148 and 1173 - Tyr 1173 is 
the major autophosphorylation site in intact cells [Downward, et al, 1984b]. These 
C terminal tyrosines appear to define an auto inhibitory region which can be 
relieved by autophosphorylation or truncation [Walton, et al, 1990] and have also 
been implicated in binding receptor substrates by their SH2 domains (Section
2.3.4.) . The domain also contains a number of other phosphorylation sites on Ser 
and Thr residues - these are probably targets for phosphorylation by PLC. One well 
characterised site is Thr-654 which is located 10 residues beneath the 
transmembrane region of EGFR. Phosphorylation at this site by PKC abolishes the
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high affinity receptor state and reduces its kinase activity [Downward, et al, 1985]. 
Since PKC is activated by EGFR this may represent a negative feedback 
mechanism to control signalling via the receptor.
2. 3 .1 . Other ligands for EGFR
A number of other ligands for the EGFR exist which bind to the receptor with near 
identical affinities, and produce the same responses in target cells. These ligands 
all possess the 6 cysteine residues spaced at defined intervals which have been 
shown to be essential for the secondary structure and biological activity of EGF 
[Davies, et al, 1996]. Apart from EGF, transforming growth factor alpha, vaccinia 
virus growth factor, amphiregulin, heparin-binding EGF, p-cellulin , cripto-1 and a 
number of other virally encoded proteins also bind to the receptor [Normanno, et al, 
1994].
Transforming Growth Factor a
TG Fa was first isolated in 1978 from the medium of retrovirally transformed 
fibroblasts [DeLarco, etal, 1978]. It had been observed that fibroblasts transformed 
by the Moloney murine sarcoma virus rapidly lost their ability to bind EGF. 
Peptide growth factors were isolated from the conditioned medium of these cells. 
These transforming growth factors (TGF) were small, heat stable polypeptides 
which were also secreted by human tumour cells and were capable of inducing 
proliferation and transformation of rat fibroblasts [Todaro, et al, 1980]. The TGF 
preparation capable of inducing transformation was subsequently shown to contain 
two peptides: TG Fa and TGFp [Derynck, 1988]. Both peptides are required to 
produce anchorage-independent growth of normal fibroblasts but it is TGFa which 
competes for EGF binding and was responsible for the observed loss of EGF 
binding in transformed cells [Carpenter, et al, 1986]. TGFa has subsequently been 
identified in a variety of retrovirally transformed cells , human tumour cells and 
embryonic cells [Ozanne, eta l, 1980; Todaro, et al, 1980; Twardzik, et al, 1982].
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Mature TGFa is a single polypeptide chain of 50 amino acids - molecular weight 
5kd. TG Fa is 37% homologous to human EGF including conservation of all 6 
cysteine residues involved in formation of intramolecular disulphide bonds 
[Marquardt, et al, 1984]. Like EGF, TGFa is synthesised as part of a larger 160 
amino acid transmembrane precursor [Derynck, et al, 1984]. Differential proteolytic 
cleavage and glycosylation of the precursor accounts for the differing molecular 
weight forms of TGFa which have been isolated from the conditioned medium of 
TG Fa producing cells [Derynck, 1988].
Unlike EGF, TGFa is known to be expressed by a wide range of tissues in both the 
adult and foetus. It is expressed during normal embryogenesis in the developing 
kidney, pharynx and otic vesicle while TGF mRNA and/or protein has been found 
in adult pituitary, brain and ovarian theca cells [Derynck, 1988]. TG Fa can also be 
detected in human milk suggesting it may be secreted by normal mammary 
epithelial cells [Zweibel, et al, 1986]. It may play a role in wound healing since it 
is expressed in activated macrophages and normal skin kératinocytes [Derynck, 
1988].
Elevated TG Fa secretion has been demonstrated in several types of human 
carcinoma cell lines, in primary tumours and in transformed fibroblasts and 
epithelial cells , and has been linked to cell transformation [Salomon, et al, 1990]. 
The role of TG Fa in breast cancer has been well studied. TG Fa is a potent 
mitogen for both normal and malignant breast cells and is produced by chemically 
transformed rat mammary carcinomas - this expression is enhanced by estrogen 
treatment [Normanno, et al, 1994]. A number of human breast cell lines have also 
been demonstrated to secrete TG Fa and in estrogen responsive cell lines this 
expression is also stimulated by estradiol. One effect of the anti-cancer drug 
tamoxifen is to block this elevation [Dickson, etal, 1987].
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The parameters of TGFa binding to mammalian EGFR is very similar to EGF and 
TG Fa has a similar activity to EGF in stimulating DNA synthesis in various cell 
lines, inducing premature eyelid opening in newborn mice and in promoting cell 
transformation [Schreiber, et al, 1986; Derynck, 1988]. However in other assay 
systems the two growth factors exert different responses - TG Fa is more potent 
than EGF in inducing membrane ruffling, neovascularisation, keratinocyte 
migration and induction of Ca^+ release from bone in culture. Thus, while acting 
via the same receptor, cellular response to the two peptides can differ [Derynck, 
1988].
Vaccinia Virus Growth Factor
The existence of a viral homologue of EGF, vaccinia virus growth factor (VVGF), 
was first detected via a search of protein sequence data bases. This protein is 
encoded in the inverted terminal repeat of the viral genome and is transcribed early 
in viral infection. The secreted protein has 77 amino acids including a region of 50 
amino acids with 35% similarity to EGF and TGFa and retains the ability to form 3 
di sulphide bonds similar to EGF. Unlike EGF and TGFa, VVGF is glycosylated. 
This growth factor is capable of stimulating the EGFR and hence cell proliferation 
[Stroobant, et al, 1985]. Thus a virus has acquired sequences coding for a growth 
factor which may allow it to subvert EGFR dependent functions and may confer 
some advantage for viral growth. The exact function of this protein in the virus is 
unknown since vaccinia virus infection does not involve increased cellular 
proliferation. However, several members of the related Pox family such as 
cytomegalovirus do cause abnormal cellular proliferation during infection 
[Carpenter, et al, 1986],
Amphiregulin
Amphiregulin (AR) is a fourth protein which binds to the EGFR. It is a 14k 
glycoprotein secreted by MCF-7 breast cancer cells which have been treated with a
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tumour promoting phorbol ester, phorbol 12-myristate 13-acetate (PMA) [Shoyab, 
et al, 1988]. AR inhibits growth of breast tumour cells but not normal cells 
[Plowman, et al, 1990]. Mature AR exists as both a 78 and 84 amino acid peptide 
which binds to, and activates the EGFR although it has a lower binding affinity than 
EGF or TG Fa [Normanno, et al, 1994]. AR also binds to the related protein c- 
erbB-3 [Gullick, 1991]. AR is expressed by a range of normal tissues and also a 
number of other tumour cell types including several breast cell lines [Normanno, et 
al, 1994].
2 .3  . 2. Molecules related to the EGFR
EGFR is only one of a family of similar proteins which share a common structure 
and, possibly, similar functions (Figure 1). All possess a large, glycosylated 
extracellular ligand binding domain, a single hydrophobic transmembrane domain, 
and a cytoplasmic tyrosine kinase domain. The family is called the class 1 receptor 
tyrosine kinases and in addition to EGFR (c-erbB-1) it includes, c-erbB-2, c-erbB-3 
and c-erbB-4. The viral oncogene v-erbB is related in structure [Hynes, et al, 
1994].
V-erbB
Initial partial sequencing of the EGFR revealed a striking similarity to the v-erbB 
oncogene of avian erythroblastosis virus [Downward, et al, 1984a]. Complete 
cDNA sequencing of the EGFR confirmed this similarity [Ullrich, et al, 1984]. A 
sequence of approximately 400 residues which includes the kinase domain is 95% 
identical between the two molecules [Carpenter, et al, 1987]. It is probable that this 
oncogene derives from viral capture of part of the cellular EGFR gene (c-erbB-1). 
The two molecules differ in that v-erbB lacks most of the extracellular ligand 
binding domain, plus 34 residues at the C-terminus including the major site of 
receptor autophosphorylation, Tyr 1173. Removal of these regulatory regions has 
led to the proposal that this molecule functions as a constitutively active, ligand
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independent, protein tyrosine kinase in AEV-transformed cells [Downward, et al, 
1984a & 1984b] (Section 2.3.4.).
C-erbB-2
The neu oncogene (also called HER2) from chemically-induced rat neuroblastomas 
was isolated in 1985 by its ability to transform normal NIH3T3 fibroblasts. This 
was shown to have significant homology to the EGFR [Schechter, et al, 1984]. 
Independently an erbB-related gene, c-erbB-2, was sequenced and cloned from a 
human breast carcinoma cell line. Analysis of these 2 genes identified the neu 
oncogene as the activated rat homologue of the proto-oncogene c-erbB-2 
[Yamamoto, et al, 1986]. The normal protein is a 185K glycoprotein which is 
widely expressed on epithelial cells, particularly on secretory epithelia [Gullick,
1991]. The function of the receptor in normal tissue is not clear although it may be 
important in neural and neuromuscular junction development [Dickson, et al, 
1996a]. Comparison of the sequences of EGFR and human c-erbB-2 reveals many 
similarities. There is 40% identity between the extracellular domains of these two 
proteins with conservation of the two Cys rich regions. The catalytic domains are 
82% identical and c-erbB-2 has autophosphorylation sites related to those of EGFR 
[Gullick, 1990].
Oncogenic activation of neu/erbB-2 occurs due to a single mutation of valine to 
glutamate in the transmembrane domain of the receptor which apparently causes the 
mutant protein to exist in a permanent dimer with activated tyrosine kinase in the 
absence of ligand [Weiner, et al, 1989]. This may be due to stabilisation of the 
dimer by intrareceptor hydrogen bonding between the glutamate residues 
[Sternberg, et al, 1989]. Other potential methods of activation exist, including 
truncation of the extracellular or cytoplasmic domains [Segatto, et al, 1988], The 
gene can also be activated oncogenically by overexpression and this process has
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been implicated in the development of several human cancers [Di Fiore, et al, 
1987b] (Section 3).
C-erbB-2 does not itself bind EGF or TGFa but heterodimers of EGFR/c-erbB-2 
have been demonstrated to bind EGF. These have a increased affinity for EGF and 
a higher protein tyrosine kinase activity than homodimers [Dougall, et al, 1993]. It 
is possible that co-expression of EGFR and c-erbB-2 may confer an additional 
growth advantage on a cell at low ligand concentrations. Co-expression commonly 
occurs in human breast cancers [Gullick, 1990]. The implications of this for 
tumour growth are discussed in Section 3.3.2.
A potential ligand for c-erbB-2 was identified in the conditioned medium of ras 
transformed rat fibroblasts. This heat stable, 44K glycoprotein (called neu 
differentiation factor or NDF) was capable of stimulating neu receptor in mammary 
cells resulting in their differentiation to mature, milk-producing cells [Bacus, et al, 
1994]. NDF stimulates tyrosine phosphorylation of c-erbB-2 and can be covalently 
cross linked to the receptor in some human breast cancer cells [Carraway, et al, 
1994]. The human form of NDF, heregulin, was isolated as a protein secreted by 
MDA-MB-231 breast cancer cells which stimulated c-erbB-2 kinase activity in 
MCF-7 cells [Normanno, et al, 1994]. NDF is not able to stimulate erbB-2 kinase 
activity in all cells suggesting that another receptor may exist for this protein. More 
recent studies demonstrate that activation of c-erbB-2 by heregulin is dependant on 
coexpression of c-erbB-3 or c-erbB-4 and that heregulin actually binds directly c- 
erbB-4 and weakly to c-erbB-3 [Lemmon, et al, 1994], Another factor of 15-17K 
called neu-activating factor (NAF) has been proposed as an erbB-2 specific ligand 
[Dickson, etal, 1996b].
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C-erbB-3 and c-erbB-4
C-erbB-3 or HER-3 was isolated due to its sequence homology with v-erbB [Kraus, 
et al, 1989]. It is less related EGFR and c-erbB-2 than they are to each other 
[Rajkumar, e ta l, 1994], c-erbB-3 lacks certain residues which are highly conserved 
in the catalytic domains of other tyrosine and ser/thr kinases which suggests that 
this protein either lacks or has only a weak kinase activity [Hynes, et al, 1994]. c- 
erbB-3 has been found expressed at moderately high levels on epithelial cells and 
on cells of neuroectodermal origin. The protein is expressed at low level on normal 
myoepithelial cells of the breast but may have elevated expression in some breast 
cancers [Bacus, et al, 1994]. Most breast cell lines which overexpress c-erbB-2 
also overexpress c-erbB-3 [Rajkumar, etal, 1994].
C-erbB-4 is the most recently discovered member of the type 1 growth factor 
receptor family [Plowman, etal, 1993]. This shows a greater homology in its kinase 
domain to EGFR and c-erbB-2 than to c-erbB-3. However the extracellular domain 
of C-erbB-4 is more similar to c-erbB-3 (65%) than to the other two (41-46%) 
[Carraway, et al, 1994]. c-erbB-4 is overexpressed by a number of breast cell lines 
[Rajkumar, etal, 1994].
It is not yet clear whether c-erbB-3 and c-erbB-4 are commonly amplified in human 
cancers but both possess transforming activity in fibroblasts in vitro. Their function 
in normal development and physiology is even less certain [Dickson, et al, 1996a].
2. 3. 3. EGFR activation
The EGFR is a protein tyrosine kinase. This activity is essential to signalling via 
the receptor since mutations which abolish the tyrosine kinase activity abolish the 
biological function of the receptor [Cadena, et al, 1992]. A key question in the 
activation of the EGFR is how a signal initiated by ligand binding to the external 
domain is transmitted to the cytoplasmic kinase domain. Two models have been
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proposed: an intramolecular model in which a signal generated in the extracellular 
domain would be transmitted via the single transmembrane span to activate the 
intracellular kinase domain, or, an intermolecular model where receptor activation 
would be achieved by allosteric interactions between receptor subunits. Most of the 
available evidence supports the intermolecular model of activation [Schlessinger,
1988]. This model also bypasses the need for transmission of a conformational 
change through the hydrophobic transmembrane region which is inherent in the 
intramolecular model - recent NMR studies of this domain have indicated that such 
a conformational change is unlikely to occur [Rigby, etal, 1996].
An essential feature of the intermolecular model of activation is interaction between 
receptors. Early studies demonstrated that EGF and other growth factors induce 
oligomerisation of their receptors and that this plays an important role in 
transmembrane signalling. EGFR aggregation in response to ligand binding has 
been observed in living cells, in membranes and in solubilised membrane 
preparations [Schlessinger, et al, 1978a; Yarden, et al, 1987]. The use of non­
denaturing gel electrophoresis has demonstrated the irreversible, temperature 
dependent, formation of high molecular weight forms of the EGFR consistent with 
receptor dimérisation. This ability to undergo oligomerisation is an intrinsic process 
and is essential to signalling via the receptor [Yarden, et al, 1987]. Chemical cross 
linking studies have shown that EGF induces dimérisation in whole cells [Cochet, 
et al, 1988]. Antibody studies have demonstrated that oligomerisation of receptors 
alone may be sufficient for receptor activation. The EGFR can be activated by 
bivalent or multivalent antibodies but not by Fab fragments which lack the ability to 
cross link receptor monomers [Schreiber, et al, 1983]. Further evidence of the 
importance of dimérisation in the activation of the receptor comes from mutational 
studies. Insertion of an extra Cys into the extracellular region of EGFR results in a 
constitutively active dimeric receptor [Sorokin, et al, 1994]. The oncogenic activity 
of the neu oncogene has also been attributed to an intermolecular interaction
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stabilising a dimeric form of the receptor to result in a constitutively active receptor 
[Weiner, etal, 1989].
Intermolecular activation of the EGFR requires the receptor to be mobile on the cell 
surface in order to allow interactions between monomers. EGFR mobility has been 
measured by a number of methods and in a number of systems. The lateral 
diffusion coefficient, D l for EGFR is in the range of 2.8xlO'i® to 8.5 xlO cm^s-i 
[Schlessinger, et al 1978b; Hillman, et al, 1982; Rees, et al, 1984]. Such rapid 
diffusion rates make the intermolecular model of receptor activation kinetically 
feasible [Schlessinger, 1988].
A general oligomerisation model has been proposed for activation of growth factor 
receptor kinases and has been confirmed for the EGFR . This model holds that 
inactive receptor monomers exist in a state of equilibrium with active receptor 
dimers and that ligand binding increases the receptors affinity for its neighbours 
and stabilises the dimeric form [Schlessinger, 1988]. Receptor dimers possess 
enhanced binding affinity for EGF and elevated levels of PTK activity. Although it 
has been assumed that stabilisation of the dimeric form of the receptor is due to a 
conformational change induced by ligand binding, some evidence now exists that 
EGF may be a dimer in solution [Lemmon, et al, 1994].
Receptor binding studies in a number of cell types have shown that the EGFR exists 
in two forms with distinct affinities for EGF. 5-10% of the total receptor is a high 
affinity form with Kq of 1-3 XlO^i^M while the remaining receptors have a low 
affinity with Kq 2-15 XlQ-^M. Mitogenicity has been attributed to the high affinity 
receptors [Shechter, et al, 1978; Kawamoto, et al, 1983; King, et al, 1982] It has 
been proposed that the high affinity sites represent oligomeric forms of the receptor 
while the low affinity form represents receptor monomers. Measurements of lateral 
diffusion suggested that the low affinity receptors are highly mobile while the high
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affinity types are essentially immobile which would be consistent with the 
oligomerisation model [Rees, etal, 1984].
This allosteric model of activation can also be applied to heterodimeri sation such as 
the interaction between EGFR and erbB-2 and other members of the family of type I
1 growth factor receptors. Although erbB-2 does not bind EGF, EGF stimulation of 
cells results in rapid tyrosine phosphorylation of erbB-2. This could occur via the j
formation of heterodimers in which EGFR activates erbB-2. Heterodimers of I
EGFR and c-erbB-2 which have a higher affinity for EGF than EGFR homodimers I
have been demonstrated and in cells expressing both molecules, heterodimeri sation ;
is preferred [Dougall, et al, 1993]. Heterodimerisation of members of the EGFR :
family may serve to increase the diversity of signalling both through altered ligand i
binding and interaction with cytoplasmic signalling pathways. Since EGFR and c- 
erbB-2 have different autophosphorylation sites, each would recruit a different set 
of downstream proteins (Section 2.3.4.) and this has the potential to increase the 
diversity of signalling [Lemmon, et al, 1994]. The existence of two further 
members of the family which can form hetero-oligomers, c-erbB-3 and c-erbB-4, 
further increases this potential [Carraway, et al, 1994],
2 .3 . 4. Receptor autophosphorylation and signal transduction
Dimérisation and kinase activation of the EGFR leads to receptor auto­
phosphorylation and a further conformational change to facilitate binding and 
phosphorylation of cellular substrates [Dickson, et al, 1996a]. Evidence exists that 
autophosphorylation is an intermolecular process. Cross-phosphorylation of 
tyrosine kinase negative mutants occurs when they are coexpressed with wild type 
receptors. These mutant receptor are described as dominant -negative since they 
form inactive heterodimers with wild-type receptors when expressed in the same 
cell and inhibit the mitogenic response via the wild-type EGFR [Honegger, et al,
1989 & 1990].
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Autophosphorylation plays an important regulatory role in kinase activity [Bertics, 
et al, 1985]. Autophosphorylation sites in the EGFR lie at the C terminal of the 
receptor not within the kinase domain as in other receptors [Carpenter, 1987]. The 
sites can act as alternative substrates for the EGFR kinase - they can competitively 
inhibit the receptor but do not affect Vmax. Autophosphorylation acts to remove 
this competitive inhibition and allow exogenous substrates to be phosphorylated 
[Bertics, et al, 1988]. The molecule v-erbB which lacks this regulatory domain is 
proposed to function as an upregulated tyrosine kinase in virally transformed cells 
[Carpenter, 1987].
Autophosphorylation sites also act as specific recruitment sites for proteins which 
transmit the signal downstream of the receptor. These proteins are characterised by 
a conserved domain of approximately 100 amino acid residues known as a src- 
homology-2 (SH2) domain. This region forms a binding pocket for the 
phosphorylated tyrosine and the immediate surrounding residues on the receptor 
and thus mediates the interaction between the activated receptor and downstream 
signalling proteins [Boonstra, et al, 1995]. At least 7 SH2 domain containing 
proteins have been shown to associate with the EGFR including phospholipase Cyi 
(PLCyi), the ras GTPase activating protein (ras-GAP) and the p85 subunit of 
phosphoinositol-3-kinase [Margolis, eta l, 1989; Ellis, eta l, 1990; Hu, et al, 1992]. 
Further interactions occur indirectly via docking protein such as the adaptor protein 
ShC [Dickson, 1996a]. The specificity of the interaction of the tyrosine kinase with 
its substrates is determined by the sequences surrounding the autophosphorylation 
site and sequences within each SH2 domain [Carpenter, 1992]. The formation of 
receptor signalling complexes mediate the major effects of ligand-EGFR interaction 
on ion fluxes, cellular phosphorylation events, gene expression, DNA synthesis and 
malignant growth [Dickson, 1996a].
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One of the first characterised signal transduction cascades activated by the EGFR 
was PLCy and turnover of phosphatidylinositol bisphosphate (PIP2) [Margolis, et 
al, 1989; Meisenhelder, et al, 1989]. PLCy catalyses PIP2 to produce two second 
messengers - inositol trisphosphate (IP3) and diacylglycerol (DG). IP3 acts to 
release Ca^+ from intracellular stores resulting in raised intracellular Ca^+ levels 
and activation of the Ca^+/calmodulin dependent serine/threonine kinase,, while 
diacylglycerol activates protein kinase c (PKC) [Carpenter, 1992]. Activation of 
PKC has a regulatory role since the EGFR itself is a substrate for PKC. 
Phosphorylation by PKC on C terminal residues including Thr 654 leads to 
decreased EGFR kinase activity, decreases the receptors affinity for its ligand and 
attenuates the biological response to EGF [Hunter, et al, 1984; Downward, 1985; 
Livneh, etal, 1988].
2. 3 .5 . Receptor Internalisation and degradation
Electron microscope studies have shown that EGFR on the cell surface are initially 
diffusely distributed. On ligand binding they rapidly (within milliseconds) form 
clusters associated with coated pits and internalise - 84% of ferritin labelled EGF is 
internalised and localised to the lysosome after 30 min at 37°C [Haigler, et al, 
1979]. This process is highly temperature dependent with a maximal rate at 
physiological temperature [Wiley, etal, 1982].
Ligand binding results in rapid internalisation of the receptor [Carpenter, 1987] and 
degradation of both ligand and receptor in the lysosome [Dunn, et al, 1983; 
Benguinot, et al, 1984]. As a result ligand binding results in a substantial decrease 
in the number of cell surface receptors: a process called receptor down-regulation. 
As much as 80% of a cell's surface binding can be lost after exposure to growth 
factor and growth factor treatment also increases the rate of receptor degradation 
[Sorkin, et al, 1993]. EGF rapidly produces a 10-fold increase in the rate of
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receptor degradation (from a half life of 10 hours to 1 hour) but does not influence 
the biosynthesis of receptor molecules [Carpenter, 1985]. Receptors may also be 
recycled back to the cell surface after internalisation - this has been described in 
pancreatic carcinoma cells, 3T3 fibroblasts and hepatocytes [Korc, et al, 1985; 
Wakshull, etal, 1985; Gladhaug, etal, 1987].
EGFR receptors, unlike LDL receptors, only associate with clathrin coated pits after 
ligand binding. Ligand binding must therefore induce a conformational change in 
the receptor which facilitates clathrin binding [Schlessinger, 1986] Internalisation 
of complexes is essential for signal transduction [Decker, 1989]. C-terminal 
truncations of the receptor interfere with internalisation suggesting that intracellular 
sequences in the receptor are essential for endocytosis [Livneh, et al, 1986b]. The 
area of the receptor which appears to be essential for internalisation lies between 
residues 993 and 1022 at the C-terminus [Sorkin, et al, 1993]. These regions may 
be involved in interactions with clathrin coated pits [Sorkin, et al, 1996]. Tyrosine 
kinase activity is also essential for internalisation: internalisation is blocked by 
antibodies against phosphotyrosine [Glenney, et al, 1988] and studies have shown 
that a receptor deficient in PTK activity fails to cluster in coated pits or internalise 
[Lamaze, et al, 1995]. PTK activity appears to be essential for receptor degradation 
since the kinase negative mutant also failed to be targeted to the lysosome and was 
recycled to the cell surface [Honegger, et al, 1987b & 1989]. However, 
internalisation does not appear to be controlled by autophosphorylation since an 
EGFR lacking the major sites of autophosphorylation but possessing PTK activity, 
underwent normal ligand induced endocytosis [Glenney, etal, 1988]. The processes 
involved in normal receptor trafficking may be regulated by tyrosine 
phosphorylation of cellular substrates.
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The role of internalisation is unclear - internalised receptor complexes appear to 
have a high tyrosine kinase activity towards exogenous substrates [Cohen, et al, 
1985]. This may partly explain why although the initial process of activation and 
internalisation is very rapid, continual occupation of receptors for up to eight hours 
is required to commit Go cells to DNA synthesis - internalised receptor or its 
degradation products may be involved in this signalling [Kay, et al, 1986]. 
Internalisation also serves to remove complexes from the cell surface and 
attenuation o f the signal by internalisation may play an important role in 
modulating the cells proliferative response to EGF. Mutant receptors which have 
active tyrosine kinase but do not undergo internalisation, induce mitogenesis and 
transformation of normal fibroblasts at much lower ligand concentrations than wild 
type receptors [Wells, etal, 1990].
3. EGFR family and cancer
Abnormalities in growth factor signalling pathways, particularly altered levels of 
expression of normal receptor proteins and mRNAs, are very common in human 
malignancies. This frequency of occurrence suggests that overexpression of a 
normal growth factor or its receptor is a cause and not a consequence of malignant 
transformation. Such overexpression may confer a selective growth advantage on a 
cell progressing along the malignant pathway by enhancing the level of stimulation 
of proliferation [Gullick, 1991]. Since members of the EGFR family and their 
ligands are frequently overexpressed they have been implicated in breast cancer 
development
3 .1 . EGFR in breast cancer
Although studies have demonstrated oncogenic activation of the EGFR by 
structural alterations, receptor overexpression is a much more common feature of 
human cancers [Dickson, et al, 1996a]. The first demonstration of elevated levels of 
EGFR was in frozen sections of lung tumours [Hendler, et al, 1984]. Normal breast
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epithelial cells express the EGF receptor at a low level while elevated expression is 
found in many breast cell lines and also in breast tumours [VanAgthoven, et al, 
1994]. EGFR expression is found in approximately 35-60% of primary breast 
tumours with no clear differences in positivity observed between the different assay 
methods used [Clark, 1996]. Many different tumour types have now been 
examined for elevated levels of the receptor and a significant number of tumours of 
the brain, lung, bladder, head and neck, and gastric tumours have been shown to 
overexpress EGFR. Overexpression has also been detected in cell lines derived 
from many of these tumour types [Gullick, 1990]. In breast cancer, overexpression 
is only rarely due to amplification of the EGFR gene -only 2% of cases. 
Differences in expression occur at the transcription and protein levels [Chrysogelos, 
1994]. By contrast, in head and neck tumours the most common mechanism of 
overexpression is gene amplification [Dickson, etal, 1996a].
In 1987, the EGFR and its ligands were directly implicated in the process of cancer 
development. Overexpression of normal EGFR in transfected fibroblasts resulted 
in cell transformation but only in the presence of the ligand, EGF [Di Fiore, et al, 
1987a]. Coexpression of EGFR and TG Fa in the same cells also resulted in 
transformation - a process mirrored in actual tumours where the genes for both the 
receptor and ligand are commonly overexpressed [Derynck, et al, 1987; Di Marco, 
et al, 1989; Castellani, et al, 1994]. High TGFa levels and elevated EGFR 
expression were also found in cell lines derived form breast tumours [Ennis, et al,
1989]. TGFa can induce cell transformation in culture but is known to be only 
weakly transforming alone [DeLarco, et al, 1978; Derynck, 1988]. It has been 
proposed that TGFa functions in malignant transformation via an autocrine loop i.e. 
the tumour produces TG Fa which stimulates its own proliferation via the EGFR. 
In tumours expressing both components of this autocrine system i.e. TGFa or EGF 
and the EGFR, growth may proceed at an advanced rate. Autocrine growth may 
account for the reduced requirement for serum for the growth of transformed cells
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in culture since these would have a lesser need for exogenous growth factors 
[Sporn, et al, 1980].
In ER positive cell lines expression of EGF and TG Fa has been shown to be 
influenced by estrogen [Bates, et al, 1988]. Both these growth factors have been 
shown to be produced by breast tumours, although TGFa is perhaps the principal 
ligand in tumour tissue. Thus it is possible that, in addition to its direct effect on 
breast tissue, estrogen exerts its mitogenic effect indirectly by stimulating the 
production and secretion of peptide mitogens such as TGFa which in turn stimulate 
cell growth [Kon, 1989]. Conversely, the antiestrogen tamoxifen inhibits estrogen 
stimulated secretion of TGFa and EGF and reduces the amount of TGFa in human 
breast cancer biopsies [Dickson, et al, 1987; Gullick, 1990]. Abnormal or 
constitutive overexpression of these secondary factors may represent one 
mechanism by which cells overcome their estrogen dependence. In hormone 
independent breast cell lines, TGFa is produced constitutively which is consistent 
with the idea that growth factors are involved in a more malignant, hormone 
independent phenotype [Dickson, etal, 1988].
Evidence exists which indicates an in vivo role for the TGFo/EGFR pathway in the 
development of breast cancer. Transgenic mice which overexpress TG Fa in 
multiple tissues, frequently develop adenocarcinoma of the mammary gland. This 
suggests TGFa is oncogenic in breast tissue in vivo [Sandgren, et al, 1990].
3 .2 . C-erbB-2 in breast cancer
C-erbB-2 is normally expressed at low levels in epithelial and myoepithelial cells of 
normal breast tissue [Gullick, 1990]. The c-erbB-2 gene is amplified and/or 
overexpressed in between 10% and 30% of breast, ovarian and gastric cancers and 
occasionally, in some other tumour types such as colon, oesophageal, kidney and 
bladder cancers [Gullick, et al, 1989]. The most common mechanism (90% of
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human cancers although expression of both proteins has been detected in human 
breast cancer cells [Kraus, et al, 1989; Plowman, et al, 1993].
cases) resulting in high c-erbB-2 protein expression is gene amplification [Hynes, et
al, 1994]. C-erbB-2 overexpression has been found in all stages of breast
.carcinoma, but not benign breast disease suggesting the gene is not amplified before 
the onset of true malignancy and is an early event in tumorigenesis [Gusterson, et 
al, 1988]. Metastatic lesions continue to express c-erbB-2 suggesting a continuing 
function for the protein [Hynes, et al, 1994]. c-erbB-2 has also been examined for 
its prognostic significance since an early study demonstrated an association 
between amplification of c-erbB-2 oncogene and poor prognosis in breast cancer 
[Slamon, etal, 1987] (Section 3.3.2.).
It has been demonstrated that overexpression of the normal c-erbB-2 gene also 
results in transformation of fibroblasts. This overexpression was suggested to be 
more potent as a transforming agent than overexpression of EGFR [Di Fiore, et al, 
1987b]. Analysis of the c-erbB-2 gene in human breast cancer cells has 
demonstrated amplified levels consistent with this model of transformation 
[Gullick, 1990]. There is no evidence to suggest that a structural mutation similar 
to that found in the transmembrane region of neu is involved in human breast 
cancer [Lemoine, et al, 1989].
It remains to be determined if c-erbB-3 and c-erbB-4 are similarly overexpressed in
3. 3. EGFR family and prognosis in breast cancer
3. 3 .1 . EGFR
In 1985, a study of 104 breast tumours reported that there was a significant inverse 
relationship between EGFR and ER and that a greater number of EGFR were found 
in metastatic tumours compared to primary tumours [Sainsbury, et al, 1985]. A 
further study of 135 primary tumours confirmed the existence of an inverse
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relationship with ER status and suggested EGFR as a potential indicator of 
prognosis. EGFR positivity in primary tumours was higher in node-positive than 
node-negative tumours and EGFR-positive tumours had a significantly lower 
relapse free survival (RFS) and overall survival (OS) than EGFR-negative tumours. 
EGFR was found to subdivide the ER-positive group into good and poor prognosis 
subgroups [Sainsbury, et al, 1987]. Several studies have now reported on the 
relationship between EGFR status and survival. Of fifteen studies reviewed in 1994, 
five studies showed a significant relationship between EGFR status and RFS and 
OS [Klijn, et al, 1994]. In one study EGFR status was the most important variable 
in determining RFS and OS in node negative patients and second only to lymph 
node status in node positive [Sainsbury, et al, 1987]. Prognostic factors are of 
particular importance in the node-negative subgroup in making decisions about 
adjuvant therapy. However, although EGFR had prognostic significance at 5 year 
follow-up, this significance was lost by 10 years [Klijn, et al, 1994]. Such a loss of 
prognostic significance with long term follow-up has also been reported for ER 
status [Clark, 1996].
The role of EGFR as a predictive factor for hormone responsiveness or resistance is 
perhaps better defined. Cell culture studies suggest an association between EGFR 
and hormone resistance. Transfection of EGFR into hormone dependent cancer 
cells induces progression to a hormone independent state and acquired tamoxifen 
resistance in cell lines is associated with elevated EGFR [Van Agthoven, et al, 
1992; Long, et al, 1992]. Several studies in breast cancer patients have shown that 
EGFR positive tumours, even when also ER positive, are more likely to be resistant 
to endocrine therapy which suggests that coexpression of EGFR tends to overide 
the beneficial effects of ER status [Nicholson, et al, 1989, 1991 & 1993]. 
Conversely EGFR negative patients, particularly if also ER positive, tend to have 
high response rates to endocrine therapy [Clark, 1996]. One study reported that the 
response rate for such patients is 80% with 43% achieving complete or partial
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remission [Nicholson, et al, 1994]. EGFR may therefore identify a poor prognosis 
subgroup of patients best treated with initial chemotherapy [Klijn, et al, 1993].
Since the first demonstration of a relationship, many groups have also demonstrated 
a strong negative relationship with ER status [Clark, 1996] Mean EGFR positivity 
is twice as high in ER- or PR-negative patients than in ER- or PR-positive patients 
[Klijn, et al, 1992]. Such inverse correlation is also found in breast cell lines 
[Davidson, etal, 1987]. It appears that in breast tumours, but not in normal tissue, 
ER and EGFR expression are mutually exclusive within individual cells although 
both may be present in the tumour [Van Agthoven, et al, 1994]. There is also 
evidence of a statistically significant association between EGFR and poor tumour 
grades and increased proliferation indices [Clark, 1996]. A few studies report an 
association with age, menopausal status, histological type, tumour size and axillary 
node status but evidence on these associations is generally unclear or conflicting 
[Klijn, et al, 1992]. EGFR may also be correlated with overexpression of mutated 
p53 or angiogenesis factors [Clark, 1996].
Studies in multi drug resistant cell lines have shown onset o f drug resistance is 
associated with enhanced expression of EGFR and hormone insensitivity [Vickers, 
et al, 1988; Dickstein, et al, 1993]. EGF treatment has been shown to protect breast 
tumour cells from actinomycin D cytotoxicity which suggests a role for EGFR in 
the drug resistant phenotype. It is possible that EGFR signalling pathways control 
p-glycoprotein function at transcriptional or protein levels and would be consistent 
with data which suggests that EGFR positive tumours respond less well to 
chemotherapy [Davies, et al, 1996].
3. 3. 2. C-erbB-2
An initial study of c-erbB-2 in breast cancer showed a strong association between c- 
erbB-2 and short relapse free interval and survival [Slamon, et al, 1987]. c-erbB-2 3
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has been proposed as an independent indicator of poor prognosis in node positive 
breast cancer patients [Slamon, et al, 1989]. Further studies which examined the 
ability of c-erbB-2 status to predict clinical behaviour, particularly those involving 
large patient numbers, have also tended to reveal a significant association between 
elevated levels of c-erbB-2 and poor prognosis in node positive patients [Barnes, 
1993]. Conflicting evidence does exist on the prognostic significance of c-erbB-2 
in node positive patients and c-erbB-2 is not generally found to be prognostic in the 
node negative subgroup [Hartmann, et al, 1993; Clark, 1996]. An association 
between c-erbB-2 and poor prognosis has also been demonstrated in ovarian and 
lung cancers [Slamon, et al, 1989; Kern, etal, 1990].
Some studies suggest that co-expression of EGFR and c-erbB-2 has an additive 
adverse effect and this may reflect the high PTK activity of the heterodimers 
[Harris, et al, 1989; Wright, et al, 1992a]. Cell culture studies show that 
coexpression of EGFR and c-erbB-2 at levels which are not on their own 
transforming induces transformation of mouse fibroblasts [Kokai, et al, 1989]. 
There is however no consensus on a positive relationship between EGFR and c- 
erbB-2 in breast cancer [Klijn, et al, 1992]. Studies suggest that while erbB-2 is an 
independent prognostic indictor, a combination of c-erbB-2 and EGFR expression 
has an additive adverse effect [Harris, etal, 1989; Nicholson, et al, 1990].
ErbB-2 expression has also been studied as a predictive indicator for response to 
hormonal and chemotherapy. Some evidence suggests that c-erbB-2 overexpression 
may be associated with a reduced response to endocrine therapy and chemotherapy 
[Barnes, 1993]. Several studies have shown that erbB-2 expression correlates with 
a poor response to tamoxifen [Nicholson, et al, 1990; Wright, et al, 1992a; Hynes, 
et al, 1994]. The association between c-erbB-2 and poor response to tamoxifen is 
found in both ER-positive and -negative tumours [Nicholson, et al, 1990]. In ER 
positive breast cell lines, tamoxifen increases erbB-2 expression and enhances
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signalling via the erbB-2 pathway [Taverna, et al, 1994]. This is decreased by 
estradiol. Tamoxifen also induces the expression of erbB-2 immunoreactivity in 
vivo [Johnston, et al, 1993]. In one study patients with elevated c-erbB-2 who had 
a poor response to tamoxifen, responded to chemotherapy better than patients with 
low erbB-2 levels [Klijn, et al, 1993]. However other studies show that high erbB- 
2 correlates with a poor response to chemotherapy.[Gusterson, et al, 1992; Wright, 
etal, 1992b].
The relationship between c-erbB-2 expression and other indicators of prognosis has 
been extensively studied but many of these have produced conflicting results. Most 
studies found no association between c-erbB-2 and nodal status [Slamon, et al, 
1987; Wright, et al, 1989]. The majority of studies relating c-erbB-2 to steroid 
receptor status demonstrate a moderately strong inverse relationship between 
expression and ER status and possibly a weaker relationship with PR status 
[Gullick, 1990]. c-erbB-2 may also be associated with increasing tumour grade and 
large tumour size [Gullick, 1990].
Definitive information is not yet available about the prognostic, or predictive 
significance, of c-erbB-3 or c-erbB-4 [Clark, 1996]. Preliminary studies however, 
suggest that erbB-4 may be an indicator of good prognosis [Bacus, et al, 1994].
3 .4 . EGFR and c-erbB-2 as therapeutic targets
The association of expression of EGFR and c-erbB-2 and poor prognosis makes 
these receptors an obvious target for therapeutic intervention [Baselga, et al, 1994]. 
A problem arises in selective targeting to tumours since both receptors are 
expressed by normal tissue in a non-mutated form. One area of interest is 
interfering with signal transduction via the receptor. Tyrosine kinase inhibitors 
such as tyrphostins are being examined for their anticancer potential [Reddy, et al,
1992]. Although these compounds target the ATP binding site common to many
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kinases, specificity to individual tyrosine kinases has been achieved. One 
compound PD153035 has a Ki of 5pM for EGFR whereas other tyrosine kinases are 
inhibited at micromolar concentrations [Fry, et al, 1994]. Antibodies raised against 
the ligand binding site of the EGFR can block cell proliferation and a number of 
such antibodies have entered clinical trials [Baselga, et al, 1994].
4. Membrane fluidity
4 .1 . Introduction
Membranes are of fundamental importance to cell structure and function. All 
biological membranes have a common composition and structure with the major 
constituents being lipids, such as phospholipids, and proteins. The fluid mosaic 
model proposed by Singer and Nicholson in 1972 is still the simplest structural 
description of biological membranes. In this model, membrane lipids are organised 
into a bilayer which is associated with both integral and peripheral membrane 
proteins [Singer, et al, 1972]. The membrane is not rigid but is essentially a two- 
dimensional dynamic structure in which both lipids and proteins freely diffuse.
There are three potential forms of movement for membrane components:
(i) Lateral diffusion where molecules move within the plane of the 
membrane.
(ii) Rotation of membrane components along axes perpendicular to the plane 
of the membrane.
(iii) Transbilayer movement or 'flip-flop' from one leaflet of the bilayer to 
another. This would be highly energetically unfavourable for proteins 
with the need for large hydrophilic peptides to traverse the hydrophobic 
interior of the bilayer, but enzymes (flippases) do exist which speed the 
rate of flip-flop of lipids [Menon, 1995].
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In many respects, the classic fluid-mosaic model is an oversimplification. Different 
classes of lipids are not homogeneously distributed throughout the membrane but 
may exist in distinct domains which have a different structure and physical 
properties to other parts of the membrane [Klausner, et al, 1980; Tocanne, et al, 
1988]. The distribution and mobility of membrane proteins also varies. Some 
proteins, such as rhodopsin, may be free to diffuse while others are partly or even 
completely immobilised. In reconstituted synthetic bilayers proteins may diffuse 
freely and rapidly, but the majority of membrane proteins in vivo either diffuse at a 
very slow rate or are essentially immobile [Cherry, 1979].
4. 2. Factors which affect lipid and protein fluidity
Membrane lipid fluidity is influenced by a number of factors. The most important 
parameter in determining membrane fluidity is the cholesterol/ phospholipid ratio - 
the higher this ratio the lower the membrane fluidity. Cholesterol increases 
membrane microviscosity which increases the degree of order of the lipid domain 
[Shinitsky, 1984]. The phospholipid sphingomyelin has a similar effect due to the 
rigid conformation of its apolar chains at physiological temperatures [Van 
Blitterswijk, 1984]. The next most important parameter determining membrane 
fluidity is the degree of unsaturation of the phospholipid acyl chains. 
Polyunsaturated fatty acids such as linolenic acid and arachidonic acid have a 
marked fluidising effect on the membrane [Van Blitterswijk, 1988]. Finally, 
membrane proteins have an ordering effect on the membrane similar to the effect of 
cholesterol [Van Blitterswijk, 1984].
The lateral diffusion of membrane proteins may be constrained in several ways. 
This may be the result of viscous resistance of the bilayer or the formation of 
aggregates [Jacobsen, et al, 1987]. Steric inhibitions due to high concentrations of 
receptor in the membrane can also restrict protein diffusion. Studies in liposomes 
reveal that the diffusion of bacteriorhodopsin decreases with increasing protein
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content [Jacobsen, et al, 1987]. Protein lateral diffusion may also be constrained by 
interactions between the protein and immobile elements in the cell interior. Lateral 
diffusion of the erythrocyte Band 3 protein is restricted by its interaction with 
spectrin in the red cell cytoskeleton while deletion of the cytoplasmic domain of 
major histocompatibility (MHC) class II antigens significantly increases their 
lateral diffusion [Wade, et al, 1989]. However, the EGFR, like MHC Class 1 
antigens and VSV-G glycoproteins, appears not to be constrained by cytoskeletal 
interactions since deletions of large parts of the cytoplasmic domain do not affect 
its lateral diffusion [Livneh, et al, 1986a]. The extracellular matrix may also play a 
role in constraining protein diffusion - the major determinant of the mobility of 
VSV-G glycoprotein is located in the extracellular domain [Zhang, et al, 1992]. In 
confluent cultured cells the major constraint to lateral diffusion may be the 
association between major histocompatibility antigens and the extracellular matrix 
[Weir, et al, 1986]. Lateral diffusion of proteins in reconstituted lipid vesicles 
which lack a cytoskeleton or extracellular matrix is similar to that of lipids. 
Diffusion of the same proteins in intact cells is at least 100-fold slower suggesting 
that interactions with other elements of the cell are indeed responsible for the 
reduction in rate. The mobile fraction in intact cells is also typically less than the 
100% measured in artificial bilayers [Jacobsen, et al, 1987].
Protein diffusion may also be affected by the presence of lipid domains which 
restrict the areas within which proteins are free to diffuse [Tocanne, et al, 1988]. 
For example, sodium channels in cultured neuronal cells have a rapid diffusion over 
the cell body with almost complete recovery, a reduced rate and extent of diffusion 
over the hillock region of the cell while at the presynaptic ending the channels are 
almost immobile [Angelides, et al, 1988]. Macrodomains are particularly well 
defined in epithelial cells where the maintenance of the cells polarity is critical in its 
function - it is probable that apical and basolateral domains are preserved by 
cytoskeletal attachments and the physical barrier formed by tight junctions
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[Jacobsen, et al, 1987]. A large body of evidence suggests that smaller domains 
(microdomains) which differ in composition and/or physical state of lipids are also 
present in membranes. These domains could explain the existence of lipid immobile 
fractions which are a common feature of many cells and may have implications for 
the function of proteins located within them [Klausner, et al, 1980; Tocanne, et al, 
1988].
4. 3. Measurement of membrane fluidity
Lateral diffusion of membrane proteins was first demonstrated in 1970 by a fusion 
experiment. A mouse and a human cell line were labelled with rhodamine and 
fluorescein respectively which allowed the surface antigens from each to be 
distinguished. After fusion of the two cell types, it was observed that protein 
diffusion must have occurred since the two labels were both heterogeneously 
distributed over the surface of the heterokaryon [Frye, et al, 1970].
The rate of lateral diffusion of a protein was first quantified in 1974. The lateral 
diffusion coefficient (Dl) of rhodopsin in the disc membrane of rod outer segments 
was estimated to be 3 .5 x 1 0 - 9  cm^s"l. In this experiment rhodopsin in one half of 
the membrane was bleached with a pulse of light to create an asymmetric 
distribution of rhodopsin across the rod. The rate of return to a symmetric 
distribution was then measured spectrophotometrically [Poo, et al, 1974]. This 
technique formed the basis of fluorescence recovery after photobleaching or FRAP 
(also known as fluorescence photobleaching recovery (FPR) or fluorescence 
microphotolysis).
FRAP enables the study of the lateral motion of lipids and proteins within the intact 
bilayer of single cells. Poo and Cone utilised the intrinsic natural chromophore of 
rhodopsin, retinal, but in the majority of experiments the molecule of interest must 
first be labelled . Fluorescent labels allow a high level of sensitivity of detection.
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Methods of labelling include the insertion of fluorescent lipid analogues into the 
bilayer [Cherry, 1979], labelling of proteins with fluorescent antibodies, Fab 
fragments or lectins [Jacobsen, et al, 1984; Jesaitis, et al, 1986] or the use of 
fluorescent ligands to label receptors [Shechter, et al, 1978]. The advantage of the 
FRAP technique is that it is non-invasive and can be applied to a single intact cell 
or even a small section of the cell surface [Cherry, 1979].
The FRAP technique is discussed in more detail in Chapter 2 but briefly the 
technique is as follows. A low power argon laser beam is focused on a small area 
(1.5|im) of membrane. The laser light excites the fluorophores in this area causing 
them to fluoresce. The power of the laser is then briefly increased which 
irreversibly bleaches the fluorescence in that area of the membrane and creates a 
concentration gradient of labelled molecules. By monitoring changes in the level of 
fluorescence the recovery of fluorescence due to unbleached molecules diffusing 
into the area can be followed. Figure 2 shows an idealised recovery curve of the 
type obtained by this method. Information on both the rate of recovery and the 
fraction of molecules which are free to diffuse can be obtained by analysis of such 
traces [Axelrod, et al, 1976] (Section 6.2). Typically the measured recovery in cell 
membranes is less than 100% indicating that a proportion of the total protein is 
immobile within the timescale of the experiment. FRAP experiments have 
determined that the diffusion coefficients (D l)  of lipids are in the order of 10"8 
cm^s"!. The lateral mobility of proteins varies markedly from a highly mobile 
protein like rhodopsin with a D l of 4xl0"9cm^s'^ to a relatively immobile protein 
like the major surface glycoprotein of fibroblasts with a D l of lO-^^cm^s'^ [Cherry, 
1979].
A number of other techniques exist to measure fluidity including fluorescence 
polarisation, nuclear magnetic resonance and electron spin resonance [Van 
Blitterswijk, 1984]. Fluorescence polarisation is probably the most widely used of
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Figure 2. Principle of fluorescence recovery after photobleaching (FRAP) 
- diagram of an idealised recovery curve obtained by FRAP
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these techniques. Fluorescent probes inserted into the membrane are excited with 
plane-polarised light. The polarisation of the emitted light will vary depending on 
the extent of molecular motion during the lifetime of the excited state from fully 
polarised, when the fluorophore is rigidly fixed, to unpolarised if the fiuorophore 
moves rapidly. Comparison of the steady-state fluorescence polarisation of the 
same probe embedded in different membrane environments gives an assessment of 
the relative fluidity of these membranes [Van Blitterswijk, 1981]. The most 
popular probes used for fluorescence polarisation are 1,6-diphenyl-1,3,5,-hexatriene 
(DPH) and its 4'-trimethylamino derivative (TMP-DPH) [Bashford, 1994]. In whole 
cells these membrane permeant probes will report an average fluidity weighted 
according to the distribution of dye among varying membrane compartments 
including endomembranes and cytoplasmic lipid droplets [Van Blitterswijk, et al, 
1981]. The probes also partition equally into lipid phase domains and thus the 
measured fluidity gives no resolution of membrane domains.
4. 4. Criticisms of the FRAP technique
The use of a very intense bleaching pulse of laser light in FRAP measurements has 
led to a number of criticisms of this technique. It has been suggested that the laser is 
responsible for the slow rates of protein diffusion and incomplete recoveries. 
Although intense light may cause protein cross-linking, this does not appear to be a 
problem with the short time of bleach pulse in experimental FRAP [Sheetz, et al, 
1979]. Examination of cells after FRAP measurements by scanning electron 
microscopy showed no evidence of damage to the cell membrane. The cells were 
also shown to remain viable and thus it was concluded that cellular damage caused 
by FRAP is not responsible for low recovery rates and slow diffusion coefficients 
observed in some experiments [Jacobsen, et al, 1978]. Values for rhodopsin fluidity 
obtained by FRAP closely agree with those obtained by the original absorption 
experiment [Wey, et al, 1981], In addition, values obtained by FRAP for H2 
antigens from mouse fibroblasts were similar to the heterokaryon experiments
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[Edidin, et al, 1982]. Recovery kinetics are also not apparently affected by repeated 
bleaching of the same spot or by ten-fold changes in bleaching intensity [Jacobsen, 
et al, 1978], Local heating effects on the cell surface could conceivably cause 
problems with FRAP. However, calculations show that any local heating produced 
by FRAP is negligible (0.03%) [Axelrod, 1977]. Thus damage to cells induced by 
the technique of FRAP itself does not appear to be a significant factor influencing 
the experimental data produced by such studies.
4.5 . Role of membrane fluidity in cellular functions
It is now clear that membrane fluidity strongly influences many cellular processes 
including activity of membrane associated enzymes, receptors and channels 
[Shinitsky, 1984]. The enzyme adenylate cyclase is highly dependent on membrane 
fluidity. Adenylate cyclase activity decreases when membrane fluidity is decreased 
by increased cholesterol content. This is probably due to decreased efficacy of 
collision coupling between the enzyme and the occupied receptor [Houslay, 1985]. 
In the retina, lateral diffusion of bleached rhodopsin molecules is a critical step 
whereby photons are converted to electrical signals [Axelrod, 1983]. Lateral 
diffusion allows a single photoexcited rhodopsin molecule to activate the G-protein 
transducin and triggers a cascade which leads to hyperpolarisation of the outer rod 
segment and subsequent nerve transmission [Stryer, 1987]. Lateral diffusion may 
also play a role in cell invasion by viruses. During Semliki Forest virus infection, 
newly synthesised viral glycoproteins diffuse from random sites of incorporation in 
the cell membrane to form aggregates at the viral capsid. Cells with greater fluidity 
are more susceptible to expression of early viral antigens during Epstein Barr virus 
infection [Pozzi, et al, 1996].
Membrane fluidity and lateral diffusion are important in the activation of many 
cellular receptors. The binding characteristics of cell surface membrane antigens 
and receptors to their ligands has been shown to be altered by modification of the
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membrane lipid composition and fluidity [Axelrod, 1983; Neufeld, 1986]. 
Clustering of many receptors such as the insulin and EGF receptors is an essential 
step in their activation (Section 2.3.3.). Multivalent antibodies which can induce 
receptor clustering, can induce some of the mitogenic effects of EGF and results in 
internalisation of the receptor. However, monovalent Fab fragments which cannot 
induce clustering, do not have mitogenic activity although this can be restored by 
crosslinking the fragments with anti-immunoglobulin antibodies [Schreiber, et al,
1983]. Since these receptors are initially diffusely distributed on the membrane 
surface [Schlessinger, et al, 1978a], aggregation presumably involves lateral 
diffusion of receptor monomers . Both the EGFR and the insulin receptor have 
been demonstrated to be laterally mobile by FRAP [Schlessinger, et al, 1978b]. 
Clustering is also essential for internalisation of receptors. Thus both the activation 
and down-regulation of transmembrane tyrosine kinase receptors is dependant on 
the lateral motion of receptor molecules within the bilayer.
Carrier-mediated transport processes are also affected by membrane fluidity 
[Axelrod, 1983]. An increase in cholesterol content, which would stabilise lipid 
fluidity of the membrane, increases the activity of the organic cation transporter in 
renal brush border membranes [Nabekura, et al, 1996]. The activity of p- 
glycoprotein, the membrane associated ATP dependent pump which is involved in 
multi-drug resistance is altered by agents which modulate membrane fluidity such 
as tamoxifen or detergents (Section 4.6.2.). Increased membrane fluidity or rigidity 
may alter the activity of channels by increasing membrane resistance to protein 
conformational changes [Wadkins, et al, 1993].
4. 6. Membrane fluidity and cancer
Many studies have examined changes in membrane fluidity in the development of 
cancer. Factors examined include both the chemical composition of membrane 
such as cholesterol content or the degree of unsaturation and physical techniques for
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measuring fluidity such as fluorescence polarisation and FRAP [van Blitterswijk, 
1984]. Changes in fluidity parameters have been found in almost all types of 
tumour cell examined but the physiological significance of such changes remains 
unclear. Alterations may be commonly found because tumour cells lack the 
homeostatic mechanisms which maintain correct fluidity in normal cells [Shinitsky,
1984].
Transformed fibroblasts have reduced lipid fluidity relative to non-transformed 
cells [Kawasaki, et al, 1989]. Leukaemia cells have been extensively examined for 
changes in both membrane composition and fluidity. The consensus of these 
studies is that leukaemia cells have increased membrane fluidity relative to normal 
blood cells. This is mainly due to a decrease in the cholesterol/phospholipid ratio 
[Deliconstantinos, 1987]. The magnitude of the increased membrane fluidity 
reflects the virulence of the leukaemic cells [Shinitsky, 1984]. The best studied 
solid tumour type, hepatomas, consistently show an increased cholesterol/ 
phospholipid ratio and an increased DPH fluorescence polarisation value indicating 
such tumours have a more rigid plasma membrane compared to normal liver cells 
[Galeotti, et al, 1984; Cheeseman, 1993]. Unfortunately, although membrane 
changes are relatively common in cancers, little overall consensus about the type of 
change exists [Van Blitterswijk, 1984].
Studies which have examined membrane fluidity in relation to metastasis have 
generally shown that increased metastatic potential is associate with increased 
membrane fluidity [Deliconstantinos, 1987; Taraboletti, et al, 1989]. This may be 
due to alterations in the mobility and cell surface exposure of antigens, receptors 
and adhesive molecules which may affect the metastatic process. Adhesion of 
tumour cells to endothelial cells is enhanced by increased membrane fluidity as a 
result of decreased cholesterol synthesis [Ramachandran, et al, 1986].
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Changes in membrane fluidity may be important in regulating the growth and 
metastasis of tumour cells by altering the activity of membrane bound receptors, 
enzymes and pumps (Section 4.5). Membrane modifying agents may therefore be 
effective against tumour growth by altering the activity of these molecules 
[Grunicke, 1991]. Changes already present in tumour membrane composition and 
fluidity may result in the cancer cell having a disadvantage compared with normal 
cells when treated such agents. Membrane active agents are being studied in an 
attempt to overcome drug resistance (Section 4.7). Alterations in membrane 
fluidity may also have an impact on immunotherapy for tumours by exposing or 
masking antigens and receptors on the cell surface. Increased rigidity of tumour 
cell membranes has been used to enhance their immunogenicity by exposing cryptic 
antigens [Skornik, etal, 1984].
4 .7 . The cel! membrane in drug resistance
4. 7 .1 . Changes in the plasma membrane in drug resistant cells
A number of studies have also looked at fluidity of drug resistant cells relative to 
their drug sensitive parent cells. Doxorubicin resistant P388 cells have a higher 
degree of lipid structural order and decreased fluidity relative to the parent cell line 
[Ramu, et al, 1983]. In Chinese hamster ovary cells a decrease in membrane fluidity 
is consistently found both in cells which are selected for drug resistance and cells 
which are transfected with the mdr gene [Callaghan, et al, 1992]. However these 
observed differences in fluidity are not consistent between different resistant cell 
lines - other studies report increases in membrane fluidity [Wheeler, et al, 1982; 
Rintoul, et al, 1984]. Changes in fluidity may be associated with alterations in 
membrane lipid composition. Although studies of drug resistant cells have shown 
no differences in gross lipid composition, significant differences may exist in minor 
lipid components [Callaghan, et al, 1992]. For example drug resistant P388 cells 
have an increased triacylglycerol content and phosphatidylethanolamine: 
sphingomyelin ratio relative to their drug sensitive parent [Ramu, et al, 1984a].
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The drug resistant line also has a higher cholesterol and lower phosphatidylserine 
content. This change in lipid composition has been suggested to contribute to the 
drug resistant phenotype [Escriba, et al, 1990]. Alterations in membrane fluidity 
may also result from changes in plasma membrane protein content such as 
overexpression of p-glycoprotein or EGFR [Meyers, et al, 1986; Vickers, et al, 
1988; Dickstein, et al, 1993]. Multidrug resistant cell lines have increased 
sensitivity to membrane active agents such as detergents and to disruption by 
physical shear. This could be due to disruption of normal membrane structure by 
lipid alterations or the high levels of membrane protein [Gottesman, 1993].
4. 7. 2. Agents which reverse drug resistance
Drug resistance is the major obstacle to successful treatment of cancer and the 
ability to overcome it is obviously a major goal in cancer chemotherapy. With the 
identification of p-glycoprotein as a mechanism for multidrug resistance, a target 
for anticancer therapy was identified. A number of agents which are capable of 
reversing p-glycoprotein mediated multi-drug resistance - chemosensitisers - have 
been identified both in vitro and in animal models [Lehnert, 1993]. It is believed 
that these compounds function by blocking p-glycoprotein mediated efflux of 
cytotoxic drugs thereby increasing the intracellular accumulation of the drug by 2- 
to 5- fold and restoring its cytotoxicity [Gottesman, et al, 1993].
An early observation was that the calcium channel blocker, verapamil, was capable 
of circumventing multidrug resistance [Tsuruo, et al, 1981]. Subsequently, a wide 
variety of drugs with a similar effect have been identified. Just as drugs transported 
by p-glycoprotein vary greatly, there is significant heterogeneity in drugs capable of 
reversing the phenotype. In addition to calcium channel blockers such as verapamil 
and nifedipine, calcium antagonists, steroids such as progesterone and tamoxifen 
and the immunosuppressants cyclosporin and FK506 have all been reported to 
circumvent multi-drug resistance [Gottesman, et al, 1993]. Tamoxifen's anti-mdr
47
action may be related to the drugs ability to reduce membrane fluidity [Kayyali, et 
al, 1994]. Many chemosensitisers are hydrophobic compounds which would be 
expected to interact with membrane lipids. P-glycoprotein function is affected by 
compounds which increase and decrease membrane fluidity. [Woodcock, et al, 
1992; Sinicrope, et al, 1992; Callaghan, et al, 1993]. A number of compounds 
which reverse multidrug resistance, including tamoxifen, have entered clinical trials 
[Bosch, etal, 1996].
5. Tamoxifen
5.1 . Introduction
Tamoxifen, (I- (p- dimethylaminoethoxyphenyl)- 1,2- trans-diethyl-but-1 -ene, ICI 
46,474) (Figure 3) is a synthetic triphenylethylene compound synthesised during 
the 1950’s and marketed by ICI under the brand name Nolvadex. It was initially 
developed as an anti-estrogen oral contraceptive but was found to be capable of 
inducing ovulation in subfertile women [Wolf, et al, 1995]. Subsequent research led 
to its use in endocrine therapy of breast cancer where the benefits of tamoxifen 
treatment were first observed in metastatic breast cancer: 22% of post menopausal 
patients responded to treatment with tumour regression [Cole, et al, 1971]. 
Adjuvant use of tamoxifen produces survival advantages and prevents the 
appearance of a second primary breast cancer [Early Breast Cancer Trialists' 
Collaborative Group, 1992; Plowman, 1993]. Currently, tamoxifen is the first line 
endocrine treatment of choice in both pre- and post-menopausal women with all 
stages of breast cancer [Wolf, et al, 1995]. Trials are also underway to evaluate the 
efficacy of tamoxifen as a preventative treatment in women at high risk of 
developing breast cancer [Nayfield, etal, 1991].
5. 2. Mechanism of action
Originally, the anti tumour action of tamoxifen was thought to be solely due to its 
ability to compete with estrogen for binding to the estrogen receptor which prevents
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estrogen stimulation of growth [Wakeling, et al, 1984]. Molecular modelling has 
shown that the compound is indeed capable of adopting a structural conformation 
which closely resembles the steroid nucleus [Wiseman, et al, 1992]. Tamoxifen 
also exhibits partial estrogen agonist action which again may be related to its 
similarity in conformation to estrogen itself (see below).
The active metabolite of tamoxifen, 4-hydroxytamoxifen, even more closely 
resembles this structure due to the possession of an OH group at an analogous 
position to the steroid [Wiseman, et al, 1992]. 4-hydroxytamoxifen which is 
produced in humans by the metabolism of tamoxifen by cytochrome p450 has a 
greater biological activity than tamoxifen. 4-hydroxytamoxifen binds to the ER 
with high affinity which is almost equivalent to estradiol and, like estradiol, has a 
slow dissociation rate from the receptor and can translocate ER to the nucleus. 
[Wiseman, 1994b].
The action of tamoxifen is influenced by the biological context in which it acts. 
Depending on the system under investigation, tamoxifen may act as an estrogen 
agonist, partial agonist or an antagonist. The agonist action of tamoxifen is also 
probably related to its conformational similarity to estrogen. The action may vary 
between animal species, cell type and even vary in the same tissue between in vivo 
and in vitro conditions [Wakeling, 1987a]. The agonist action of tamoxifen may 
account for one of the drug's serious side effects - an increased risk of endometrial 
cancer. The endometrium is strongly stimulated by estrogens and tamoxifen action 
in this tissue is predominantly estrogenic [Wolf, et al, 1995]. The standard dose of 
tamoxifen of lOmg twice a day is associated with a doubling of the risk of 
endometrial cancer [Fisher, et al, 1994], Tamoxifen also has beneficial side effects 
which have been ascribed to its estrogenic action. Tamoxifen has an estrogenic 
action in preserving bone density - of particular importance to post-menopausal 
women in preventing osteoporosis [Wolf, et al, 1995; Grainger, 1996]. Tamoxifen
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also has an estrogenic effect on serum cholesterol levels acting to reduce levels of 
the serum lipids cholesterol, LDL and apolipoprotein B which are all risk factors 
for heart disease[Wiseman, 1994b].
The assumption that the tamoxifen acts simply by competitive inhibition of the 
estrogen receptor is an oversimplification. Both estrogen receptor positive and 
negative cancer cells have been shown to respond to the drug [Taylor, et al, 1984; 
Chouvet, et al, 1988; Langdon, et al, 1990]. Inhibition of cell growth by 
micromolar concentrations of tamoxifen is not overcome by estradiol suggesting 
that the drug is not solely acting via the ER [Darbre, et al , 1984; Reddel, et al,
1985]. Tamoxifen resistance, which often occurs after an initial period of 
responsiveness, is not associated with a loss of estrogen receptor and this is also the 
case in variants of MCF-7 cells which have developed tamoxifen resistance - these 
have identical receptor levels to the wild type cells [Kon, 1989].
Tamoxifen is known to have a number of effects unrelated to its ability to act via 
the estrogen receptor. It is known to inhibit both protein kinase C and Ca^+- 
calmodulin-dependent cAMP phosphodiesterase [Lam, 1984; O ’Brian, et al, 1986]. 
It may be that tamoxifen's ability to inhibit cancer growth is due in part to its anti- 
PKC activity since agents which block PKC are often effective at inhibiting the 
tumour promoting activity of phorbol esters [Verma, 1988]. In hormone-dependent 
breast cell lines, tamoxifen can induce secretion of the negative growth regulator, 
transforming growth factor p (TGFp) [Knabbe, et al, 1987], Induction of TGFp by 
tamoxifen in tumours has been reported and this occurs in both ER-positive and 
-negative tumours [Butta, et al, 1992] TGFp has a negative effect on growth 
stimulation via the EGFR and this may partly account for the effects of tamoxifen 
on estrogen receptor negative cells [Arteaga, et al, 1988]. Tamoxifen also inhibits 
estrogen stimulated secretion of TGFa and EGF and long term tamoxifen treatment 
decreases EGFR expression [Dickson, et al, 1987; Berthois, et al, 1989],
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Triphenylethylene antiestrogens such as tamoxifen may also exert their effects via 
interactions with a group of proteins called antiestrogen binding sites (AEBS) 
[Wolf, et al, 1995]. AEBS are membrane-associated microsomal proteins which 
have been found in cell types examined including breast cancer cells [Watts, et al, 
1987].. Non-steroidal anti-estrogens bind to these sites with high affinity - the 
binding affinity to AEBS may be greater than to the ER. However, the actual 
cellular function of these proteins remains hypothetical [Wolf, et al, 1995].
Tamoxifen has been shown to affect the functioning of p-glycoprotein and thus 
potentiates the toxicity of chemotherapeutic drugs which are substrates for this 
protein. In cultured P388 leukaemia cells, tamoxifen can reverse doxorubicin 
resistance [Ramu, et al, 1984b]. Modulation of the action of p-glycoprotein has also 
been observed in other cell lines including breast cancer cells at clinically 
achievable concentrations of tamoxifen [Berman, et al, 1991; Leonessa, et al, 1994; 
De Vincenzo, et al, 1996]. This use for tamoxifen is now being investigated in 
clinical trials [Trump, et al, 1992; Mill ward, et al, 1992]. Although tamoxifen 
modulates the activity of pgp it is probably not a substrate for pgp [Wiseman, et al, 
1992]. This action is unlikely to be mediated by the estrogen receptor since it can 
be demonstrated in ER negative cells [De Vincenzo, et al, 1996]. Tamoxifen is 
highly lipophilic and can incorporate into membranes, decreasing membrane 
fluidity by a mechanism similar to cholesterol [Custodio, etal, 1993a]. Its ability to 
inhibit pgp may arise from this ability to decrease membrane fluidity sufficiently to 
sterically inhibit pgp function [Kayyali, et al, 1994]. Tamoxifen has also been 
shown to inhibit HIV virus production by cultured infected cells [Laurence, et al, 
1990]. This may be again due to its ability to decrease membrane fluidity which 
would inhibit lysis of viral infected cells [Wiseman, 1994b].
The use of tamoxifen is limited because some estrogen receptor positive tumours 
fail to respond to the drug initially while others develop resistance during tamoxifen
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treatment [Maass, eta l, 1980; Osborne, etal, 1992]. Cells treated with tamoxifen in 
the laboratory which are initially inhibited by anti-estrogens will also eventually 
develop drug resistance. However, patients who develop resistance to tamoxifen 
continue to respond to second and third line endocrine therapies indicating that 
resistance is a specific phenomenon and not a general loss of endocrine 
responsiveness [Wolf, etal, 1995].
5. 3. Pure Antiestrogens and other antiestrogens
Although the mixed agonist-antagonist action of non-steroidal antiestrogens such as 
tamoxifen are responsible for many of their beneficial side effects, many 
undesirable effects also occur e.g. endometrial stimulation, development of 
resistance and possibly, hepatic effects [Wolf, et al, 1995]. These problems led to 
the development of so called pure antiestrogens such as IC Il64,384 and 101182,780 
(Figure 3).
These new compounds are steroidal in base and should in theory exert only 
estrogen antagonist effects. The compounds are derived from 17(3-estradiol by 
addition of an alkyl chain substituted at the 7 a  position [Wakeling, 1987b; 
Wakeling, et al, 1991]. However these compounds do have effects in the absence 
of estrogens [Coradini, et al, 1994]
101164,384 binds to the estrogen receptor with a ten-fold higher affinity than 
tamoxifen and is more effective than tamoxifen in inhibiting the growth of 
estrogen-responsive breast cancer cells [Wakeling, eta l, 1988]. lOI 164,384 has no 
estrogenic effects on the uterus and competitively inhibits the trophic actions of 
tamoxifen on the uterus and mammary gland and on tamoxifen-resistant breast 
tumours [Wakeling, etal, 1989; Nicholson, et al, 1988; Gottardis, 1989]. However, 
ICI 164, 384 has poor oral bioavailability which led to the development of ICI 
182,780. This compound binds to the ER with the same affinity as estradiol and is
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more effective at inhibiting mammary tumour cell lines in vitro and transplants into 
nude mice in vivo [Wakeling, et al, 1991 & 1992]. ICIl 82,780 is also active against 
tamoxifen resistant tumours in vitro and in vivo and lacks a uterotrophic effect 
[Howell, et al, 1996]. Both ICI164,384 and ICI 182,780 have been reported to 
modulate the mdr phenotype in vitro [Kirk, etal, 1994; De Vincenzo, et al, 1996].
A number of new non-steroidal antiestrogens have also been developed. 
Toremifene is similar in effectiveness to tamoxifen but is less estrogenic. It has 
been studied as a potential modulator of multidrug resistance [Bajetta, et al, 1994; 
Howell, et al, 1996]. The tamoxifen derivative droloxifene (3-hydroxytamoxifen) 
has several advantages over tamoxifen including a shorter terminal elimination half 
life, lower accumulation, improved drug tolerability, decreased occurrence of 
resistance and decreased risk of endometrial cancer [Wiseman, 1994b], It is on 
clinical trial in women with advanced breast cancer [Bruning, 1992].
5. 4. Antioxidant action of tamoxifen
Antioxidants play an important role in protecting DNA, proteins and membrane 
lipids against oxidative damage. In the cell membrane, free radicals can cause lipid 
peroxidation, or oxidative breakdown, which leads to the formation of lipid 
hydroperoxides and to secondary products such as biologically active aldehydes. 
Lipid hydroperoxides themselves break down to generate radicals which further 
propagate lipid peroxidation in an autocatalytic process [Halliwell, 1989]. The 
process can be inhibited by antioxidants: preventative antioxidants which act to 
prevent lipid hydroperoxide breakdown and chain-breaking antioxidants which 
scavenge the free radicals that propagate the process [Cheeseman, 1993]. Many 
antioxidants are found in the diet including vitamins A, C and E [Hunter, 1996]. 
Damage due to lipid peroxidation is important in two respects; direct damage to the 
membrane structures and indirect damage caused by the release of active products. 
In cancer this is important since DNA damage as a result o f the products of
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membrane lipid peroxidation is likely to be important in malignant progression 
[Vaca, et al, 1988]. The products of lipid peroxidation have been demonstrated to 
be capable of tumour initiation [Chung, et al, 1993].
Tamoxifen and its derivatives and 17p estradiol have been shown to have an 
antioxidant action inhibiting lipid peroxidation in a number of model and native 
systems[Wiseman, et al, 1990a & 1990b]. This action is probably due to the ability 
of tamoxifen to stabilise the membrane in a mechanism similar to cholesterol 
[Wiseman, et al, 1990a & 1993a]. Cholesterol (and its derivatives) is thought to 
stabilise membranes against lipid peroxidation via an interaction between the 
hydrophobic rings of cholesterol and fatty acid side chains present in membrane 
phospholipids which reduces the fluidity of the membrane bilayer [Wiseman, 
1994a]. Tamoxifen's preventative effect against nuclear membrane peroxidation 
may help prevent DNA damage and subsequent malignant progression [Wiseman, 
1994b].
This role in the protection of DNA against oxidative damage may explain why 
tamoxifen has a number of other potential clinical uses. The role of tamoxifen as an 
antioxidant may partly explain its cardioprotective action since oxidative damage to 
low density lipoproteins (LDL) is well documented as being a cause of 
atherosclerosis [Wiseman, 1993b &1994b]. 17P-estradiol which similarly decreases 
membrane fluidity also protects against oxidative LDL damage[Wiseman, 1994b]. 
ICI 164,384 has also been shown to have an anti oxidant action. This steroidal 
antiestrogen may have a greater effect against lipid peroxidation than tamoxifen 
[Wiseman, 1994c].
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6. Aims of this thesis
The cell membrane is the site of action of many proteins involved in cell signalling j
I
and tumour growth and development. Alterations in the membrane fluidity may I
affect the activity and expression of these proteins. The epidermal growth factor j
receptor is a transmembrane protein tyrosine kinase which has been implicated in j
the growth and development of breast cancer. Activation of the EGFR depends on : I
the lateral diffusion and dimérisation of receptor monomers and alterations in i
membrane fluidity may affect this process and hence signalling via this receptor.
Membrane fluidity may be altered by drugs such as the antiestrogen tamoxifen 
which has previously been reported to decrease membrane fluidity in both 
liposomes and breast cancer cells.
The aims of this thesis were to examine whether tamoxifen and related compounds 
did induce changes in membrane fluidity and how such changes in membrane 
fluidity might influence both EGFR function and overall breast cancer cell growth. , j
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Chapter 2 
Materials & Methods
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1, Suppliers
Cell culture materials
DMEM, fetal calf serum (FCS), phenol red free RPMI, phenol red free DMEM and 
phosphate free medium were obtained from Sigma.
Fetal calf serum, RPM I-1640 and penicillin/streptomycin were obtained from 
Gibco.
Glasgow.
Radiochemicals
^^P orthophosphate were obtained from Amersham.
^2^1-EGF was obtained from Vienna Labs.
Miscellaneous Materials
Anti-EGFR antibody R1 and Hyperfilm x-ray film were obtained from Amersham. 
coverslips and microscope slides were obtained from BDH.
Acrylamide:bisacrylamide, Bradford dye reagents and prestained high molecular 
weight SDS-PAGE markers were obtained from BioRad.
Staphylococcus aureus cells (Pansorbin) was obtained from Calbiochem.
58
Fine Chemicals
All chemicals were of AR grade or equivalent and were obtained from Fisher 
Scientific (Fisons) with the following exceptions which were obtained from Sigma: 
Bovine serum albumin (fraction V), dextran, dithiothreitol, PMSF, sodium 
orthovanadate and TEMED.
t;
Cell culture plasticware was obtained from Nunc and Costar.
Human recombinant EGF and TGFa were obtained from Sigma and R&D Systems.
Adriamycin was obtained from the Beatson Oncology Centre, Western Infirmary,
T3^P-ATP, Biotrak EGF-receptor tyrosine kinase enzyme assay kit and carrier-free
AF18, BODÏPY-phosphatidylcholine, BODIPY-sphingomyelin and FITC-EGF 
were obtained from Molecular Probes, Inc.
Ultima Flo scintillation fluid was obtained from Packard.
Sephadex G 10 and G25 were obtained from Pharmacia.
Goat anti-mouse antibody and serums were obtained from Scottish Antibody 
Production Unit.
Aprotinin, calf thymus DNA, 17P-estradiol, fluorescein isothiocyanate isomer-1, 
FITC-BSA, Hoechst N033258, leupeptin, MTT, ribonuclease A, soyabean trypsin 
inhibitor, tamoxifen and trypan blue (0.4% solution) were obtained from Sigma.
Addresses:
Amersham International pic, Little Chalfont, Bucks., UK
Amicon Ltd, Stonehouse, Gloucestershire, UK
BDH, Merck Ltd., Lutterworth, Leics., UK
BioRad Laboratories Ltd, Hemel Hempstead, Herts., UK
Boehringer Mannheim UK Ltd., Lewes, East Sussex, UK
Calbiochem-Novabiochem, Beeston, Nottingham, UK
Fisher Scientific UK, Loughborough, Leics., UK
Gibco BRL, Life Technologies, Inchinnan Business Park, Paisley, UK
Molecular Probes, Cambridge Bioscience, Newmarket Rd., Cambridge, UK
Packard, Pangboume, Berks., UK
Pharmacia, St Albans, Herts. UK
R&D Systems Europe, Abingdon, Oxon., UK
Scottish Antibody Production Unit, Law Hospital, Carluke, UK
Sigma-Aldrich Co. Ltd, Poole, Dorset, UK
Vienna Laboratories, Vienna, Austria
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2. Buffers and Solutions
All solutions were prepared using deionised H2 O, with the exception of cell culture 
solutions which were prepared with high-purity tissue culture grade H2 O.
2 .1 . Buffers
2.1.1 Phosphate buffered saline
137mM NaCl; 2.7mM KCl; 8 m M Na2HP0 4 ; 1.8mM KH2PO4 , 
adjusted to pH 7.2 with IN HCl
2.1.2 ETN buffer
lOmMEDTA; lOmM Tris base; lOOmMNaCl 
adjusted to pH 7.0 with IN HCl
2.1.3 HE buffer
20mMHEPES; 1.5mMEDTA; 10% (v/v) glycerol 
adjusted to pH 7.4 with IN HCl
2.1.4 Hank’s modified buffer
l.Sm M CaCh; 5.4mM KCl; O.SmMMgCh; 0.5mMMgSO4; 137mM 
NaCl; 4mM NaHCOg; 0.4mM NaH2P0 4 .2 H2 0 . 
adjusted to pH 7.2 with IN HCl
2.1.5 Glycine buffer 
O.IM glycine; O.lMNaCl 
adjusted to pH 10.5 with IN  NaOH
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2. 2. Cell Culture Solutions
2.2.1 Routine sub-culture medium (MCF-7, MDA-MB-231 & A431 cells) 
RPMI-1640 medium with L-glutamine and 25mM HEPES; 10% (v/v) 
fetal calf serum.
This was further supplemented when necessary with 100 units/ml penicillin 
and 50|ig/ml streptomycin.
2.2.2 Dulbeccos Modified Eagles Medium ( MCF-7AdrR cells )
DMEM with L-glutamate and 4500mg/l D-glucose, without sodium 
bicarbonate. This was prepared from powdered stock with the addition of 
44 mM sodium bicarbonate and 25mM HEPES and supplemented with 
10% (v/v) FCS.
This was further supplemented when necessary with 100 units/ml penicillin 
and 50pg/ml streptomycin.
2.2.3 Versene
125mM NaCl; 2.7mM KCl; 6.3mM Na2HP0 4 ; 3.2mM KH2HPO4 ;
0.5mM EDTA; 0.0015% (w/v) phenol red
2.2.4 Cell Freezing Medium
90% (v/v) FCS; 10% (v/v) dimethyl sulphoxide
2.2.5 Dextran Coated Charcoal (DCC)
0.5% (w/v) sieved, prewashed charcoal; 0.005% (w/v) dextran; 
suspended in HE buffer, stirred continuously for 30 minutes at room 
temperature
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2.2.6 Dialysed Heat-Inactivated Dextran-Coated Charcoal-Stripped Fetal 
Calf Serum (DHIDCCFCS)
100ml of PCS was dialysed against four 1 litre changes of Hank's modified 
buffer over 48 hours at 4®C. The serum was then heat inactivated by 
incubating at 56®C for 45 minutes. A pellet of dextran coated charcoal 
(derived from 12.5ml of DCC solution) was added and this mixture was 
stirred for 30 minutes at 4®C before centrifuging at 10,000g to pellet the j
charcoal. The supernatant was filter sterilised through a 0.2 micron filter.
2.2.7 Experimental Medium ( MCF-7, MDA-MB-231 and A431 cells)
RPMI-1640 with L-glutamate, without phenol red and sodium bicarbonate.
This was prepared from powdered stock with the addition of 23.8mM 
sodium bicarbonate and 25mM HEPES
2.2.8 Experimental Medium ( MCF-7AdrR cells)
DMEM with L-glutamate and 4500mg/l D-glucose, without phenol red 
and sodium bicarbonate. This was prepared from powdered stock with 
the addition of 48mM sodium bicarbonate and 25mM HEPES.
2. 3. SDS PAGE Solutions
2.3.1 30% Acrylamide/bisacrylamide stock 
29.2% (w/v) acrylamide; 0.8% (w/v) bisacrylamide
2.3.2 7.5% Separating gel 
0.375M Tris-HCl pH8.8; 0.1% (w/v) SDS; 7.5% (v/v) 
acrylamide/bisacrylamide stock; 0.05% (w/v) ammonium persulphate 
(APS); 0.05% (v/v) TEMED
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All the reagents except APS and TEMED were combined and the 
monomer solution degassed under vacuum for 5 minutes followed by 
addition of the APS and TEMED to initiate polymerisation.
2.3.3 4.0% Stacking gel
0.125M Tris-HCl pH 6.8; 0.1% (w/v) SDS; 4.0% (v/v)
2.3.7 Coomassie Blue destain
40% (v/v) methanol; 10% (v/v) acetic acid
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acrylamide/bisacrylamide stock; 0.05% (w/v) ammonium persulphate; 
0.1% (v/v) TEMED 
All the reagents except APS and TEMED were combined and the 
monomer solution degassed under vacuum for 5 minutes followed by 
addition of the APS and TEMED to initiate polymerisation.
2.3.4 Sample buffer
2% (w/v) SDS; 10% glycerol; 60mM Tris-HCl pH6.8; lOOmM 
dithiothreitol; 0.05% (w/v) bromophenol blue
2.3.5 Electrode buffer, pH 8.3
25mM Tris; 192mM glycine; 0.1% (w/v) SDS
2.3.6 Coomassie Blue stain
0.25% (w/v) Coomassie Brilliant Blue R-250; 40% (v/v) methanol; 10% 
(v/v) acetic acid
2. 4 , Miscellaneous solutions
2.4.1 Hypotonic buffer pH7.2
20mM HEPES; 3mMKCl; 3mM MgCl2; lOOlig/ml PMSF; 2|ig/mi 
aprotinin; 5|ig/ml leupeptin; 50|ag/ml soyabean trypsin inhibitor
2.4.2 Membrane resuspension buffer pH 7.2
50mM HEPES; O.lmM EDTA; 0.05% (w/v) BSA; 10% (v/v) glycerol; 
100p,g/ml PMSF; 2p.g/ml aprotinin; 5pg/ml leupeptin; 50p.g/ml soyabean 
tiypsin inhibitor
2.4.3 Lysis Buffer pH8
150mMNaCl; 20mM Tris; lOmM NaH2P0 4 ; 5mMEDTA; 10% (v/v) 
glycerol; 1% (v/v) Nonidet P40; 0.5% (w/v) deoxycholate; 0.1% (w/v) 
SDS; ImM PMSF; 100p,M sodium orthovanadate; 2p.g/ml aprotinin; 
5|ig/ml leupeptin; 50|ig/ml soyabean trypsin inhibitor
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considered to be representative of an early stage of disease progression.
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3. Cell Culture Methods
3.1. Cell Lines
.Four cell lines expressing the EOF receptor were used in this study, the breast cell 
lines MCF-7 and its adriamycin-resistant subclone MCF-7AdrR and MDA-MB- 
231, and the squamous epithelial cell line A431. MCF-7 and MDA-MB-231 were 
purchased from the European Collection of Animal Cell Cultures, Porton Down,
Salisbury, UK. The A431 and MCF-7AdrR lines were a gift from Dr Ian Freshney,
Department of Medical Oncology, University of Glasgow.
MCF-7 and MCF-7AdrR
The MCF-7 cell line was derived from a pleural effusion from a patient suffering 
from adenocarcinoma of the breast who had received radiotherapy and endocrine 
therapy [Soule, et al, 1973]. This cell line is the most widely used and best
■'v.characterised of all human breast cell lines and exhibits some of the characteristics 
of differentiated mammary epithelium . In addition to the expression of estrogen 
receptors, the cells express estradiol-induced progesterone receptors and receptors 
for androgens, luteinizing hormone releasing hormone, glucocorticoids, insulin,
retinoic acid and prolactin [Clarke, et al, 1996]. Since the cell line is estrogen 
dependent, is sensitive to antiestrogens and has a low metastatic potential, it is
■:,:v
The adriamycin resistant subform, MCF-7 AdrR, was generated by continuous 
subculture in the presence of a gradually increasing non-lethal concentration of 
adriamycin. This cell line is approximately 200 fold more resistant to adriamycin
Athan the parent cell line and is also resistant to a number of other cytotoxic drugs 
including actinomycin D and vinblastine [Fairchild, et al, 1987], The cell line has 
an elevated expression of p-glycoprotein and this has been reported to be associated
:___
with an increased expression of the EGF receptor and loss of hormone 
responsiveness [Vickers, et al, 1988].
MDA-MB-231
MDA-MB-231 was also generated from a pleural effusion in an adenocarcinoma 
patient who had received endocrine therapy and chemotherapy [Caillieau, et al, 
1973]. The line is not responsive to steroid hormones and has an elevated 
expression of the EGF receptor relative to the MCF-7 line [Davidson, et al, 1987]. 
MDA-MB-231 cells are highly tumorigenic and can produce lung métastasés from 
mammary fat pad tumours in nude mice [Clarke, et al, 1996].
A431
A431 was derived from an epidermal carcinoma of the vulva [Giard, et al, 1973].
This cell line is characterised by a large number of EGF binding sites (greater than !
10^ sites/cell) [Fabricant, et al, 1977] The existence of this cell line facilitated
.many of the early studies of the EGF receptor although many of its responses to 
EGF are atypical [Gill, eta l, 1981]
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3. 2. Routine Growth and Subculture of Cell Lines
All cells were routinely grown in 75cm^ tissue culture flasks in a 37®C incubator 
with atmospheric air enriched with 5% €0%. Experimental plates and dishes were 
grown in a humidified atmosphere to prevent evaporation of medium. All routine 
and experimental media were changed every 48 hours and antibiotics were not 
routinely added to medium.
3. 2 .1 . Subculture technique
Cells were passaged when they occupied 80-90% of the surface of the culture flask. 
The growth medium was aseptically decanted and the cell monolayer washed twice 
with a small volume (approximately 5ml) of sterile PBS prewarmed to 37^C. 4ml 
trypsin/versene solution (0.05% trypsin (w/v) in versene solution) was added per 
75cm^ flask and the flasks were then incubated at 37^C for 2 minutes. After 
checking that the cells were well rounded, most of the trypsin/versene was removed 
to leave 0.5-1ml per flask and the flasks returned to the incubator to allow the cells 
to detach fully. Trypsinisation was stopped by adding an excess (at least 5ml) of 
fresh growth medium followed by rapid pipetting to ensure an even cell suspension. 
The suspension was then dispensed into new culture flasks containing fresh growth 
medium (approximately 10-15ml). For routine subculture, the cells were split in a 
ratio of 1:3.
For experimental plates the technique was slightly different. After trypsinisation 
and resuspension, the cell suspension was counted using a haemocytometer and 
diluted to the required number of cells per ml. This cell suspension was then plated 
down on experimental plates; 200|il per well for 96 well plates, 1ml per well for 24 
well plates, 2ml per well for 6 well plates or 35mm dishes, 5ml for 60mm dishes, 
10ml for 100mm dishes. After 24 hours, the routine medium was removed, the 
cells were washed twice with PBS and the appropriate experimental medium was 
added.
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3.2 . 2. Cryopreservation of cell lines
All cells used in experiments were of a similar passage number. To ensure this, 
frozen stocks were prepared and stored at -170OC and new stocks were grown from 
frozen every few months.
To prepare frozen stocks, cells were grown to 80% confluence in 175cm^ flasks. 
Cells were trypsinised and resuspended as described in section 2.2.1, The cell 
suspension was counted using a haemocytometer, transferred to a sterile universal 
container and centrifuged for 5 min at 500g. The cell pellet was resuspended in 
freshly prepared cell freezing medium at a cell density of approximately 5 X 10^ 
cells/ml and 1ml aliquots were transferred to sterile Cryo tubes. These were frozen 
to -70°C in a polystyrene container lined with cotton wool to ensure a slow rate of 
freezing. Once frozen the vials were immediately transferred to liquid nitrogen 
vats.
To grow cells from frozen stocks, the vial was thawed rapidly in a water bath at 
37°C (approximately 1 minute). The vials were removed while a few ice crystals 
still remained and the cell suspension was transferred to a universal container to 
which 10ml cold routine medium had been added. This was centrifuged at 500g for 
5 minutes, the supernatant was discarded and the pellet was slowly resuspended in 
10ml of prewarmed medium. A small aliquot was removed and mixed with an 
equal volume of 0,4% trypan blue. This dye will only enter damaged cells and thus 
allows non-viable cells to be excluded during counting with a haemocytometer. 
The cell suspension was then diluted to a density of 5 xlO^ viable cells/ml, 
transferred to 25cm^ flasks and incubated at 37^C. After 24 hours the medium was 
replaced with fresh routine medium.
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3 .2 . 3. Mycoplasma testing of cell lines
Mycoplasma is a serious intracellular contamination which is widely found in 
cultured cells [Russel, et al, 1975]. The infection cannot be detected with the naked 
eye but can cause alterations in cell metabolism, growth and viability leading to 
variability in experimental results [Hay, 1994]. All cell lines used were checked 
every two months for this contamination.
Cells were plated down onto 13mm diameter sterile glass coverslips in 60mm 
dishes in antibiotic free medium. The cells were allowed to reach approximately 
50% confluence before fixing and staining. 5ml freshly prepared Carnitovs fixative 
(75% (v/v) methanol; 25% (v/v) glacial acetic acid) was added to each dish without 
decanting the medium. After 2 minutes the fixative/medium was aspirated, a fresh 
5ml of fixative was added and this was left for 5 minutes. This step was repeated 
with a further 5ml of fixative for 5 minutes before all fixative was removed and the 
dishes allowed to air dry. The dishes were then flooded with 0.5pg/ml Hoechst 
33258 in distilled water, left for 30 minutes then washed 5 times in deionised water. 
Finally the slips were inverted onto a drop of mounting fluid (90% glycerol; 10% 
PBS) and viewed under a fluorescent microscope fitted with an appropriate filter. 
Mycoplasma was indicated by the presence of uniformly shaped bodies of 
extranuclear DNA which stained with the Hoechst dye. Any contaminated cell line 
was destroyed and new stocks, frozen before the last negative test date, were 
retrieved from frozen.
4. Hoechst DNA Assay
The assay depends on the intercalation of Hoechst 33258 dye with solubilised DNA 
to yield a complex which fluoresces with a maximum emission at 450nm [Leake & 
Habib 1987].
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The fluorescence enhancement of the standards was used to construct a standard 
curve from which values for the concentration of DNA in the samples could be 
extrapolated.
A 1 mg/ml stock solution of calf thymus DNA dissolved in ETN buffer was used to 
prepare DNA standards. The concentrations used were 0,10, 20, 30,40 , 50 and 60 
pg/ml DNA. These standards were prepared in ETN buffer and stored at -20^C for 
up to 1 month.
i
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Cell monolayers were harvested by trypsinisation. The cells were pelleted and the I
DNA was solubilised in 0.2% SDS in ETN buffer by incubation at 37°C for 30
minutes.
lOOp.1 aliquots of each standard and sample in duplicate were placed in plastic test 
tubes and 3ml of ETN buffer containing lOOng/ml Hoechst and 5p.g/ml RNase was 
added. After thorough mixing, the tubes were incubated for 30 minutes in the dark 
at room temperature. The fluorescence enhancement at 450nm was measured with 
an excitation wavelength of 360nm using a Hitachi Perkin-Elmer MPF-2A 
fluorescent spectrophotometer.
5. MTT assay
This assay is used to determine viable cell numbers. MTT (3-(4,5-dimethylthiazol- 
2 -yl)-2 ,5 -diphenyltetrazolium bromide) is a yellow, water soluble, tétrazolium salt 
which is reduced by dehydrogenase enzymes in the mitochondria to an purple 
formazan product. This product is insoluble in aqueous solutions but can be 
dissolved in dimethyl sulphoxide and the absorbance read at 570nm [Mossman, 
1983].
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Cells were trypsinised and resuspended at a concentration of between 1 and 5x10^ 
cells/ml depending on the assay and the cell line used. The cell suspension was 
plated down onto a flat bottomed 96 well plate (200|il per well). Growth medium 
only was added to the first column. Plates were incubated in a humidified 
atmosphere for 24 hours at 37 °C.
After 24 hours the medium was removed from the wells with a hypodermic needle 
attached to a suction line and replaced with experimental medium containing the 
appropriate growth factors and drugs. The medium was replaced with fresh medium 
after 48 hours. |
-S
After the appropriate incubation time, 50pl of MTT (5mg/ml in PBS) was added to 
each well, the plates were wrapped in aluminium foil and returned to the 
humidified incubator. After a minimum of 4 hours incubation with MTT, the 
medium was removed from the wells and 200pl per well DMSO added to dissolve 
the MTT-formazan crystals. Finally 25pi per well glycine buffer was added and the 
absorbance was read at 540nra immediately using a plate reader. The wells in 
column 1 were used to blank the plate reader
j
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6 . Bradford Protein Assay |
-■f
The Bradford protein assay is based on the principle that there is a shift in the 5
absorbance maximum of an acidic solution of Coomassie Brilliant Blue G-250 from
465 to 595nm when binding to protein occurs [Bradford, 1976].
A series o f protein standards in the range of l-20pg/ml was created using bovine 
serum albumen (BSA). A Img/ml stock of BSA was diluted on the day of assay in i
the same buffer as the samples to be measured to create standards o f 1,2,5,10,15 f
and 2 0 pg/ml protein.
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800pl of standards and appropriately diluted samples were placed in 75x12mm 
glass test tubes in duplicate. 200pl Biorad dye reagent was added per tube and 
mixed gently. After a 15 minute incubation at room temperature, the absorbance at 
595nm was read using a spectrophotometer. A standard curve was then constructed 
of absorbance of the protein standards versus protein concentration. This was used 
to calculate the protein concentration of the unknown samples.
7. Fluorescence Recovery After Photobleaching (FRAP)
7 .1 . Apparatus
Figure 4 is a schematic representation of the apparatus used in FRAP experiments 
[Johnston, 1982]. The apparatus consists of a IW water-cooled continuous argon 
laser (Lexel model 85) set at a wavelength of 514.5nm. Light from the laser passes 
through a spatial filter (Oriel Scientific) which removes higher spatial frequencies 
from the beam profile and improves the contrast ratio of the modulated beam by 25 
fold [Garland, 1980]. Light then passes through a collimating lens to focus the 
beam into the microscope apparatus (Leitz). In the fluorescent microscope, the 
beam is diverted through an epi-illuminator, reflected via dichroic mirrors and 
focused via a 40X objective lens onto the sample. Fluorescence from the sample is 
detected via a photomultiplier tube which feeds data into an oscilloscope (Gould).
This is connected to a Hewlett-Packard model 8 6 A computer. The control 
electronics consist of a laser control pack which regulates the power of the laser and 
a digital-acousto-optic modulator (Model 304D, Coherent Associates) which 
controls the on/off state of the beam and allows attenuation of the intensity of the 
beam. This system has the advantage that measuring and bleaching beams differ 
only in duty cycle time and are perfectly spatially aligned [Garland, 1980].
I
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7. 2. FRAP technique
A highly attenuated beam is directed into the back of the microscope and focused 
by a 40X objective lens onto a small spot (1.5pm radius) on the surface of the 
specimen. This excites the fluorophores within this area and the resulting 
fluorescence is detected by the photomultiplier tube. The level of signal is 
monitored and recorded via the oscilloscope. Once a steady reading of fluorescence 
signal has been established, the laser control unit is used to briefly (70-100 ms) 
increase the power of the laser by 10,000 fold. This high intensity pulse 
irreversibly bleaches the fluorophores in that spot. The time course of recovery of 
fluorescence levels was then followed via the oscilloscope. Recovery will be due to 
diffusion of unbleached molecules from the surrounding area into the spot (Figure 
2). Traces were then transferred to a computer and the data was analysed using a 
curve fitting programme. The values obtained for half life of recovery i.e. the time 
taken for recovery to proceed to half the final recovery, are used to calculate values 
for the lateral diffusion coefficient. All FRAP measurements were taken at a 
constant temperature of 22®C.
The equation used to derive values for the lateral diffusion coefficient was derived 
by Axelrod [Axelrod, eta l, 1976]. This assumes 2 dimensional diffusion and a laser 
beam with a Gaussian profile.
D l = (w2/4ti/2)y 
where Dl  is the lateral diffusion coefficient
w is the radius of the spot at l/e^ intensity 
t i / 2  is the half life of recovery
7  is a constant that depends on the beam profile and the bleaching 
parameter, K which in turn depends on the % bleach. Factors which 
influence the percentage bleach are laser intensity, duration of bleach pulse, 
quantum efficiency of bleaching and the fluorescence extinction coefficient.
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The fraction of molecules which are free to diffuse within the membrane is derived 
from the percentage recovery relative to the initial level of fluorescence. The 
fluorescence recovery (R) is given in percentage terms:
R =100x(F«,-Fo)/(F i-F o)
Foo is the fluorescence signal at an infinite time after bleaching 
Fo is the fluorescence signal immediately after bleaching and before 
recovery
Fi is the fluorescence signal before bleaching
In an idealised lipid bilayer Dl would be expected to be approximately 10"^cm^/s 
and recovery of fluorescence would ultimately be 100% [Cherry, 1979].
7. 3. Estimation of the spot size
The size of the spot was maintained at a constant radius of 1.5pm. This was 
checked before each set of experiments by performing photobleaching on a thin 
layer of FITC labelled bovine serum albumin in 95% glycerol. This method also 
ensures that incomplete recovery is not simply an artefact of the system [Foley, et
%
.■8.
al, 1986]. The laser is focused onto a thin film of this solution on a microscope 
slide, the fluorescence is bleached and the recovery is recorded and analysed by 
computer. The kinetics of recovery derived by the computer are used to derive a 
value for the spot size from the equation given in Section 7.2. Using this system 
FITC-BSA in 95% glycerol repeatedly demonstrated 100% recovery rates.
7 .4 . Fluorescent probes
Lipid probes were dissolved as a concentrated stock in ethanol (2mg/ml) and stored 
at -2 Q0 C.
FITC conjugated antibodies and EGF were prepared as follows: Antibody or EGF 
was dissolved in 0.25M sodium carbonate pH 9.0 containing O.IM sodium chloride
i
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at a final protein concentration of between 10 and 20 mg/ml. 0.05mg of fluorescein 
isothiocyanate isomer 1 was added per mg of protein and the mixture was rotated 
overnight at 4®C.
Free FITC was separated from the conjugate by passing down a Sephadex G25 
column (or G 10 for EGF). The column was equilibrated with PBS for 1 hour 
before use. The sample was then applied to the column and eluted with PBS. The 
first coloured fraction which represents the conjugate was collected and 
concentrated by centrifugation in an Centricon concentrator (Amicon). The 
fluorescein/protein ratio was determined by measuring the absorbance of the 
conjugate at 280 and 490nm:
molar ratio = 2.87 x A490
A28O- 0.35 X A490
This ratio is usually between 1 and 4 for antibodies
7. 5. Sample preparation
Cells were plated down in 35mm tissue culture dishes at a density of approximately 
2.5x10^ cells/ml. and allowed to grow to no more than 50% confluence. To label 
cells with lipid probes, the medium was removed and the cells were washed twice 
in serum- free routine medium . 1ml of serum-free medium containing 5pl probe in 
ethanol carrier (lOpg) was then added per dish and the cells were incubated at room 
temperature for 15 to 60 minutes depending on the experiment. After this 
incubation, the labelling medium was removed and the cells were washed four 
times in serum-free medium. Finally 2ml serum-free medium was added per dish 
and the dishes were mounted under the FRAP microscope to allow measurements.
The location of the probes can be checked using trypan blue quenching. 0.25% 
trypan blue will quench the fluorescence of all probes located in the outer 
monolayer by resonance energy transfer but will not enter living, intact cells.
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Quenching will therefore result in a loss of fluorescence from probes located at the 
cell surface and any fluorescence remaining above background levels indicates 
internalisation of the probe [Foley, et al, 1986].
8 . Whole cell EGFR receptor binding assay
Cells were grown to approximately 80% confluence in 24 well plates in 
experimental medium containing DHIDCCFCS. The medium was removed from 
the wells and the cell monolayers were washed twice with PBS. 200pl of serum- 
free medium containing 0.5nM l^^I-EGF was added to 4 wells, 200|il of serum-free 
medium containing 0.5nM ^25I_E q p  ^^d 50nM unlabelled EGF was added to a 
further 4 wells. The q^^d in this assay was labelled using the
lactoperoxidase method. The remaining wells were used to estimate the DNA 
content by the Hoechst assay (Section 4.). The plates were incubated at 37®C for 
30 minutes before binding was terminated by the addition of 1ml ice-cold PBS. 
The wells were then washed twice with 0.5ml PBS, l(K)p,l 5N NaOH was added to 
each well and the plates incubated at 37®C for 15 minutes. The extract was then 
transferred to gamma tubes and counted using a gamma counter.
9. EGF receptor tyrosine kinase assays
These assays were performed using an Amersham kit which is designed to be 
specific for the EGF receptor tyrosine kinase. The principle of the assay is that the 
enzyme present in membrane preparation of cells catalyses the transfer of the y- 
phosphate of adenosine-5'-triphosphate to the tyrosine group of a synthetic peptide 
substrate. This peptide (poly tyr-glu) has been designed to be specific for the EGF 
receptor tyrosine kinase. EGF is used to activate the enzyme and the difference 
between enzyme activity in the presence and absence of added EGF can be used to 
determine the EGF dependant tyrosine kinase activity. The phosphorylated peptide 
is separated by binding papers and the extent of phosphorylation can be determined 
by scintillation counting
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9 .1 . Preparation of cell homogenates
Cells were grown to confluence in 100mm tissue culture dishes in routine medium.
24 hours before preparation of membranes, the cell monolayers were washed twice 
with PBS and serum-free medium was added. Cells were removed by scrapping 
with a rubber policeman and pelleted by a 5 minute spin at 500g. The supernatant 
was removed and the pellet resuspended in 2 ml ice cold hypotonic buffer and left 
on ice for 10 minutes. The cell suspension was then homogenised using a glass- 
glass homogeniser and the resulting cell preparation was centrifuged at 40,000g 
(4®C) for 30 minutes. The pellet was resuspended by gentle homogenisation in a 
small volume of membrane solubilisation buffer.
9. 2. Assay Procedure
5|il EGF or water as appropriate, was added to lOpl of cell membrane homogenate 
in an Eppendorf tube. lOfxl of substrate buffer was added to each tube and the 
reaction was started by the addition of 5pl magnesium ATP buffer containing 
40mCi/ml y^^P-ATP. The final concentration of EGF was 5 xlO"^M. The tubes 
were vortexed briefly, microfuged for 2 0  seconds to wash all reagent to the base of 
the tube, and incubated at 30®C for 30 minutes. The reaction was stopped by the 
addition of lOpl stop reagent and the tubes were again vortexed and microfuged.
8
The phosphopeptide was then separated from the reaction mix. 30pl of the 
terminated reaction mix was spotted onto the centre of a binding disc in a wash 
tray. The discs were allowed to dry briefly and then washed twice in 1% (v/v) acetic 
acid for 2  minutes with gentle shaking, followed by three washes in distilled water.
After the final wash the disc was placed in a scintillation vial, 10ml scintillant was 
added and the vials were counted for 3 minutes using a 32p programme on a 
scintillation counter.
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9. 3. Calculation of results
A number of controls were included in this assay to allow calculation of the EGF 
dependant tyrosine kinase activity. In the presence of sample and EGF, the ^2p 
counted on the papers represents non-specific 32p-ATP binding, specific binding of 
the phosphopeptide and binding of phosphorylated proteins in the cell extract. By 
performing the assay in the presence of sample but not EGF, the counts due to non 
specific 32p_ATP binding and non EGF dependant tyrosine kinase phosphorylation 
of both the peptide and cellular proteins can be determined and subtracted from the 
total counts in the presence of EGF.
10. Determination of EGF receptor tyrosine kinase activity in whole cells
10.1. Labelling intact cells with 2^p
1 x 1Q6 cells were plated down in 60mm tissue culture dishes and grown to 
confluence. To label the intracellular pool with ^^P, the medium was removed, 
monolayers washed twice with PBS and Irai phosphate-free medium containing 
0.5mCi/ml 32p was added per dish. The dishes were incubated for 16 hours in a 
humidified incubator at 37°C. Cell viability in this medium over this time period 
had previously been confirmed using trypan blue exclusion to detect non-viable 
cells (Section 2.2.2.). Over 90% of cells remained viable over this period. The ^^P 
medium was then aspirated and fresh phosphate-free medium added, containing 
10‘^ M EGF as appropriate. The cells were incubated for a further 15 minutes at 
37®C in the presence of ligand before lysis. Lysis was achieved as follows: the 
medium was removed, the dishes placed on ice and the monolayers washed once in 
ice cold lysis buffer before addition of 1ml lysis buffer per dish. The cells were 
incubated on ice for 30 minutes with occasional rocking. The cell lysate was then 
scraped to the side of the dish with a rubber policeman and transferred to an 
Eppendorf tube. The lysates were cleared by centrifugation at 100,000g, 4°C, for 30 
minutes.
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10.2. Preparation of preloaded fixed aureus Cowan I (SAC)
The lysate was first precleared with normal rabbit serum bound to protein A cells, 
prepared as follows. 9ml fixed S. aureus Cowan I (SAC) was thawed and 
centrifuged at 5000g for 5 min. The pellet was resuspended in lysis buffer and the 
volume adjusted to equal the original volume. I ml normal rabbit serum was added 
and incubated on ice for 30 minutes. The preloaded SAC was then washed three 
times in lysis buffer by centrifugation and resuspension and finally resuspended in 
half the original buffer volume before storing at -70®C.
10.3. Immunoprécipitation of EGF receptors
Cell lysates were incubated with 10% (v/v) preloaded SAC for 2 hours at 4^0. The 
preloaded SAC was removed by centrifugation at 10,000g for 5 minutes and the 
supernatant was carefully removed and transferred to a fresh Eppendorf tube 
containing anti-receptor antibody (lOOpl R1 clone tissue culture hybridoma 
medium per 1 ml lysate) and rotated at 4^0 for 1 hour. 50pl 10% SAC (washed 
twice by centrifugation and resuspension in lysis buffer) was added per 1ml lysate 
and rotated for 30 minutes at 4®C. The SAC was pelleted by centrifugation at
10,(K)0g, 4°C for 1 minute and the pellet was washed three times by resuspension in 
1ml lysis buffer followed by centrifugation . After the final centrifugation all the 
lysis buffer was removed and the pellet was resuspended in 50p.l sample buffer, 
heated to S5^C for 10 minutes, microfuged, and the supernatant run on SDS-PAGE.
11. SDS PAGE
11.1 Preparation of discontinuous SDS-PAGE gels
The methodology for discontinuous SDS-PAGE is based on that of Laemmli in 
which the use of an upper stacking gel and a lower resolving gel results in a better 
band resolution than a continuous gel with no stacking section [Laemmli, 1970].
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The gel apparatus used was a BioRad Mini-Protean II dual slab cell and the gels 
were assembled according to the manufacturers instructions. 0.75mm combs and 
spacers were used to assemble the gels. Resolving gel monomer solution was 
prepared as for section 1.3.2. omitting APS and TEMED. The monomer solution 
was degassed under vacuum for 5 minutes and APS and TEMED were then added 
and the resolving gel was poured into the assembled gel apparatus to a 
predetermined level. This was obtained by inserting the comb before pouring the 
gel and marking a position 1cm below the bottom of the teeth. After the resolving 
gel was poured it was immediately overlaid with isobutanol to ensure an even 
surface on the gel and allowed to polymerise for 45 minutes. After polymerisation, 
the isobutanol was rinsed off completely with deionised water. The surface was 
dried with filter paper before addition of the stacking gel mixture. The stacking gel 
was poured to the top of the glass plates, the comb was inserted immediately and
- “the gel allowed to polymerise. After polymerisation, the comb was removed and the
wells were rinsed thoroughly with deionised water. Finally the gel apparatus was 
assembled according to the manufacturers instructions - the upper buffer chamber 
was filled with electrophoresis tank buffer and the lower chamber was filled to .a
level that covered the bottom 1cm of the gel. Any air bubbles were removed from
the bottom of the gel by swirling the buffer in the lower chamber to achieve good 
electrical contact.
11.2, Loading and electrophoresis of samples and standard proteins
Samples and standards were loaded carefully into the wells with a Gilson 
micropipette. Care was taken to prevent overspill between wells. The 
electrophoresis cell was then attached to a BioRad constant voltage power supply 
(Model 200/2.0) and a constant voltage of 200v was applied to the gel. 
Electrophoresis was continued until the bromophenol blue tracker dye was at the 
bottom of the gel. The gel was then removed from the apparatus and stained for 
total protein content by the Coomassie blue method.
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To determine the molecular weight of observed proteins, one lane in each gel 
contained a set of electrophoresis standards (BioRad high molecular weight 
standards diluted 1 :2 0  in sample buffer and heated to 85*^G for 1 0  minutes before 
use). The standard mix used contained rabbit skeletal muscle myosin (Mr 200,(XX)), 
E. coli p-galactosidase (Mr 116,000), rabbit muscle phosphorylase b (Mr 97,400), 
bovine serum albumin Mr 66,000) and hen egg white ovalbumin (Mr 45,000). A 
linear calibration curve can be obtained by plotting the logarithm of the molecular 
weight of the standard against the distance that protein has migrated in the gel.
11. 3. Coomassie Blue staining of SDS-PAGE gels
Gels were soaked in Coomassie Blue stain solution for 1 hour at room temperature. 
Destaining was achieved by soaking in 4 changes of destain solution with gentle 
agitation for between 4 hours to overnight.
1 1 .4 . Autoradiography
Stained gels were dried before autoradiography as follows. The gel was placed onto 
a piece of Whatman 3MM paper cut to slightly larger than the size of the gel. The 
upper surface was protected with a layer of Saran wrap (Dow). The gels were then 
dried for 1 hour at 85°C under constant vacuum. Dried gels were exposed to x-ray
Cells were grown to confluence in 100mm dishes . The medium was removed and 
the cell monolayers washed twice with 2mM EDTA in PBS before overlaying the
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film in an autoradiography cassette. The period of exposure varied with the degree
■■'V
of labelling from 24 to 72 hours. X-ray film was developed using a Kodak X-Omat 
Film Processor Model ME3.
12. Determination of internalisation of f^^I-EGF
This assay is a modification of one used to measure Fc')Rl receptor internalisation 
[Harrison, (zZ, 1994].
monolayer with 5ml EDTA/PBS. The dishes were then left at room temperature 
until all the cells had detached to give a single cell suspension. This suspension 
was then counted with a haemocytometer, centrifuged at 500g for 5 minutes to 
pellet the cells and the cells were resuspended in routine medium at a density of 1 0  ^
cells/ml. 1251-EGF was added at a concentration of lO'^M and the cells were 
incubated on ice for 30 minutes. This allows cell surface occupation of the EGFR 
in the absence of internalisation. After the labelling period the cells were washed in 
a 1 0  fold excess of cold medium to remove unbound ligand, the cells were pelleted 
by centrifugation at 1000g for 5 minutes and re suspended in fresh medium at a 
density of 2  x 1 0 ^ cells/ml.
Non-specific binding which was determined in the presence of a 100 fold excess of 
unlabelled EGF accounted for less than 5% of the total cell associated counts
The cell suspension was then divided into 500pl aliquots, rapidly warmed to 37®C 
and assayed at various time points. One 500pl aliquot was retained on ice 
throughout for determination of internalisation at time zero. At each time point, 
duplicate lOOpl aliquots were diluted 20 fold in ice-cold PBS at pH7.2 and at 
pH2.5. After a 5 minute incubation on ice in the PBS wash, cells were pelleted by 
centrifugation at 2000g for 5 minutes. The supernatant was removed and cell- 
associated counts were determined in a gamma counter.
The pH7.2 wash gives the total cell associated counts both internal and external,
while the acid wash typically removes 80-85% of the cell surface associated counts 
[Haigler, et al, 1980]. Thus for each time point the percentage of the total cell 
associated counts can be determined and from this an idea of rate of internalisation 
can be gained.
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13. Computer Software
This thesis was created on an Apple Macintosh® computer using Microsoft Word® 
Version 5.1. Statistical analysis of data was performed using the Instat™ statistical 
programme version 2.01 (Graphpad Software) and graphs were created using CA~ 
Cricket Graph III® version 1.0 (Computer Associates Ltd.). Diagrams were created 
using Clarisworks™ version 1.0Bv3 (Claris Corporation).
13. Statistics
The Instat™ statistical programme version 2.01 was used to calculate means and 
standard deviations and perform statistical tests of significance. Unless otherwise 
stated control and experimental means were compared using a two-tailed unpaired 
Student t test. The t test assumes a Gaussian distribution of data with the standard 
deviations of the two populations being equal. Significance of results is reported by 
the p value with p values below 0.05 considered significant.
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Chapter 3 
Results
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3. h  DNA content and MTT reduction as a measure of cell number
In this thesis two methods were used to assess cell growth and survival; 
measurement of DNA content and reduction of MTT. In each case it is important 
to ensure that the level of DNA and MTT reduction do accurately reflect cell 
number. Two initial experiments were performed to show the correlation between 
each method and cell number.
3 .1 .1 . Correlation of cell number and DNA content.
Method
80% confluent 7 5 cm2  flasks of cells were trypsinised, counted and resuspended at a 
density of 5x10^ cells/ml as described in Methods section 2.2.1 The cells were then 
allowed to plate down in two 6 -well plates. After 24 hours, the cells were removed 
from 2  wells by trypsinisation and resuspension in routine medium to a final 
volume of 1ml. A small sample (lOOpl) was removed and the number of cells 
counted on a haemocytometer. The remaining cells were lysed and a DNA assay 
performed as in Methods section 3. Every 24 hours both cell count and DNA assay 
were repeated with a further 2  wells.
Results
Figure 5 shows the linear correlation obtained when cell number is plotted against 
DNA content. A good correlation exists between the amount of DNA in the sample 
as measured by the Hoechst assay and the number of cells in the same sample.
3 .1 .2 . Correlation of cell number and MTT reduction.
Method
80% confluent 7 5 cm2 flasks of cells were trypsinised, counted and resuspended at a 
density of 5x10“^ cells/ml as described in Methods section 2.2.1. The cells were 
then allowed to plate down in 6  well plates. After 24 hours, the cells were removed
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from 2  wells by trypsinisation and resuspension in routine medium to a final 
volume of 1ml. A small sample was removed and the number of cells counted on a 
haemocytometer, 400fi.l aliquots were placed in Eppendorf tubes and the MTT 
assay was performed as in Methods section 4 with a modification for suspension 
cells. Essentially, after 4 hours incubation with lOOpl MTT, the cells were pelleted 
by centrifugation then resuspended in 400pl DMSO. 50p,l glycine buffer was
added and the absorbance was measured at 540nm in a spectrophotometer. Every 
24 hours both cell count and MTT assay were repeated with a further 2 wells.
Results
Figure 6  shows the linear correlation obtained when cell number is plotted against 
absorbance at 540nm. A good correlation exists between the amount of MTT 
reduction by a sample and the number of cells in the same sample.
Conclusion
Both DNA concentration and MTT reduction are linearly correlated with cell 
number and so it is valid to use either as a measure of cell number or proliferation.
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Figure 5. Correlation of cell number with DNA content.
This graph shows an example of the correlation found between cell number and DNA 
concentration. Each data point represents a sample of cells which has been counted 
using a haemocytometer to obtain the number of cells/ml and assayed for DNA 
content by the Hoechst method (Methods section 4.).
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Figure 6 . Correlation of cell number with MTT reduction
This graph shows an example of the correlation found between cell number and 
MTT reduction as measured by absorbance at 540nm. Each data point represents a 
sample of cells which has been counted using a haemocytometer to obtain the 
number of cells/ml and assayed by a modification of the MTT method (Methods 
section 5.).
90
Cell number versus MTT reduction
I
%I 0 .5 -
0II I I <N
Cell number/ml 
y = 0.00006X + 0.027 r = 1.000
91
"i.
3. 2, Effect of EGF and TGFa on breast cancer cell growth
EOF has been implicated in both normal breast cell growth and in the development 
and growth of breast tumours [Bates, et aly 1988 & 1990]. It was important to 
characterise the dose-response to EGF of each of the cell lines used, under normal 
conditions, since cells with different levels of EGFR have differing responses to 
EGF [Davidson, et aly 1987; Godden, et aly 1992]. The effect o f TG Fa on MCF-7 
cell growth was also examined in the presence and absence of EGF, to confirm that 
this ligand is acting through the same receptor as EGF.
Method
80% confluent flasks of cells were trypsinised, counted and resuspended at a 
density of 5x10^ cells/ml as described in Methods Section 2.2.1. The cell 
suspension was plated down onto 6  well plates and allowed to settle for 24 hours. 
The routine medium was then removed and the monolayers were washed twice with 
sterile PBS. Different concentrations of EGF (or TGFa or EGF and TG Fa in the 
case of MCF-7 cells) in phenol red free medium containing 2% DHIDCCFCS were 
then added in duplicate to wells in the 6  well plates. Phenol red free medium was 
used since a contaminant in phenol red is known to be estrogenic and this could 
affect growth [Berthois, et al, 1986]. DHIDCCFCS has had all detectable steroids 
and growth factors removed.
After 72 hours at 37°C, the medium was removed and the monolayers washed twice 
in PBS. The cells were harvested by trypsinisation, resuspension and 
centrifugation. The cell pellets were lysed by incubation with 0.2% SDS for 30 
minutes at 37°C. The DNA content was assayed by the Hoechst method as 
described in Methods section 3.
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Results
Figure 7 shows dose-response curves for the three breast cancer cell lines and the 
A431 cell line in response to EGF, MCF-7 cell growth was stimulated by EGF 
with maximal stimulation at lOOng/ml EGF. In contrast MDA-MB-231 and MCF- 
7AdrR cells were not growth stimulated by EGF and growth was inhibited at higher 
concentrations of EGF. This supports previous reports that of these three cell lines, 
only MCF-7 cells are stimulated by EGF [Osborne, et al, 1980; Godden, et al, 
1992]. The A431 cell line was inhibited by all concentrations of EGF used in this 
study which agrees with previous findings [Gill, et al, 1981; Davidson, et al, 1987]. 
Growth stimulatory effects of EGF are confined to the cell lines with relatively low 
numbers of EGFR.
Figure 8  shows the effect of TG Fa in addition to EGF on the growth of the MCF-7 
cell line. Growth stimulation due to TG Fa alone was very similar to that of EGF 
with maximal stimulation for both growth factors at lOOng/ml, Addition of EGF 
and TG Fa together had a similar effect to addition of EGF alone. The lack of an 
additive effect of these two growth factors is additional evidence that both are 
acting via the same cell surface receptor and are competing for binding to this 
receptor. Ligand binding studies have previously shown that EGF and TG Fa 
compete for binding to the EGFR although purified TG Fa has only around half the 
binding activity of EGF [Winkler, et at, 1986]. The activities of EGF and TGFa 
have been compared in a number of biological assays and in some of these the two 
growth factors have similar activity. The two growth factors are equivalent in their 
ability to stimulate DNA synthesis in a number of cell lines, to induce anchorage 
independent growth of transformed fibroblasts and to induce eyelid opening in 
newborn mice [Schreiber, et al, 1986; Derynck, 1988].
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Figure 7. Dose response curves for EGF in tumour cell lines.
MCF-7, MDA-MB-231, MCF-7AdrR and A431 cells were exposed to a range of 
concentrations of EGF from O.lng/ml to lOOOng/ml for 72 hours. Data is expressed 
as a percentage of the control of untreated cells and each data point represents the 
mean of 3 experiments performed in duplicate. The error bars indicate standard 
deviation.
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Figure 8. Dose response curves for EGF and TGFa in the MCF-7 breast cancer 
cell line.
MCF-7 cells were exposed to EGF alone, TG Fa alone or both EGF and TGFa. 
Each growth factor was added in a range of concentrations from O.lng/ml to 
lOOOng/ml for 72 hours.
Data is expressed as a percentage of the control of untreated cells and each data point 
represents the mean of 3 experiments performed in duplicate. The error bars indicate 
the standard deviation.
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3. 3. Lateral diffusion of lipids and proteins in breast cancer cells 
3. 3 .1  Lipid probes
In this thesis the technique of fluorescence recovery after photobleaching was used 
to investigate changes in membrane fluidity in breast cancer cells. Initial 
experiments were performed using this technique to define some fluidity parameters 
under normal growth conditions for the cell lines under investigation. A number of 
synthetic lipid probes were utilised for FRAP studies on untreated cells.
Method
80% confluent 75cm^ flasks were trypsinised, counted and resuspended at a density 
of 2 xlO"^cells/ml in routine medium as described in Methods section 2.2.1. The 
cells were allowed to plate down in plated down in 35mm tissue culture dishes for 
at least 24 hours. 24 hours before use, the routine medium was aspirated, the 
monolayers washed twice with sterile PBS and serum-free medium was added. 
Cells were then stained with lipid probes as described in Methods section 6.4. using 
a 15 minute incubation at room temperature for AF18 and a 30 minute incubation at 
room temperature for the BODIPY-PC and BODIPY-SPM probes. The location of 
the probes was checked by fluorescence quenching with trypan blue - none of the 
probes had significantly internalised.
Results
Figure 9 shows the general form of the results obtained in FRAP experiments. This 
trace was obtained from an experiment using FITC-BSA in 95% glycerol. The 
percentage recovery in this case was 99.6% and the lateral diffusion coefficient was 
240.4 xlO‘1^  cm^/s.
Figure 10 shows an example of a typical curve obtained from a FRAP experiment 
on MCF-7 cells labelled with AF18. The percentage recovery was 37.0% and the 
lateral diffusion coefficient 27.08 xlO"^^ cm^/s.
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Figures 11, 12, and 13 show results from untreated cells stained with the three lipid 
probes used in this study. 5-N (octadecanoyl) aminofluorescein (APIS) is a 
fluorescent lipid analogue with a fluorescein head group and a single 18 carbon fatty 
acid tail which labels most membrane domains. The other two probes used are 
fluorescent derivatives of the membrane phospholipids sphingomyelin and 
phosphatidylcholine. Different lipid probes were used since these may associate 
with different domains in the membrane [Tocanne, et al, 1989). Both 
sphingomyelin and phosphatidylcholine are enriched in the outer monolayer of the 
membrane but sphingomyelin is associated with less fluid membrane domains [Van 
Meer, 1993].
The AF18 probe exhibits similar fluidity in all three breast cell lines. The apparent 
difference in rate of diffusion observed between the MCF-7 and MCF-7AdrR cell 
lines is not significant (p= 0.1504) and no significant differences are observed 
between the % recovery values of this probe in the three cell lines (Figure 11).
The rate of lateral diffusion of both BODIPY probes is decreased in the MCF-7 
AdrR cell line relative to the MCF-7 parent cell line (p= 0.0001 for BODIPY-SPM, 
p<0.0001 for BODIPY-PC). A smaller decrease in D l is observed in the MDA- 
MB-231 line relative to MCF-7 (p <0.0001 for BODIPY-PC, p = 0.0081 for 
BODIPY-SPM). No significant differences are observed in the % recovery of these 
two probes in the three cell lines (Figures 12 and 13).
The values obtained for D l in this study were within the range of values previously 
reported for lipid diffusion in cells [Tocanne, et al, 1989J. The percentage recovery 
values obtained for all lipid probes was typically less than 50% which indicates that 
a large fraction of each probe is immobile. In synthetic lipid bilayers and some cell 
systems, percentage recovery values are usually 100% [Cherry, 1979]. However, 
previous studies have reported similarly low recovery values for lipid probes in a
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number of cell types [Tocanne, et al, 1989]. The presence of lipid immobile 
fractions suggests that the membrane is composed of lipid microdomains which 
differ in composition and physical state [Klausner, etal, 1980].
It has been suggested that higher growth rates and metastatic potential in tumour 
cells are associated with greater membrane fluidity [Deliconstantinos, 1987;
Taraboletti, et al, 1989]. These results contrast with such observations since the 
highly turaorigenic cell line MDA-MB-231, which would be expected to be more 
fluid than the MCF-7 cell line, exhibits lower membrane fluidity. This may reflect 
differences in the techniques used to measure membrane fluidity since studies 
which show a correlation use the technique of fluorescence polarisation. In this 
technique the average fluidity in all domains in the membrane is measured and 
fluorescence polarisation results are not always consistent with results from FRAP 
experiments [Kleinfeld, et al, 1981]. However, the relationship between fluidity
,and growth rate and metastasis may be dependant on the tumour type since a 
previous study in breast cancer found no correlation between fluidity and metastasis f
[Chatterjee, etal, 1976].
I
Comparisons between the MCF-7 and MCF-7 AdrR cell lines show that the lateral 
diffusion coefficients of both BODIPY probes are significantly smaller in the drug 
resistant cell line. This would indicate that the membranes of the drug resistant 
cells are less fluid than their drug sensitive counterpart. This supports previous 
fluorescence polarisation studies which found that drug resistant cells had less fluid 
membranes [Ramu, et al, 1983; Callaghan, et al, 1992]. It is possible that this 
reduction in fluidity is due to the increased membrane protein content of the MCF- 
7AdrR cell line which could act to stabilise the membrane within microdomains.
Both p-glycoprotein and EGFR are overexpressed in this cell line [Vickers, et al,
1988].
Figure 9. Example of a single FRAP curve obtained with FITC-BSA in 95% 
glycerol
This figure shows a curve obtained after a FRAP experiment on a thin film of 
FITC-BSA in 95% glycerol. Fluorescence (fraction of initial prebleaching level) is 
plotted against time. The solid line represents the curve fitted by computer 
program.
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Figure 10. Example of a single FRAP curve obtained with MCF-7 cells stained 
with the AF18 probe.
The cells were labelled with lOjig/ml AF18 in serum-free medium for 15 minutes at 
room temperature. This figure shows a curve obtained after a single bleach. 
Fluorescence (fraction of initial prebleaching level) is plotted against time. The 
solid line represents the curve fitted by computer program.
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Figure 11. Fluidity of the AF18 probe in breast cancer cell lines.
Untreated MCF-7, MDA-MB-231 and MCF-7 AdrR cells were stained for 15 
minutes at room temperature with AF18.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
No significant difference exists in either % recovery or D l  values between MCF-7 
and MDA-MB-231 (p= 0.166 for % recovery, p=0.4603 for D l), MCF-7 and MCF- 
7AdrR (p= 0.076 for % recovery, p=0.1504 for D l)  or MDA-MB-231 and MCF- 
7AdrR (p= 0.054 for % recovery, p=0.577 for D l)
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Figure 12 Fluidity of the BODIPY-phosphatidylcholine probe in breast cancer 
' cell lines.
Untreated MCF-7, MDA-MB-231 and MCF-7AdrR cells were stained for 30 
minutes at room temperature with BODIPY-phosphatidylcholine.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
No significant differences exist in % recovery values between MCF-7 and MDA- 
MB-231 (p= 0.051), MCF-7 and MCF-7AdrR (p= 0.5304) or MDA-MB-231 and 
MCF-7AdrR (p= 0.055).
Lateral diffusion is decreased in both the MDA-MB-231 and MCF-7AdrR cell lines 
relative to MCF-7 (p< 0.0001). The difference between MDA-MB-231 and MCF- 
7AdrR is not significant (p= 0.054).
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Figure 13 Fluidity of the BODIPY-sphingomyelin probe in breast cancer cell 
lines.
Untreated MCF-7, MDA-MB-231 and MCF-7AdrR cells were stained for 30 
minutes at room temperature with BODIPY-sphingomyelin.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
No significant difference exists in % recovery values between MCF-7 and MDA- 
MB-231 (p= 0.316), MCF-7 and MCF-7AdrR (p= 0.620) or MDA-MB-231 and 
MCF-7AdrR (p= 0.462).
Lateral diffusion is decreased in both the MDA-MB-231 and MCF-7AdrR cell lines 
relative to MCF-7 (p=0.0081 and p< 0.0001 respectively). Lateral diffusion of this 
probe in MDA-MB-231 cells is decreased relative to MCF-7AdrR (p= 0.0002).
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3. 3. 2. Lateral diffusion of the epidermal growth factor receptor
The most direct method of labelling the EGFR for FRAP is to use labelled 
epidermal growth factor. A number of studies have used fluorescently labelled 
EGF to study the EGF receptor in fibroblasts and A431 cells which have high 
numbers of EGFR [Schlessinger, et al, 1978; Hillman, et al, 1982; Rees, et al, 
1984]. In order to study EGFR lateral diffusion in our cells, the binding of 
commercially available FITC-EGF and our own labelled EGF (Methods section 
7.4) to breast cancer cells was studied. As EGF has only a single N-terminal site to 
allow FITC conjugation whereas antibodies possess multiple sites [Schechter, et al, 
1978; Benveniste, et al, 1988] a labelled monoclonal antibody to EGFR was also 
used in order to obtain higher levels of fluorescent signalling. The antibody, clone 
R l, was labelled with fluorescein as described in Methods section 7.4.
Method
80% confluent 75cm^ flasks were trypsinised, counted and resuspended at a density 
of 1 x1Q4 cells/ml in routine medium as described in Methods section 2,2.1. The 
cells were allowed to plate down on 13mm diameter sterile glass coverslips in 
35mm tissue culture dishes for at least 24 hours, 24 hours before use, the routine 
medium was aspirated, the monolayers washed twice with sterile PBS and serum- 
free medium was added. The coverslips were then washed with sterile PBS. To 
label with EGF, 50jil of lO'^M FITC-EGF was added and incubated for 15 minutes 
in the dark. Coverslips were incubated with dilutions of antibody for 1 hour. These 
incubations were performed on ice to prevent internalisation of the label. The slips 
were then washed with cold PBS and inverted onto a drop of PBS on a slide before 
examining by fluorescence microscopy and quantitation of the fluorescence levels.
I l l
Results
Using FITC-EGF, staining was clearly observed in the A431 and MDA-MB-231 
cell lines. However the MCF-7 cells exhibited very little, weak staining (MCF- 
7AdrR were unavailable at this point and were not included in these experiments). 
The relative intensity of staining was quantified and varied as expected with intense 
staining in the A431 cell line and weak staining in the MDA-MB-231 line (data not 
shown).
FRAP measurements were attempted on the A431 and MDA-MB-231 cell lines - 
this proved impossible for the MDA-MB-231 cell line since the level of signal was 
below that required for adequate detection with this apparatus. FRAP 
measurements were taken with the A431 cell line. The % recovery was 46.7% (+/- 
12.14) and the lateral diffusion coefficient, D l was 2.54 xlO"l^ (+/-2.06), These 
results are consistent with previously published results which give values in the 
range of 2.8 xlO'^^ to 8.5 x lO'l^ [Schlessinger, et al, 1978; Hillman, et al, 1982; 
Rees, etal, 1984].
Using the anti-EGFR antibody to label cells, staining was observed in all three cell 
lines used with the most intense staining in the A431 cell line, inteimediate staining 
in the MDA-MB-231 line and weak staining in the MCF-7 line. However, despite 
the increased level of signal it was still impossible to take FRAP measurements in 
the MCF-7 cell line. Measurements with the A431 cell line were readily achieved 
and these again closely agreed with previously published results taken with labelled 
EGF [Schlessinger, etal, 1978; Hillman, etal, 1982; Rees, etal, 1984].
From these studies it was concluded that direct measurement of EGFR lateral 
diffusion in breast cell lines was not feasible using the existing equipment.
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3. 4. Effect of tamoxifen on membrane fluidity
Having defined the normal fluidity parameters of the cell lines used, the effect of 
drugs which may alter this fluidity was examined. The non-steroidal antiestrogen 
tamoxifen is a highly lipophilic compound and both tamoxifen and its metabolite 4- 
hydroxytamoxifen have been shown to incorporate into lipid bilayers and induce 
structural changes in the model and native membranes [Custodio, et al, 1991,1993a 
& 1993b] Furthermore this interaction has been shown to decrease membrane 
fluidity in liposomes and breast cell lines by the technique of fluorescence 
polarisation [Wiseman, et al, 1993a; Clarke, et al, 1989] Since this decrease in 
membrane fluidity could have a profound effect on the growth of cells and their 
response to exogenous factors, experiments were performed to confirm this effect 
on membrane fluidity using the FRAP technique.
Method
80% confluent 75cm^ flasks were trypsinised, counted and resuspended at a density 
of 1 xlO'^cells/ml in routine medium as described in Methods section 2.2.1. The 
cells were allowed to plate down in plated down in 35mm tissue culture dishes for 
24 hours. After 24 hours routine medium was aspirated, the monolayers washed 
twice with sterile PBS and phenol red free medium containing 2% DHIDCCFCS 
and tamoxifen or ethanol carrier as appropriate was added. 24 hours before FRAP, 
serum containing medium was withdrawn and replaced with drug dilutions in 
serum-free medium. Cells were then stained with lipid probes as described in 
Methods section 6.4 using a 15 minute incubation at room temperature for A PI8 
and a 30 minute incubation for the other probes.
Results
Figure 14 shows the effect of tamoxifen incubation on AF18 fluidity. The ethanol 
carrier increased membrane fluidity slightly, relative to untreated cells (see section
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3.4.). Ethanol has a well characterised fluidising effect on cell membranes [Yiin, et 
al, 1984]. Even the lowest concentration of tamoxifen used (lO'^M) reduced 
membrane fluidity as measured by lateral diffusion coefficient D l, while higher 
concentrations reduced lateral diffusion even more (P < 0.0001). The % recovery 
values are not significantly altered by treatment (P = 0.4937). The results shown 
are from a 24 hour incubation with the drug - results from longer incubations aie 
comparable (data not shown).
Figure 15 shows the effect of 10"^M tamoxifen on the fluidity of the other lipid 
probes. Like AF18, the % recovery of BODIPY-PC and BODIPY-SPM was not 
significantly altered by tamoxifen (P= 0.051, P= 0.1553). Lateral diffusion of both 
probes was significantly decreased by tamoxifen (P< 0.0001). Thus the decrease in 
lateral diffusion is not just observed with the AF18 probe which may reflect a 
consistency in the effect of tamoxifen between different domains within the 
membrane.
Figure 16 shows the effect of 10"^M tamoxifen on fluidity of AF18 in the two 
estrogen receptor negative cell lines, MDA-MB-231 and MCF-7AdrR. In both cell 
lines, tamoxifen significantly decreased the lateral diffusion of AF18 (P< 0.0001). 
The apparent decrease in the % recovery of the probe after tamoxifen treatment is 
not significant in either the MDA-MB-231 or MCF-7 AdrR cell lines (p = 0.347, p = 
0.254).
Conclusion
Tamoxifen has a general effect in reducing membrane fluidity which is reflected 
over a number of lipid domains and is not dependent on expression of the estrogen 
receptor. This effect could have profound implications for cell growth by altering 
the activity of membrane associated proteins. The membrane action of tamoxifen 
may partly explain why higher concentrations of tamoxifen have effects which are
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the average fluidity of all membranes in the cell and across all domains. Large 
changes in fluorescence polarisation do not necessarily imply similar changes in 
lateral diffusion rates of other membrane constituents [Kleinfeld, et al, 1981].
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not reversed by estradiol [Reddel, et al, 1985] and may contribute to tamoxifen's 
action in estrogen receptor negative cells particularly at high concentrations.
This observation that tamoxifen can decrease fluidity confirms previous 
observations in liposomes and breast cancer cells [Wiseman, et al, 1993a; Clarke, et 
al, 1989]. In these studies, the technique of DPH fluorescence polarisation was
.;iused to assess changes in membrane fluidity. Fluorescence polarisation measures
Figure 14. Effect of tamoxifen on the fluidity of the AF18 probe in MCF-7 cells.
Cells were exposed to a range of concentrations of tamoxifen (10"^ to lO'^M) or 
ethanol carrier for 24 hours.
Each data point represents the mean of 24 measurements taken during 3 separate. 
experiments. The error bars indicate the standard deviation.
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Figure 15. Effect of tamoxifen on the fluidity of the BODIPY-PC and BODIPY- 
SPM probes in the MCF-7 cell line.
Cells were exposed to ethanol carrier or lO’^ M tamoxifen for 24 hours.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
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Figure 16. Effect of tamoxifen on the fluidity of the AF18 probe in the MDA-MB- 
231 and MCF-7 AdrR cell hnes.
Cells were exposed to ethanol carrier or lO'^M tamoxifen for 24 hours.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
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3. 5. Effect of cholesterol, 17(3-estradiol and ICI 182,780 on membrane fluidity
A number of other steroidal and related compounds have been suggested to have a 
similar membrane stabilising effect to tamoxifen and to be effective as membrane 
antioxidants [Wiseman, et al, 1993a]. Tamoxifen's ability to decrease membrane 
fluidity has been attributed to its ability to adopt a conformation similar to 
cholesterol [Wiseman, 1992]. Cholesterol has a well defined ability to decrease 
membrane fluidity in biological membranes: the most important parameter defining 
membrane fluidity is the cholesterol : ph ospholipid ratio [Van Blitterswijk, 1984]. 
The steroidal anti-estrogen TCI164,384 has also been reported to inhibit lipid 
peroxidation and this may be due to a similar membrane stabilising effect 
[Wiseman, 1994c]. FRAP was used to examine the effect of cholesterol, 17p- 
estradiol and ICI 182,780 on membrane fluidity. ICI 182,780 has a structure 
related to ICI 164,384 and is currently being used in clinical trials [Wakeling, et al, 
1992; Nicholson, etal, 1993b; Howell, etal, 1996].
Method
80% confluent 75cm^ flasks were tiypsinised, counted and resuspended at a density 
of 1 xlO^cells/ml in routine medium as described in Methods section 2.2.1. The 
cells were allowed to plate down in plated down in 35mm tissue culture dishes for 
24 hours. After 24 hours routine medium was aspirated, the monolayers washed 
twice with sterile PBS and phenol red free medium containing 2% DHIDCCFCS 
and 10‘^M tamoxifen, 17(3-estradiol, ICI 182,780 or ethanol earner as appropriate 
was added. 24 hours before FRAP, serum containing medium was withdrawn and 
replaced with drug dilutions in serum-free medium. Cells were then stained with 
AF18 as described in Methods section 6.4 using a 15 minute incubation at room 
temperature.
1 2 2
Results
Figure 17 shows the effect of cholesterol, estradiol and ICI 182,780 on the fluidity 
of MCF-7 cells measured using the AF18 probe. All three compounds significantly 
decreased AF18 fluidity relative to control treated cells (P<0.0001). The decrease 
in fluidity by these steroids is not significantly different to that produced by 
tamoxifen (P= 0.1155). Although 17p-estradiol has previously been shown to be 
more effective than tamoxifen in decreasing membrane fluidity [Wiseman, et al, 
1993a], these results show no significant difference. This may be due to the 
different techniques used to measure fluidity.
Tamoxifen and related compounds all significantly decrease membrane fluidity in 
breast cancer cells. Since the membrane is the site of many molecules with 
important roles in the control of cell growth, this effect could have implications for 
tumour growth.
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Figure 17. Effect of tamoxifen, 17p estradiol and ICI 182,780 on the fluidity of the 
AF18 probe in the MCF-7 cell hne.
Cells were exposed to ethanol carrier or lO'^M tamoxifen, 17P estradiol or ICI 
182,780 for 24 hours.
Each data point represents the mean of 30 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
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3. 6. Effect of tamoxifen and the steroidal antiestrogen ICI182,780 on breast 
cancer cell growth
The antiestrogen tamoxifen has been proposed to inhibit breast cancer cell growth 
by competitively inhibiting the estrogen receptor [Wakeling, et al, 1984]. 
Tamoxifen exhibits a diversity of molecular actions which cannot all be accounted 
for by its action as an estrogen receptor antagonist The drug is effective against 
some estrogen receptor negative cell lines and some tumours and inhibition by high 
concentrations of tamoxifen is not reversed by estradiol [Langdon, et al, 1990; 
Darbre, et al, 1984; Reddel, et al, 1985]. Tamoxifen also functions as a partial 
estrogen receptor agonist which causes a number of side effects such as an 
increased risk of endometrial cancer. The steroidal anti-estrogens ICI164,384 and 
ICI 182,780 were developed in an attempt to overcome some of the harmful side 
effects caused by the estrogenic action of tamoxifen and to help overcome 
resistance to tamoxifen. These drugs have a structure based on 17p-estradiol and 
should be devoid of estrogenic activity [Wakeling, etal, 1988 & 1991]. However 
studies report that 101164,384 exhibits anti cancer actions which are not dependent 
on estrogen [Wiseman 1994c]. Growth assays were performed using the three 
breast cell lines to determine the dose-response curves of both drugs in the absence 
of estrogens.
Method
80% confluent flasks of cells were trypsinised, counted and resuspended at a 
density of 5x104 cells/ml as described in Methods Section 2,2.1. The cell 
suspension was plated down onto 6 well plates and allowed to settle for 24 hours. 
The routine medium was then removed and the monolayers were washed twice with 
sterile PBS. Stock concentrations of tamoxifen and ICI 182,780 were prepared in 
absolute alcohol and diluted 1:100 in culture medium before addition to cells. The 
drug dilutions were prepared in phenol red free medium containing 2%
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DHIDCCFCS and added in duplicate to wells in the 6 well plates. Control cells 
were incubated in steroid free medium with the same final concentration of ethanol 
carrier as the experimental medium. Phenol red is a weak estrogen so in addition to 
the use of stripped fetal calf serum it is important to use phenol red free medium in 
these assays [Berthois, etal, 1986].
After 72 hours at 37®C, the medium was removed and the monolayers washed twice 
in PBS. The cells were harvested by trypsinisation, resuspension and centrifugation. 
The cell pellets were lysed by incubation with 0.2% SDS for 30 minutes at 37®C. 
The DNA content was assayed by the Hoechst method as described in Methods 
section 3.
Results
Figure 18 shows the effect of tamoxifen on the growth of the breast cell lines used 
in this study. Growth of the MCF-7 cell line was slightly stimulated by low 
concentrations of tamoxifen (10‘l^M  to lO’^M) and only inhibited by 
concentrations above lO'^M. The two estrogen receptor negative cell lines, MDA- 
M B-231 and MCF-7 AdrR were relatively unaffected by low concentrations but 
were inhibited by concentrations above lO'^M.
Figure 19 shows the effect of ICI 182,780 on the three breast cell lines. MCF-7 
cells were significantly inhibited by ICI 182,780 at concentrations of lO'i^M and 
greater. The stimulatory effect obseiwed with 10"^^ to lO'^M tamoxifen was not 
seen with ICI 182,780 while the degree of inhibition seen with 10'^ to 10"^M was 
much greater than that observed in these cells with tamoxifen (see Figure 17). The 
MDA-MB-231 and MCF-7 AdrR cell lines were relatively unaffected by 
IC Il82,780 at lower concentrations but inhibited by concentrations greater than 
10-7M.
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Both tamoxifen and the steroidal anti-estrogen IC Il82,780 can inhibit breast cell 
growth in the absence of exogenous estrogens. This effect was most marked at 
concentrations of lO’^ M and above. At these concentrations tamoxifen's effect has 
been shown not to be inhibited by estradiol [Darbre, et al, 1984; Reddel, et al, 
1985]. It is probable that the effect at these concentrations which was also found in 
the esti'ogen receptor negative cell lines MDA-MB-231 and MCF-7AdrR was due 
to an effect not mediated by the estrogen receptor.
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Figure 18. Dose response curves for tamoxifen in breast cancer cell Hnes.
MCF-7, MDA-MB-231 and MCF-7 AdrR cells were exposed to a range of 
concentrations of tamoxifen from 10‘^^M to 10‘^M, or ethanol carrier only for 72 
hours. Cell growth was assessed by DNA assay.
Data is expressed as a percentage of the control of untreated cells and each data point 
represents the mean of 3 experiments performed in duplicate. The error bars indicate 
the standard deviation.
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Figure 19. Dose response curves for ICI 182,780 in breast cancer cell lines.
MCF-7, MDA-MB-231 and MCF-7 AdrR cells were exposed to a range of 
concentrations of ICI 182,780 from lO'^^M to lO'^M, or ethanol carrier only for 72 
hours. Cell growth was assessed by DNA assay.
Data is expressed as a percentage of the control of untreated cells and each data point 
represents the mean of 3 experiments performed in duplicate. The error bars indicate 
the standard deviation.
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3.7. Effect of tamoxifen on response to EGF stimulation
Tamoxifen may have actions other than through the estrogen receptor and may 
interfere with signalling via the EGFR [Wiseman, 1994b], Tamoxifen treatment 
decreases membrane fluidity (section 3.4.) which could interfere with the 
functioning of membrane associated receptors, enzymes and channels [Van 
Blitterswijk, 1984]. EGF receptor activation depends on the receptor ability to 
diffuse laterally. The effect of concentrations of tamoxifen which decrease 
membrane fluidity on EGF-stimulated growth of MCF-7 cells was examined. 
MCF-7 cells are maximally stimulated by lOOng/ml EGF (Section 3.2.). The other 
cell lines in this study do not exhibit a growth response to EGF.
M ethod
80% confluent flasks of cells were trypsinised, counted and resuspended at a 
density of 5xl04 cells/ml as described in Methods Section 2,2.1. The cell 
suspension was plated down onto 6 well plates and allowed to settle for 24 hours. 
The routine medium was then removed and the monolayers were washed twice with 
sterile PBS. Stock concentrations of tamoxifen were prepared in absolute alcohol 
and diluted 1:100 in culture medium before addition to cells. The tamoxifen 
dilutions were prepared in phenol red free medium containing 2% DHIDCCFCS 
and added in duplicate to wells in the 6 well plates. Tamoxifen negative control 
cells were incubated in steroid free medium with the same final concentration of 
ethanol carrier as the experimental medium. Duplicate incubations with various 
concentrations of tamoxifen were made in the presence and absence of lOOng/ml 
EGF. The medium was replaced with fresh media containing appropriate additions 
after 48 hours.
After 72 hours at 37°C, the medium was removed and the monolayers washed twice 
in PBS, The cells were harvested by trypsinisation, resuspension and centrifugation.
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The cell pellets were lysed by incubation with 0.2% SDS for 30 minutes at 37°C. 
The DNA content was assayed by the Hoechst method as described in Methods 
section 3.
Results
Figure 20 shows the effect of various concentrations of tamoxifen on EGF 
stimulation of growth. In the control treated cells (ethanol carrier only), addition of 
lOOng/ml EGF stimulated growth relative to the control by 174% (p < 0.0001). 
Treatment with lO'^M and lO’^ M tamoxifen reduced the level of stimulation by 
EGF. In cells treated with lO’^M tamoxifen, EGF-stimulated growth was not 
significantly different from growth in the absence of EGF (p=0.4732). Thus EGF 
stimulation of MCF-7 growth was reduced by tamoxifen treatment. It is possible 
that this growth inhibition is in part due to the action of TGFP which is produced by 
cells in response to tamoxifen [Knabbe, et al, 1987]. To exclude this possibility, 
we repeated the experiment in the presence of TGFP neutralising antibodies. 
Elimination of TGpp from the medium partially reversed the effect but did not 
completely remove tamoxifen inhibition of EGF-stimulated growth. This suggests 
that tamoxifen affects the functioning of EGFR by another mechanism.
Previous studies have investigated tamoxifen's ability to inhibit growth factor 
stimulated growth. Tamoxifen and 4-hydroxytamoxifen have been shown to inhibit 
EGF-stimulated MCF-7 cell growth in some studies [Vignon, et al, 1987; Freiss, et 
al, 1990a; Wosikowski, et al, 1993] although conflicting reports exist [Cormier et 
al, 1989], One study suggested the effect was due to a decrease in the level of 
expression of EGFR induced by tamoxifen treatment which resulted in lower EGF 
responsiveness [Vignon, et al, 1987]. However tamoxifen’s effect on EGFR 
expression is not observed until after 5 days treatment [Berthois, et al, 1989]. The 
effect over this time scale is also unlikely to be due to modulation of the receptor's 
affinity for EGF by tamoxifen [Freiss, et al, 1990b].
134
Figure 20. Effect of Tamoxifen on EGF-stimulated MCF-7 cell growth.
Cells were exposed to an optimal concentration of lOOng/ml EGF for 72 hours in 
the presence of a range of concentrations of tamoxifen (10~8 to lO'^M) or ethanol 
carrier only.
Cell growth was assessed by a DNA assay. Each data point represents the mean of 
3 separate experiments. The error bars indicate the standard deviation.
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3.8. Effect of tamoxifen on EGF binding to cells
One possible explanation for tamoxifen's effect on signalling via the EGFR is that 
tamoxifen alters the level of receptor, or alters the binding of EGF to the receptor. 
It has been reported that tamoxifen treatment downregulates expression of the 
epidermal growth factor receptor [Berthois, et al, 1989]. Changes in membrane 
fluidity can potentially alter the cell surface exposure and ligand binding of 
receptors [Shinitsky, 1984]. Decreasing membrane fluidity increases the exposure 
and binding capacity of the insulin receptor [Neufeld, 1986]. A whole cell EGF 
binding assay was performed to examine the effects of tamoxifen treatment on EGF 
binding and levels of receptor expression.
Method
Cells were plated down onto 24 well plates in routine medium. After 24 hours the 
medium was removed, the cells washed twice with PBS and experimental medium 
containing 2% DHIDCCFCS was added. 24 hours before the assay the medium 
was removed, the cells washed twice with PBS and experimental medium 
containing tamoxifen or ethanol carrier was added. Whole cell EGF receptor 
binding was determined as described in Methods section 8.
Results
Figure 21 shows the effect of tamoxifen treatment on the EGF binding of MCF-7 
cells. No significant difference was observed between treated and control cells. It 
is therefore unlikely that downregulation of receptor expression contributes to the 
effect of tamoxifen on EGFR function. These results also suggest that reduction of 
membrane fluidity does not significantly alter the ligand binding ability of the 
receptor. This was further confirmed using quantitative fluorescence of stained 
cells. Cells stained with anti-EGFR antibodies exhibited identical levels of staining 
both before and after tamoxifen treatment (data not shown).
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Figure 21. Effect of tamoxifen on cell surface EGF binding in MCF-7 cells.
Cells were pretreated with a range of concentrations of tamoxifen (10'^ to lO'^M) or 
ethanol carrier only for 24 hours before the EGF binding assay.
Data is expressed as fmol ^^^I-EGF bound/jig DNA and each data point represents 
the mean of 3 separate experiments performed in quadruplicate. The error bars 
indicate the standard deviation.
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3 .9 . Effect of tamoxifen on the EGF receptor tyrosine kinase activity
3. 9 .1 . Assay of tyrosine kinase in isolated membranes
EGFR receptor activity depends on its intrinsic protein tyrosine kinase activity.
Tamoxifen has been shown to reduce both membrane fluidity and cell growth 
response to EGF in MCF-7 cells. The reduction in membrane fluidity caused by 
tamoxifen could interfere with the ability of receptor monomers to diffuse laterally 
within the bilayer. This would interfere with the process of intermolecular 
activation of receptors which would be expected to result in a decrease in the 
protein tyrosine kinase activity of the receptor and hence signalling processes via 
the receptor. To assess this effect, cells were pretreated with tamoxifen, 
membranes were isolated and the EGFR-PTK activity was measured using a 
commercially available kit.
After 24 hours, membranes were prepared from the cells and the PTK activity was 
assayed using the Amersham kit as described in Methods section 8.
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Method
80% confluent flasks of cells were trypsinised, counted and resuspended at a 
density of 5xl04 cells/ml as described in Methods Section 2.2.1. The cell 
suspension was plated down onto 100mm dishes and allowed to grow to 
approximately 80% confluence. The routine medium was then removed and the 
monolayers were washed twice with sterile PBS. Stock concentrations of 
tamoxifen were prepared in absolute alcohol and diluted 1:100 in culture medium 
before addition to cells. The tamoxifen dilutions were prepared in phenol red free 
medium containing 2% DHIDCCFCS and added. Control cells were incubated in 
steroid free medium with the same final concentration of ethanol carrier as the 
experimental medium.
Results
Figure 22 shows EGFR tyrosine kinase activity in membrane treated with various 
concentrations of tamoxifen. No significant difference in PTK activity was 
detected between control cells and cells treated with 10"^, 10"^ or Iff^M tamoxifen 
(p = 0.8161, p=0.9972 and p-0.9442). These concentrations of tamoxifen have 
previously been shown to decrease membrane fluidity and to inhibit EGF 
stimulated growth. This may indicate that the observed reduction in fluidity caused 
by tamoxifen has no effect on lateral mobility and hence PTK activity of the EGFR. 
However this assay is performed using solubilised receptors. This may destroy any 
constraining effect due to fluidity - receptor dimers may be able to interact and 
activate each other without the need for lateral diffusion. Thus a whole cell 
receptor assay is needed to differentiate between these two possibilities.
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Figure 22. Effect of preincubation with tamoxifen on EGFR tyrosine kinase activity 
in membranes isolated from MCF-7 cells.
Cells were exposed to a range of concentrations of tamoxifen (10‘^M to 10‘^ M) or 
ethanol carrier control before plasma membranes were isolated as described in 
Methods section 9.1. EGFR tyrosine kinase assay was measured using the Biotrak 
EGF-receptor protein tyrosine kinase assay system (Amersham).
Each data point represents the mean of 3 separate experiments. The error bars 
indicate the standard deviation.
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3 .9 .2 . EGF Receptor Protein Tyrosine kinase assays in whole ceils
Autophosphorylation of the EGFR is the next step in the signalling pathway after 
dimérisation and activation of receptor monomers, EGFR which fail to activate 
cannot undergo autophosphorylation while constitutive activation of the receptor 
results in permanent autophosphorylation. Autophosphorylation is necessary for 
maximal biological activity of the EGFR [Helin, et al, 1991]. Autophosphorylation
:is therefore an expression of receptor's intrinsic tyrosine kinase activity and might 
be expected to be reduced if dimérisation of receptors is inhibited [Honegger, et al,
1987a]. In order to detect receptor autophosphorylation in whole cells, the cells 
were first preloaded with 32p to label the intracellular pool of ATP. Cells were then 
stimulated with EGF and the level of autophosphorylation of EGFR determined by 
autoradiography after separation by SDS-PAGE.
Method
The intracellular pool of ATP was first preloaded with ^^P by incubating the cells 
for 16 hours in the presence o f ^^P in phosphate free medium (Methods section 
9.1). Cell viability over this period was assessed by trypan blue exclusion 
(Methods section 2.2.2). MCF-7 and MCF-7AdrR cells were used for this assay 
since greater than 95% of these cells remained viable over the labelling period. The 
cells were then stimulated with EGF, lysed and the receptor immunoprecipitated as 
described in Methods section 9. Equal amounts of immunoprecipitate were run on 
SDS-PAGE as described in Methods section 10.
Results
Figure 23(a) shows the effect of tamoxifen treatment on autophosphorylation of the
:
EGFR in MCF-7 cells. In the control cells, autoradiography demonstrated that EGF 
Stimulation resulted in increased phosphorylation of the 170K EGF receptor (Lanes 
1 and 2), After pretreatment o f the cells with tamoxifen, EGF-stimulated
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incorporation of into the EGFR is significantly reduced (Lanes 3 and 4). This 
suggests that tamoxifen pretreatment reduces the tyrosine kinase activity of the 
receptor. A similar effect is found in MCF-7 AdrR cells Figure 23(b). Although 
these cells do not exhibit growth stimulation in response to EGF, ligand binding 
does induce receptor autophosphorylation (Lanes 1 and 2). Pretreatment of MCF- 
7AdrR cells with tamoxifen reduces the stimulation of incorporation into the 
EGFR (Lanes 3 and 4).
Tamoxifen's effect on EGFR phosphorylation is found in the complete absence of 
exogenous estrogens and in the MCF-7 AdrR cell line which lacks estrogen 
receptor, it must be unrelated to tamoxifen's estrogen receptor mediated actions. 
Since tamoxifen can reduce membrane fluidity, such an effect could be due to 
restricted lateral diffusion of the receptor which would inhibit the ability to form 
receptor dimers and hence reduce autophosphorylation.
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Figure 23. Effect of preincubation with tamoxifen on EGFR tyrosine kinase activity 
in MCF-7 cells (a) and MCF-7 AdrR ceUs (b). Autoradiographs of 
immunoprecipitated EGFR.
80% confluent cells were preloaded with by 16 hour incubation at 37°C with 
O.SmCFml ^^P in phosphate free medium. After exposure to EGF for 15 minutes, 
EGFR were immunoprecipitated as described in Methods section 10 followed by 
SDS-PAGE. The gel was dried and exposed to X-ray film for 24 hours.
The lanes in each autoradiograph represent the following:
1. unstimulated control treated cells
2. control cells stimulated with lO'^M EGF
3. unstimulated tamoxifen pretreated cells
4. tamoxifen pretreated cells stimulated with 10‘^ M EGF
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3.10. Effect of tamoxifen on epidermal growth factor receptor lateral diffusion
Although attempts to measure EGFR fluidity directly were restricted by low 
receptor numbers and consequent low levels of fluorescent signal, it was possible to 
directly measure EGFR lateral diffusion by FRAP in the A431 cell line. Therefore, 
this cell line was studied in order to determine if the reduction in membrane fluidity 
observed with lipid probes were also reflected by changes in EGFR fluidity.
Method
80% confluent 75cm^ flasks were trypsinised, counted and resuspended at a density 
of 1 xlO^cells/ml in routine medium as described in Methods section 2,2.1. The 
cells were allowed to plate down in 35mm tissue culture dishes for 24 hours. After 
24 hours routine medium was aspirated, the monolayers washed twice with sterile 
PBS and phenol red free medium containing 2% DFIIDCCFCS and tamoxifen or 
ethanol carrier as appropriate was added. 24 hours before FRAP, serum containing 
medium was withdrawn and replaced with drug dilutions in serum-free medium. 
Cells were then stained with AF18 as described in Methods section 6.5 using a 15 
minute incubation at room temperature or, with FITC labelled EGFRl antibody as 
described in Section 3.3.2.
Results
Figure 24 shows the effect of tamoxifen on AF18 and FITC-Rl fluidity in A431 
cells. As in the breast cell lines used there has been a significant decrease in the 
lateral diffusion coefficient of AF18 after treatment with tamoxifen (P<0.0001). 
Lateral diffusion of FITC-Rl is similarly decreased after tamoxifen treatment 
(P<0,0001).
Although A431 has a number of atypical responses to EGF and may have altered 
receptors [Gill, et al, 1981; Weber, et al, 1984], the finding that tamoxifen
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decreases EGFR mobility in this cell line strongly suggests that this effect would 
also be found in breast cells.
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Figure 24. Effect of tamoxifen on the fluidity of AF18 and the FITC-Rl anti-EGFR 
antibody probe in the A431 cell Une.
Cells were exposed to ethanol carrier or 1 0 " tamoxifen for 24 hours and then 
stained for 15 minutes with AF18 or 1 hour on ice with FITC-Rl.
Each data point represents the mean of 24 measurements taken during 3 separate 
experiments. The error bars indicate the standard deviation.
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3.11. Effect of membrane active drugs on EGF receptor internalisation 
3 .1 1 .1 . EGFR internalisation in normal cells
Ligand-induced internalisation of the EGFR is a specific quantitative indicator of 
EGFR function. Since the process of internalisation is dependent on the ability of 
the receptors to diffuse from their initial diffuse distribution to form clusters 
associated with coated pits, it has been proposed that changes in lateral diffusion 
may be reflected by changes in the rate of internalisation of the receptor [Jans, et al, 
1990; Paccaud, et al, 1993]. Studies have suggested that the rate of lateral diffusion 
of EGF, insulin and glucagon receptors is strongly correlated with their rate of 
internalisation [De Diego, et at, 1991]. We looked to investigate the relationship 
between membrane fluidity and EGFR internalisation by examining the effect of 
membrane active agents on EGFR internalisation. The first experiment performed 
defined the normal rates of diffusion of EGFR in the cell lines used.
Method
Cells were grown to confluence in 100mm tissue culture dishes. Serum was 
withdrawn 24 hours before assay to deprive the cells of endogenous growth factors 
and enhance radiolabelled EGF binding. A single cell suspension was generated by 
gentle, non-enzymatic detachment of the cells in 2mM EDTA in PBS followed by 
centrifugation and resuspension in serum free routine medium at a density of 10^ 
cells/ml. Internalisation of 135i_EGF was then determined as for Methods section 7.
Results
Figure 25 show the rates of internalisation of the three breast cancer cell lines and 
the A431 cell line under normal conditions of growth. The rate of internalisation in 
all three breast cell lines is very similar. Internalisation is very rapid with 80-90% 
of the total receptor internalised after 15 minutes. Thus in spite of the different 
levels of receptor available, endocytosis is very similar in these breast cell lines. A
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previous study using FITC labelled EGF also found no difference in the kinetics of 
internalisation of EGFR in the MCF-7 and MDA-MB-231 cell lines. In contrast the 
internalisation of the A431 cell line is incomplete, which may reflect a saturation of 
the endocytic pathway in this cell due to its vast overexpression of the receptor 
[Wiley, 1988]. In Fibroblasts artificial overexpression of EGFR at levels similar to 
A431 slows the rate of receptor internalisation and reduces the extent of total 
internalisation [Benveniste, et al, 1988].
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Figure 25. Time course of internalisation of i^^I-FGF in tumour cell Hues.
Data is expressed as a percentage of the total bound and each data point 
represents the mean of 3 separate experiments performed in duplicate. The error bars 
indicate the standard deviation. Non-specific binding determined in the presence of a 
100 fold excess of unlabelled EGF was less than 5% of the total label bound.
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3.11. 2. Effect of drugs which alter membrane fluidity on internalisation
A number of compounds affect the fluidity of lipid probes in the cell lines used. If 
internalisation is affected by the rate of lateral diffusion of the receptor, changes in 
membrane fluidity which restrict this lateral diffusion may alter the rate o f 
internalisation. MCF-7 cells were treated with estradiol, tamoxifen and ICI 
182,780 at concentrations which reduced membrane fluidity, to examine the effect 
on internalisation.
Method
Cells were grown to confluence in 100mm tissue culture dishes and treated with the 
appropriate compound or control for 24 hours before assay. Serum was withdrawn 
24 hours before assay to deprive the cells of endogenous growth factors and 
enhance radiolabelled EGF binding. A single cell suspension was generated by 
gentle, non-enzymatic, detachment of the cells in 2raM EDTA in PBS followed by 
centrifugation and resuspension in routine medium at a density of 10^ cells/ml. 
Internalisation of 1^%EGF was then determined as for Methods section 7.
Results
Figure 26 shows that none of the compounds which affect cell membrane fluidity 
significantly alters the rate of internalisation of EGFR. Thus it would appear from 
these results that membrane fluidity does not significantly affect internalisation of 
the EGFR.
Conclusion
From these results it would appear that membrane fluidity changes in breast cancer 
cells do not significantly alter rates of internalisation. This is in contrast to a ;
number of studies which suggest that the rate of internalisation is affected by the 
rate of receptor lateral diffusion [Jans, et al, 1990; De Diego, et al, 1991; Paccaud,
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et aU 1993]. However earlier studies suggested that rotational and lateral diffusion 
of EGFR were not rate determining for receptor internalisation [Schlessinger,
1983]. In one study where reduced lateral diffusion did affect internalisation, the 
reduced diffusion was also related to alterations in receptor expression which could 
saturate the available sites for endocytosis [Benveniste, et al, 1988]. In our cell 
lines none of these treatments affect EGFR expression.
One alternative possibility is that the EGFR in these breast cells are present in 
microdomains which are distinct from those occupied by the lipid probes utilised in 
this study. However this seems unlikely for several reasons. Firstly, tamoxifen’s 
ability to decrease fluidity has been demonstrated using several probes and is also 
observed using fluorescence polarisation which measure bulk fluidity in the cell 
[Clarke, et al, 1989]. Microscopic examination of cells labelled with both AF18 
and rhodamine-labelled anti-EGFR antibodies shows no difference in the areas 
stained. Finally in the A431 cell line, reduction in fluidity of AF18, is reflected by 
a similar reduction in EGFR fluidity (Section 3.10.).
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Figure 26. Time course of internalisation of l^^I-EGF in MCF-7 breast cancer cells 
treated with membrane active agents.
Cells were treated with lO'^M estradiol, tamoxifen, ICI182,780 or ethanol carrier 
only for 24 hours before assaying.
Data is expressed as a percentage of the total ^^^1 bound and each data point 
represents the mean of 3 separate experiments performed in duplicate. The error bars 
indicate the standard deviation. Non-specific binding determined in the presence of a 
100 fold excess of unlabelled EGF was less than 5% of the total label bound.
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3,12. Effect of tamoxifen on adriamycin sensitivity of MCF-7 and MCF-7 
AdrR cell lines
Tamoxifen has been shown to reduce membrane fluidity in breast cell lines by 
FRAP (Section 3.5.) and fluorescence polarisation [Clarke, et al, 1989]. This effect 
may be of particular importance in drug resistance. Compounds which affect 
membrane fluidity have been demonstrated to alter the functioning of p- 
glycoprotein and increase drug accumulation in multidrug resistant cell lines 
[Sinicrope, et al, 1992; Callaghan, et al, 1993; Drori, et al, 1995]. This effect is 
found both with compounds which decrease membrane fluidity such as cholesterol 
and membrane fluidising unsaturated fatty acids such as linoleic acid [Callaghan, et 
al, 1993]. Tamoxifen has previously been reported to reverse doxorubicin 
resistance in leukaemia cells by a mechanism not reversed by estradiol [Ramu, et 
al, 1984b]. It has been suggested that this may be due to tamoxifen's ability to 
stabilise the cell membrane [Kayyali, et al, 1994]. Steroidal anti-estrogens which 
also alter membrane fluidity have also been shown to affect the functioning of p- 
glycoprotein [Kirk, etal, 1994; De Vincenzo, et al, 1996].
Growth assays were performed to determine the effect of tamoxifen on adriamycin 
sensitivity of the MCF-7 drug sensitive cell line and MCF-7 AdrR resistant cell line. 
The MCF-7 AdrR cell line was generated from the MCF-7 parent cell line by 
incubation in increasing concentrations of the cytotoxic drug adriamycin 
(doxorubicin). MCF-7 AdrR cells have been reported to be 200 fold more resistant 
to adriamycin [Fairchild, et al, 1987]. The MTT assay was used to confirm the 
adriamycin sensitivity of these two cell lines before examining the effect of 
tamoxifen on drug sensitivity.
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Method
80% confluent flasks of cells were trypsinised, counted and resuspended at a 
density of 5x1 Q4 cells/ml as described in Methods Section 2.2.1. The cell 
suspension was plated down onto 96 well plates and allowed to settle for 24 hours. 
The routine medium was then removed and the monolayers were washed with 
sterile PBS. A range of dilutions of adriamycin, prepared in phenol red free 
medium containing 2% DHIDCCFCS were added to columns in the plates (8 wells 
per column). To examine the effect of tamoxifen drug dilutions were prepared in 
medium containing either 10’6m  tamoxifen or ethanol carrier
After 72 hours at 37®C, the viable cell number was measured by the MTT assay as 
described in Methods section 4.
Results
Figure 27 shows the results of the adriamycin dose-response experiments. As can 
be seen the parent MCF-7 cell line is sensitive to adriamycin with approximately 
50% inhibition at 0.5fig/ml. The MCF-7AdrR cell line is however relatively 
resistant to growth inhibition by adriamycin at the concentrations used. This result 
is to be expected since this line was selected by its ability to grow in increasing 
concentrations of adriamycin. Thus unlike its parent cell line it is resistant to 
adriamycin, confirming the observation of Fairchild, et al, 1987.
Figures 28 and 29 shows the effect of lO'^M tamoxifen on the dose-response of the 
two cell lines to adriamycin. It can be seen that tamoxifen did not significantly 
alter the adriamycin sensitivity of either the MCF-7 or the MCF-7 AdrR cell line.
It is unclear why our results are not consistent with other studies on the reversal of 
drug resistance by tamoxifen [Berman, et al, 1991; Leonessa, et al, 1994; De 
Vincenzo, et al, 1996]. This has been fairly extensively studied and indeed has
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entered clinical trials in some cases [Millward, et al, 1992]. It remains possible 
that the MCF-7 AdrR cell line used in our study has undergone mutation which is a 
common problem with the use of cell lines. Alternatively the results may simply 
highlight the differences which exist between cell lines and the difficulties involved 
in applying findings from cell culture experiments to an in vivo situation. The 
MCF-7 AdrR cell line has been suggested to exhibit further mechanisms of 
resistance in addition to that mediated by p-glycoprotein and also exhibit 
antiestrogen resistance [Vickers, et al, 1988; Zyad, et al, 1994]. This may account 
for the inability of tamoxifen to reverse doxorubicin resistance in these cells.
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Figure 27. Dose response curves for adriamycin in the MCF-7 cell line and its 
adriamycin resistant subclone, MCF-7 AdrR.
The two cell lines were exposed to a range of concentrations of adriamycin (from 
0.01|J.g/ml to 50 |xg/ml) for 72 hours. Cell survival was assessed by the MTT assay. 
Data is expressed as a percentage of the untreated control and each data point 
represents the mean of 3 separate experiments. The error bars indicate the standard 
deviation.
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Figure 28. Effect of lO'^M tamoxifen on the adriamycin sensitivity of the MCF-7 
cell line.
Cells were exposed to a range of concentrations of adriamycin (from O.OSftg/ml to 10 
fig/ml) for 72 hours in the presence of either 10“^ M tamoxifen or ethanol carrier only. 
Cell survival was assessed by the MTT assay.
Data is expressed as a percentage of the untreated control and each data point 
represents the mean of 3 separate experiments. The error bars indicate the standard 
deviation.
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Figure 29. Effect of lO'^M tamoxifen on the adriamycin sensitivity of the MCF-7 
AdrR cell line.
Cells were exposed to a range of concentrations of adriamycin (from 0.05p.g/ml to 10 
p,g/ml) for 72 hours in the presence of either lO'^M tamoxifen or ethanol carrier only. 
Cell survival was assessed by the MTT assay.
Data is expressed as a percentage of the untreated control and each data point 
represents the mean of 3 separate experiments. The error bars indicate the standard 
deviation.
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The epidermal growth factor receptor (EGFR) has been detected in many human 
tumours including breast cancer [Gullick, 1991]. In breast cancer, expression of the 
EGFR is associated with a poor prognosis subgroup of patients [Sainsbury, et al, 
1987; Klijn, et al, 1994]. Overexpression of the receptor in the presence of an 
activating ligand can induce the transformation of cultured fibroblasts [Di Fiore, et 
al, 1987a], EGFR-mediated signalling may therefore play an important role in the 
growth and development o f human breast cancer. The EGFR has consequently 
been identified as a potential target for anti-tumour therapies [Davies, et al, 1996].
The EGFR is a membrane-associated protein tyrosine kinase. The cell membrane is 
the site of action o f many proteins involved in cell signalling and tumour growth 
and development. The activity of membrane-associated receptors and enzymes 
may be modulated by the physical state of the membrane [Epand, 1991]. 
Alterations in membrane fluidity can also affect the expression and exposure of 
membrane associated proteins [Shinitsky, 1984]. The activation of the EGFR 
tyrosine kinase depends on the lateral diffusion and dimérisation of receptor 
monomers and alterations in membrane fluidity may affect this process and hence 
signalling via the EGFR.
It was important to perform initial experiments to define the growth response to 
EOF of the different cell lines used in this study, MCF-7 cells were growth 
stimulated by EGF with a maximal stimulation at lOOng/ml. MDA-MB-231 and 
MCF-7 AdrR breast cell lines were not stimulated by EGF and growth of these cell 
lines was inhibited by high concentrations of EGF (Figure 7). These results are 
consistent with previous studies in these cell lines which show that only cell lines 
with a low level of EGF receptor, such as the MCF-7 cell line, are growth 
stimulated by EGF [Osborne, et al, 1980; Davidson, et al, 1987; Godden, et al, 
1992],
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In this thesis, membrane fluidity in breast cancer cell lines was measured using the 
technique of fluorescence recovery after photobleaching (FRAP). This technique %
measures fluidity on small areas on the cell surface, unlike the commonly used 
technique of fluorescence polarisation which measures an average fluidity over all 
membranes in the cell and all membrane domains [Van Blitterswijk, et al, 1981].
■ITwo fluidity parameters are measured in FRAP: the percentage of molecules that 4J
are free to diffuse within the timescale of the experiment, and the rate of diffusion 
(D l) [Axelrod, et al, 1976]. Three different lipid probes were used in this study 
since it has been demonstrated that different lipid analogues probe different -
membrane environments dependent on their chemical structure [Derzko, 1980].
f
The values obtained for lateral diffusion coefficients were within previously 
described ranges for lipid diffusion [Tocanne, et al, 1989]. However, in all cases
■the % recovery was low - typically less than 50%. Similar low percentage
recoveries have been previously been reported for lipid diffusion in a variety of
systems [Tocanne, et al, 1989; McKay, et al, 1991]. High immobile fractions may
imply that these probes are located within small membrane domains. A probe |
confined to a domain which is small in size relative to the bleaching area will |;}
typically have a high immobile fraction since no reservoir for recovery of
fluorescence exists [Zhang, 1993]. Significant differences in both D l and mobile
tfraction were observed in the breast cell lines investigated which suggests that the 
different probes are located in different microdomains [Tocanne, et al, 1989].
Changes in membrane fluidity have been reported in almost all types of tumour but 
the implications of these alterations for tumour growth are poorly understood [Van 
Blitterswijk, 1984]. Previous studies of membrane fluidity in tumour cells have 
suggested that increased growth and metastatic potential in tumour cells is 
associated with increased fluidity [Deliconstantinos, 1987; Taraboletti, et al, 1989]. 
Thus the MDA-MB-231 cell line which is highly tumorigenic might be expected to
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have more fluid membranes than the MCF-7 cell line [Clarke, et al, 1996].
However, results in this thesis suggest that MDA-MB-231 cell membranes are
either less fluid than MCF-7 cells or no significant difference exists (Figures 11,12
and 13). This may simply reflect the differences in the techniques used to assess
membrane fluidity. On the other hand, a study of rat mammary carcinoma found no
correlation between metastatic potential and membrane fluidity [Chatterjee, et al,
1976] and these results would caution against any general rule relating increased
membrane fluidity with increased invasiveness. Indeed a significant decrease in
.lipid fluidity was observed in the drug resistant MCF-7 AdrR cell line relative to its 
drug sensitive parent cell line MCF-7 (Figures 12 & 13). Lipid fluidity is 
influenced by both the lipid and protein content of the surrounding membrane - 
membrane fluidity may be decreased by an increase in protein content [Shinitsky,
1984]. In the MCF-7AdrR cell line both EGFR and p-glycoprotein are 
overexpressed [Vickers, et al, 1988]. Although these proteins represent only a 
small fraction of the total protein content of the membrane, such increases may 
have a significant impact on fluidity within localised membrane domains. Previous 
studies in drug resistant cell lines have also found a decrease in membrane fluidity 
[Ramu, et al, 1984; Callaghan, et al, 1992].
Originally, the aim of this study was to measure EGFR fluidity directly using the 
FRAP technique. This had been successfully performed in fibroblasts and in the 
A431 cell line which express highly elevated numbers of the receptor [Schlessinger, 
et al, 1978; Hillman, et al, 1982; Rees, et al, 1984]. Using FITC-labelled EGF and 
anti-EGFR antibodies we obtained values for EGFR lateral diffusion which agreed 
with these previous studies in the A431 cell line. However, measurement in the 
other cell lines proved impossible due to the low level of fluorescent signal 
achieved.
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Effect of tamoxifen on membrane fluidity
The anticancer drug tamoxifen was developed as an antiestrogen and is proposed to 
act by competitively inhibiting the action of estrogens [Wakeling, eî al, 1984]. 
However, numerous lines of evidence suggest that tamoxifen has actions unrelated 
to its ability to bind to the estrogen receptor. Previous studies have reported that in 
the complete absence of estrogens, tamoxifen, particularly at high concentrations, 
can inhibit the growth of breast cancer cells including those which are devoid of 
estrogen receptors [Reddel, et al, 1985; Langdon, e ta l, 1990]. Results in this thesis 
confirm this effect (Figure 18). A number of alternative actions have been 
described for tamoxifen which may explain this effect. In addition to the ER, 
tamoxifen also binds to a group of microsomal proteins called antiestrogen binding 
sites (AEBS). AEBS, which have been found in all cell types, have been proposed 
to mediate some of the alternate actions of tamoxifen [Wolf, et al, 1995]. 
Tamoxifen also inhibits the activity of the enzymes protein kinase C and the Ca^ **"- 
calmodulin dependent cAMP phosphodiesterase [Lam, 1984; O ’Brian, et al, 1986]. 
Tamoxifen induces secretion of the inhibitory factor TGFp which is active against 
both ER positive and negative breast cancer cells [Knabbe, et al, 1987; Arteaga, et 
al, 1988].
A number of studies have previously reported that tamoxifen can have effects on 
the cell membrane. Tamoxifen is a highly lipophilic compound and has been 
shown to be incorporated into cell membranes and induce structural alterations in 
the bilayer [Custodio, et al, 1991, 1993a & 1993b]. Tamoxifen and related 
compounds are capable of adopting a conformation closely resembling the known 
modulator of membrane fluidity, cholesterol [Wiseman, et al, 1992]. In the 
membrane cholesterol acts to increase the rigidity and degree of order in fluid lipid 
domains via interactions between its hydrophobic rings and the fatty acid residues 
of membrane phospholipids [Shinitsky, 1984]. Thus addition of tamoxifen may be 
similar to increasing the cholesterol content of a membrane [Wiseman, et al, 1992].
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Studies using the technique of fluorescence polarisation have confirmed that
was significantly decreased but the percentage of probe molecules free to diffuse 
was not significantly altered (Figure 14). A similar effect was observed with the
tamoxifen decreases membrane fluidity in both liposomes and breast cancer cells
[Wiseman, et al, 1993a; Clarke, et al, 1989]. However, these results do not imply 
that tamoxifen would necessarily produce a similar effect when membrane fluidity 
is assessed by FRAP since, unlike FRAP, fluorescence polarisation measurements 
represent an average bulk fluidity of all membranes in the cell and do not 
distinguish between lipid domains [Van Blitterswijk, et al, 1981]. Studies have 
shown that results obtained by these two methods are not necessarily consistent 
[Kleinfeld, etal, 1981].
Using the FRAP technique, tamoxifen was shown to reduce lipid fluidity in MCF-7 
breast cell membranes (Figures 14 and 15). The rate of lateral diffusion of AF18
I
other lipid probes used which suggests tamoxifen may be effective in reducing
fluidity over several domains in the membrane (Figure 15). This effect is also 
apparently independent of steroid receptor status since it was observed in the steroid 
receptor negative cell lines MDA-MB-231 and MCF-7 AdrR (Figure 16). This 
finding of a general effect on membrane fluidity in breast cancer cells by FRAP 
correlates well with previous fluorescence polarisation results [Clarke, et al, 1989].
The effect of the cholesterol, 17p-estradiol and ICI 182,780 on AF18 fluidity was 
examined in the MCF-7 cell line. These compounds also significantly reduced the 
lateral diffusion of the AF18 probe with no significant difference between the 
effects of cholesterol, 17p-estradiol or ICI 182,780 and tamoxifen (Figure 17).
These results contrast with previous studies in liposomes and breast cancer cells }
where significant differences were observed between the effects of tamoxifen, 17p 
estradiol and cholesterol. 17p-estradiol was shown to be more effective than 
tamoxifen in decreasing membrane fluidity in liposomes while cholesterol was less
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effective than tamoxifen [Wiseman, et al, 1993a]. 17P estradiol was also
j
demonstrated to have a greater effect on membrane fluidity than tamoxifen in ER
: inegative breast cancer cells. However in ER positive cells, no significant difference 
was found between the effects of micromolar concentrations of tamoxifen or 17p 
estradiol on membrane fluidity [Clark, et al, 1989].
Î
Effect of tamoxifen on EGFR function
It is possible that tamoxifen's effect on membrane fluidity could directly influence 
the functioning of the membrane-associated EGFR. A decrease in membrane 
fluidity may alter the physical state of the membrane surrounding the receptor and
, ,
directly affect its activity, or, the increase in viscous drag within the lipid matrix 
could impede the receptor's ability to dimerise. Since activation of the EGFR is
4!dependant on its dimérisation we sought to relate tamoxifen's membrane effects to 
its effect on EGFR function.
■>
Of the three breast cell lines studies, only MCF-7 cells exhibited a growth response 
to EGF. Using lOOng/ml EGF, the effect of tamoxifen on EGF-stimulated cell
■ '■■growth was examined. Addition of tamoxifen at concentrations ranging from 10’^
!
to IQ-^M reduced stimulation of growth by EGF with a maximal effect seen using 
lO'^M tamoxifen (Figure 20). This growth inhibition could be due to stimulation of
Àproduction of TGFp by tamoxifen [Knabbe, et al, 1987]. However, addition of 
neutralising anti-TGFp antibodies only partly reversed the effect of tamoxifen 
which suggests that tamoxifen is affecting EGFR function by a mechanism other 
than stimulation of TGFp production.
The ability of tamoxifen, and its metabolite 4-hydroxytamoxifen, to antagonise 
growth factor stimulation of cells has previously been described by a number of 
authors [Vignon, et al, 1987; Freiss, et al, 1990a; W osikowski, et al, 1993] 
although some studies found no effect on EGF-stimulated cell growth [Cormier, et
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al, 1989]. The steroidal antiestrogens ICI 164,384 and ICI 182,780 have also been 
shown to inhibit EGF and IGF-1 stimulated growth [Wakeling, 1989; Wosikowski,
et al, 1993]. Anti estrogens have also been shown to interfere with growth factor 
induction of some, but not all responsive genes [Chalbos, et al, 1993; Wosikowski, 
et al, 1993]. These differences in observations may be due to differences in cell 
culture conditions. All studies were performed in the absence o f the weak estrogen
phenol red but differences exist in the use of treated fetal calf serum. Although 
charcoal-stripped PCS has had all detectable steroids removed, it may remain a :
.source of undefined growth promoting substances. Under serum-free conditions 
tamoxifen, droloxifene (3-hydroxytamoxifen) and ICI 164,384 all inhibit EGF and 
IGF-1 stimulated proliferation of MCF-7 cells [Wosikowski, eta l, 1993].
::
■4
It has been suggested that tamoxifen's effect on EGF stimulated growth could be 
due to a alterations in receptor expression [Vignon, et al, 1987]. A decrease in the 
EGFR receptor expression or its affinity for EGF could explain the observed 
reduction in growth response to EGF. Studies have demonstrated that tamoxifen
■
treatment of MCF-7 cells produces a dose-dependent decrease in expression o f the 
EGFR after 5 days in culture [Berthois, eta l, 1989]. Conflicting studies suggest that 
inhibition of EGF-stimulated growth is actually associated with an increase in high 
affinity EGF binding sites [Freiss, et al, 1990b]. Membrane fluidity changes have 
previously been shown to alter the affinity of the insulin receptor for its ligand 
[Neufeld, et al, 1986]. Figure 21 shows the result of a whole cell EGFR binding 
assay. In this study, no effect was seen on EGF binding after tamoxifen treatment.
The effect of tamoxifen on response to EGF is therefore unlikely to be due to either 
a decrease in receptor expression or high affinity ligand binding. 4
EGFR tyrosine kinase activity which is essential for receptor functioning, is 
activated in a process involving dimérisation of receptors [Schlessinger, 1988]. 7
Any effect which restricted the ability of the receptor to diffuse laterally may
176
reduce this process. Using an EGFR tyrosine kinase assay, the effect of tamoxifen 
was examined in isolated cell membranes. Preincubation o f cells with tamoxifen 
had no significant effect on the receptor's tyrosine kinase activity (Figure 22).
However, this assay was performed on isolated receptors and under these conditions
interactions may occur between receptors without the constraining effect of 
membrane fluidity. To exclude this possibility, a whole cell assay was performed
and the effect on EGFR autophosphorylation was examined (Figure 23). 
Autophosphorylation is necessary for the maximal biological activity of the 
receptor and would be expected to be decreased if receptor dimérisation was 
inhibited [Honegger, et al, 1987; Helin, et al, 1991]. Incubation o f MCF-7 cells 
with tamoxifen at concentration known to inhibit membrane fluidity was shown to 
decrease receptor autophosphorylation. Tamoxifen has previously been shown to 
decrease EGFR autophosphorylation in MCF-7 cells treated for 5 days with 
tamoxifen [Freiss, et al, 1990b]. The effect was also observed in ER negative cells 
indicating that is independent of the ER mediated actions of tamoxifen.
Unfortunately, using the existing FRAP equipment, EGFR mobility could not be 
directly measured in cells with low receptor numbers. Since EGFR could be 
labelled in the A431 cell line, this cell line was used to investigate the effect of 
tamoxifen on both lipid and EGFR fluidity. Using the AF18 probe, tamoxifen was 
demonstrated to decrease lipid fluidity in this cell line. A decrease in fluidity was 
also observed using anti-EGFR antibodies after tamoxifen treatment (Figure 24).
This suggests that EGFR mobility is directly affected by tamoxifen and that this 
may also occur in breast cell lines.
The effect of tamoxifen on cellular responses to EGF stimulation may therefore be 
due to its effect on the cell membrane. Tamoxifen, adopting a m olecular 
conformation similar to cholesterol, would insert into the cell membrane, increase 
the degree of lipid order and have a rigidifying effect on membrane fluidity. i
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Membrane proteins such as EGFR would then exhibit reduced lateral diffusion due 
to the greater viscosity and resistance of the membrane. Thus, on ligand binding, 
receptor dimérisation would be restricted, resulting in a decrease in receptor -£
autophosphorylation. Since phosphorylation of the receptor is essential for 
recruitment of downstream proteins containing SH2 domains, signalling via the 
receptor would be reduced resulting in a reduction in the growth response to ligand 
binding.
Studies have previously demonstrated that the activity of the insulin receptor is 
sensitive to decreases in membrane fluidity. In adipocytes, insulin signalling is 
sensitive to stabilisation of membrane fluidity by membrane active peptides. These 
peptides stabilise the membrane in a non-specific manner and this decrease in 
fluidity inhibits insulin receptor autophosphorylation in intact cells [Epand, et al, 
1991]. In vivo decreases in insulin receptor autophosphorylation and activation in 
diabetic rats, is associated with increased membrane viscosity [Nadiv, et al, 1994].
Alterations in membrane fluidity may also influence the functioning o f other 
membrane receptors involved in the regulation of breast cancer proliferation. The 
EGFR forms heterodimers with related receptor molecules such as c-erbB-2 
[Rajkumar, et al, 1994]. Such heterodimers have an increased tyrosine kinase 
activity and may be more effective in tumour promotion than EGFR homodimers 
[Wright, et al, 1992a]. Heterodimerisation may be similarly affected by alterations 
in membrane fluidity. The insulin like growth factors, IGF-I and IGF-II are potent 
mitogens for breast tissue and IGF-1 receptor are frequently expressed by primary 
breast tumours[Stewart, et al, 1992; Klijn, et al, 1993]. Tamoxifen and related 
compounds have been shown to antagonise IGF-1 stimulation of growth of breast 
cancer and other tumour types [Wakeling 1989; Newton, et al, 1994; De Cupis, et 
al, 1995]. This effect may be due to a decrease in cell surface binding of the IGF-1 
receptor [Freiss, et al, 1990b; De Cupis, et al, 1995].
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Membrane associated enzymes may also be affected by an alteration in the physical 
properties of the membrane. The activity of the enzyme adenylate cyclase is highly 
dependent on membrane fluidity [Houslay, 1985]. A decrease in fluidity by 
tamoxifen could decrease the activity of the enzyme which would result in reduced 
cellular levels of cAMP. Low levels of cAMP are inhibitory to the growth of some 
tumour cells [Dumont, et al, 1989]. However the physiological relevance of this 
effect is unclear since tamoxifen has also been demonstrated to directly inhibit the 
cAMP phosphodiesterase which under certain circumstances would increase the 
levels of cAMP [Lam, 1984].
The degree of fluidity of a membrane can also affect the expression and exposure of 
receptors, adhesive molecules and antigens [Shinitsky, 1984]. Enrichment of 
tumour cells with cholesterol, which would decrease membrane fluidity, has been 
shown to be associated with an increase in exposure of membrane-associated 
proteins [Skomick, et al, 1984]. This could have profound implications both for the 
process of metastasis and for recognition of tumour cells by the immune system.
Metastasis of tumours requires interactions between the disseminating tumour cells 
and the basement membrane and tissues. These interactions are mediated by 
adhesive molecules and alteration in membrane fluidity could alter the exposure 
and binding capacity of these molecules. An early step in the metastatic process - 
interaction between the tumour cells and the endothelium has been shown to be 
influenced by the membrane fluidity of the endothelial cells. Reduction in the 
cholesterol content of endothelial cells, which would increase membrane fluidity, 
results in enhanced adhesion of tumour cells. This effect can be mimicked with a 
membrane fluidising agent, the anaesthetic procaine [Ramachandran, et al, 1986]. 
This may explain why increased fluidity is correlated with increased tumorigenicity 
and invasive potential [Taraboletti, et al, 1989]. By decreasing fluidity tamoxifen 
could may reduce adhesion and metastasis.
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Alterations in the surface expression of membrane proteins caused by alteration in 
membrane fluidity may also have implications for the effectiveness of the immune 
system in dealing with tumours [Shinitsky, 1984]. Tumours may escape immune 
surveillance because of masking of cell surface antigens but cryptic antigens may 
be exposed by alterations in membrane fluidity. In this study, tamoxifen treatment 
produced no alteration in the cell surface binding of EGF. Other studies have 
shown that tamoxifen alters the cell surface exposure of receptors such as the IGF-1 
receptor [Freiss, et al, 1990b]. Since one area investigated in tumour therapy is the 
use of immunotherapy targeted against tumour specific antigens, tamoxifen 
treatment could enhance the efficacy of such therapy [Davies, et al, 1996].
If tamoxifen does indeed have a general effect on tumour cell growth due to its 
membrane action, breast cancer patients not previously targeted for antiestrogen 
therapy and other tumour types may benefit tamoxifen treatment. The estrogenic 
actions of tamoxifen remain a problem since these are the cause of many of the 
serious side effects associated with tamoxifen such as increased risk of endometrial 
cancer and retinopathy [Wolf, et al, 1995]. However, steroidal antiestrogens which 
lack the estrogenic effects of tamoxifen and estradiol, also have a membrane 
stabilising effect which may contribute to their anticancer effects.
EGFR internalisation
A number of studies have suggested that the rate of internalisation of EGFR and 
other receptors is related to the ability of the receptors to diffuse laterally within the 
lipid bilayer [De Diego, et al, 1991; Paccaud, et al, 1993]. This would imply that 
decreases in membrane fluidity by tamoxifen treatment could alter rates of 
internalisation. In this study no differences were found in the rates of 
internalisation in breast cell lines under normal growth conditions (Figure 25). This 
finding is similar to previous studies where breast cancer cells were found to have 
the same kinetics of internalisation [Mueller, et al, 1994]. In the A431 cell line
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however, internalisation was incomplete, possibly due to saturation of the coated 
pits needed for endocytosis [Wiley, 1988]. In this study no difference was found in 
internalisation rates after treatment with tamoxifen, estradiol or IC Il82,780 at 
concentrations which would reduce membrane fluidity (Figure 26). This may 
reflect a difference in location between membrane domains altered by tamoxifen 
and the location of the EGFR. However such an explanation seems unlikely given 
that in the A431 cell line, tamoxifen treatment can be shown to slow the lateral 
diffusion of the EGFR (Figure 24). Schlessinger (1983) suggested that lateral and 
rotational diffusion of receptors was not rate-determining for internalisation of the 
EGFR.
Tamoxifen and drug resistance
In this study tamoxifen had no effect on the adriamycin sensitivity of the MCF-7 
cell line or the multi-drug resistant cell line MCF-7 AdrR (Figures 28 & 29). This 
result is in contrast to previous findings which have shown that tamoxifen, and 
related compounds, are capable of decreasing drug efflux from liposomes and 
reversing the multidrug resistant phenotype in cancer cells [Kayyali, et al, 1994; Di 
Vincenzo, et al, 1996]. Multidrug resistance has been shown to be reversed by both 
increases and decreases in membrane fluidity [Callaghan, et al, 1993; Drori, et al, 
1995]. This has been suggested to be due to increased membrane resistance to 
conformational change which would alter the activity of p-glycoprotein [Wadkins, 
et al, 1993]. It has been suggested that the use of membrane fluidising agents to 
overcome resistance may be an advantage since cholesterol treatment induced a 
small sub population of cells to develop a more resistant phenotype [Leibovici, et 
al, 1996]. Alternate mechanisms of drug resistance may also exist since not all 
cells which exhibit the multidrug resistant phenotype express p-glycoprotein. The 
MCF-7 AdrR cell line has been suggested to exhibit alternate mechanisms of 
resistance which may account for the inability of tamoxifen to reverse doxorubicin 
resistance in this cell line [Zyad, et al, 1994].
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Future Work
The work described in this thesis has shown that the anticancer drug tamoxifen 
decreases membrane fluidity in breast cancer cells and also decreases the activity of 
the EGFR possibly due to a reduction in the lateral diffusion of the receptor. A 
number of further areas of study are suggested by these results.
Existing FRAP equipment restricts the use of the technique to measuring EGFR 
mobility in cell lines with elevated levels of receptor expression. Direct 
measurement of EGFR mobility in breast cancer cells with low numbers of receptor 
may prove possible in the future either by improvement in the sensitivity of the 
FRAP apparatus or by newer techniques such as single particle tracking or
f
modification of confocal microscopy techniques [Storrie, et al, 1996; Bayley, et al,
1995].
Tamoxifen decreased membrane fluidity after 24 hours. Longer incubations (48, 72 
and 96 hours) produced identical results but it may be useful to examine changes in
membrane fluidity over a shorter time course. It would also be worth investigating s
. . 4the effects of the long term exposure to tamoxifen (greater than six months) used in
the treatment of breast cancer patients. Another study would involve determination
of the length of time required for tamoxifen-treated cells to revert to "pre- 4
tamoxifen" levels of membrane fluidity after withdrawal of tamoxifen from the
medium.
Tamoxifen treatment may have implications for immune recognition of tumour 
cells since alterations in membrane fluidity may affect the surface expression of 
tumour cell antigens. Preliminary experiments were performed in this laboratory to 
investigate changes in cell surface carbohydrate expression by tamoxifen by 
looking for changes in the binding of fluorescent lectins such as concanavalin A.
Although very little change was observed in lectin binding after tamoxifen
4
I
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treatment, further studies with a wider range of lectins may provide greater insight 
into this area.
In this study, tamoxifen was found to have no effect on the sensitivity of the drug 
resistant MCF-7 AdrR cells to adriamycin. This contrasts with previous studies 
which have demonstrated that tamoxifen can reverse the action of p-glycoprotein. 
Tamoxifen's effect on p-glycoprotein function could be studied using fluorescent 
dyes such as rhodamine 123 which act as substrates for p-glycoprotein.
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